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Abstract: Homeostasis of Langerhans and Dendritic Cells in 
Health and Disease  
 
Dendritic Cells (DC) play a pivotal role in both the initiation of immunity and its 
regulation through tolerance induction. They represent potential targets or tools 
of therapy in autoimmunity, allergy, cancer, and transplant medicine. Despite 
recent progress in mapping tissue DC subsets in human, their ontogeny and 
mechanisms of homeostasis remain elusive.  
 
The conventional view is that maintenance of tissue DC and macrophages is 
dependent on constant replenishment from circulating monocyte precursors. 
This concept was derived from in vitro data and mouse models under perturbed 
conditions. While these observations may reflect events in inflammation, studies 
in murine steady-state biology have challenged this, with data indicating at least 
three ways in which DC may persist independently of monocytes: 1, tissue DC 
are replaced by non-monocyte, blood-borne precursors; 2, embryological cells 
seed tissues and persist in adulthood; 3, DC, or their immediate precursors, 
self-renew in tissues. These mechanisms may not be mutually exclusive. 
 
Although much has been gained from the study of DC kinetics in human 
transplant, these conditions are, at least in part, inflammatory. To understand 
the steady-state homeostasis of DC and epidermal Langerhans cells (LC) in 
human tissues, a number of approaches were taken.  
 
Firstly, a comprehensive ‘DC profile’ of normal human tissues was developed, 
starting with detailed characterization of DC, monocyte and macrophage 
populations in human peripheral blood (PB) and skin. This lead to the 
identification of new DC subsets in peripheral tissue. Cells with DC precursor 
potential were then sought, through analysis of their growth factor receptor 
expression and ability to enter into cell cycle. Correlative data was gathered to 
suggest relationships between potential blood borne DC precursors and skin 
APC. The CD34+ haematopoietic compartment was examined to identify 
potential DC progenitors. The granulocyte/macrophage progenitor (GMP) and a 
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more recently described multilymphoid progenitor (MLP) were identified and 
shown also to be present in PB. CD34+ cells were identified in peripheral tissue. 
 
While cell and gene knockout experiments have significantly advanced 
understanding of murine DC, these experiments are not possible in human. The 
second approach was therefore to undertake a search for subjects with 
spontaneous DC or monocyte deficiencies. Two novel syndromes were 
identified; Dendritic Cell, Monocyte, B and NK Lymphoid (DCML) deficiency (4 
subjects) and autosomal recessive IRF8 deficiency (1 subject). In both cases, 
severe depletion of peripheral blood monocyte and DC subsets was associated 
with absence of tissue DC but preservation of LC and some tissue 
macrophages. Examination of CD34+ stem cell compartments revealed distinct 
stem cell defects resulting in loss of MLP and depletion of GMP in DCML 
deficiency, but accumulation of these subsets in IRF8 deficiency. As predicted 
by mouse models, DC deficiency was associated with a reduction in circulating 
regulatory T cells, in the context of elevated Flt3-ligand. 
 
Finally, lesions of Langerhans Cell Histiocytosis (LCH), a histiocytic disorder 
presenting with pathological accumulation of langerin+ DC in tissues, were 
studied. Analysis of langerin distribution in normal skin and lung identified a 
langerin+ DC, independent of LC. In keeping with in vitro culture data, 
preliminary observations show that langerin may be up-regulated on mDC in 
inflammatory conditions. These data suggest that langerin expression in LCH 
lesions may reflect its upregulation, rather than determine the LC origin of LCH 
cells. 
 
A variety of techniques have been used to explore DC in normal tissue, novel 
syndromes of DC deficiency and Langerhans cell histiocytosis. These studies 
provide new insights into the ontogeny and homeostasis of human DC and LC.  
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Chapter 1. Introduction 
 
Dendritic cells (DC) are key sentinels of the immune system, specialised in 
antigen capture and presentation. They are found in almost all tissues where 
they encounter antigen prior to migrating to lymph nodes to initiate immunity or 
tolerance. From where they derive and how they are maintained in sites of 
antigen exposure remain important unresolved questions. Elucidating the 
homeostasis of human DC is vital to understanding the induction of immunity 
and tolerance in health, the role of DC in pathology and how to harness their 
therapeutic potential in treatments. 
 
1.1 Introduction to Dendritic Cells 
1.1.1 DC as Antigen Presenting Cells 
The major cells classified as professional antigen presenting cells (APC) 
include DC, macrophages and B cells. These cells have the ability to 
internalise, process and present antigen as peptide in the context of MHC Class 
II. B cells are relatively weak APC and differ from DC and Macs in their 
possession of specific antigen receptors, surface immunoglobulins. They will 
not be considered further here. Macrophages are long lived in tissue and are 
generally responsible for clearance of debris and tissue repair after 
inflammation (1). However, various tissue macrophages are able to adopt 
specialised functions depending on their anatomical locations (reviewed in (2)). 
For example, alveolar macrophages are responsible for clearing respiratory 
pathogens and debris from the lung so express high levels of scavenger 
receptors (3), while osteoclasts in bone are responsible for bone remodeling 
(4).  
 
Many cell types can become ‘non-professional’ antigen presenting cells through 
up-regulation of MHC class II expression, usually under inflammatory 
conditions. This is commonly seen in response to Interferon gamma (IFN!) and 
can be seen in cells including T cells, NK cells, endothelial cells and fibroblasts 
(5). In contrast, DC express MHC Class II constitutively, are specialised to 
capture and process antigens in vivo (6) and are able to up-regulate co-
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stimulatory molecules required for efficient stimulation of T cells. They 
orchestrate responses in both the innate and adaptive immune systems to 
initiate either immunity or tolerance. The pivotal nature of DC in the immune 
system is indicated by their ability to recognise a broad range of potentially 
pathogenic antigens and harness an array of appropriate responses (7). 
 
1.1.2 Historical perspective 
Although the epidermal Langerhans Cell (LC) was the first described APC, 
identified in 1868 by Paul Langerhans, it was originally thought to be of 
neuronal origin. It was not until 1979 that it was recognised as a bone marrow 
derived cell (8). By then, the initial description had been made in 1972 
(published in 1973) by Ralph Steinman et al., of adherent stellate cells, distinct 
from macrophages, in mouse spleen (9). The first indication that DC were 
potent stimulators of T cells was seen in the in vitro Mixed Lymphocyte 
Reaction (MLR) in which context DC were described as ‘accessory cells’. They 
were found to be 100 times more effective than total spleen cells (containing 
approximately 1% DC) at stimulating a T cell response (10).  
 
Through the study of murine Langerhans Cells it was noted that freshly isolated 
LC could present antigen but were poor stimulators in an MLR, while the 
reverse was true of LC cultured with GM-CSF (11) (12). This lead to the 
concept of the necessity of DC maturation following antigen capture, prior to 
migration and efficient interaction with T cells (13).  
 
1.1.3 Role of DC in Innate Immunity 
The innate immune system is phylogenically the oldest form of host defense 
against infection. It relies on a limited number of germ line encoded receptors 
which recognise conserved microbial antigens, including pathogen recognition 
receptors (PRR), Tol-like receptors (TLR) and lectins (14), expressed by many 
cells including neutrophils, monocytes and macrophages. Signaling via these 
receptors leads to the rapid induction of antimicrobial genes and inflammatory 
cytokines. Specific to DC, signaling via TLRs leads to the up-regulation of co-
stimulatory molecules and increased antigen-presenting capacity (15). This 
links the DC to the adaptive arm of immunity. 
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1.1.4 Role of DC in Adaptive Immunity 
The two key features of the adaptive immune system are: i) the exquisite 
specificity for antigens and ii) the development of memory leading to improved 
function on re-exposure to antigen. This is largely controlled through the 
interaction between DC and naïve CD4+ T cells. The presentation of antigen in 
the context of Class II expression on DC allows the activation of T cells with 
specificity for that antigen. After clonal selection, T cells undergo extensive 
expansion and differentiation to helper or killer phenotypes (16). T cell memory 
is also acquired (17). The secretion of selective cytokines by DC is thought to 
regulate these processes. For example, secretion of IL-12, the major cytokine of 
activated DC, leads to a T helper (Th) type 1 response (18), while secretion of 
IL-23 induces Th17 responses (19).  
 
The steps involved in DC activation of T cells within a lymph node were 
summarised by Kapsenberg in a ‘three signal model’ (20). Following antigen 
capture in the periphery and migration of DC to the LN, DC present the 
pathogenic antigen in the context of MHC class-II to the T cell via its T cell 
receptor (TCR); Signal 1. Signal 2 is co-stimulatory involving CD80 or CD86 
expressed on activated DC, and CD28 on T cells. Signal 3 is a polarizing signal, 
mediated by soluble or membrane-bound factors, instructing T cells to develop 
a T-helper type I (Th1) or type II response. It is determined by the nature of the 
original antigen-DC interaction where the antigen binding of specific PRRs or 
TLRs will lead to the production of specific molecules to drive either a Th1 or 
Th2 response (Figure 1.1). 
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1.1.5 Antigen presentation by DC 
Like almost all cells, DC are able to present endogenous proteins in the context 
of MHC Class I through proteasome processing of cytosolic components. This 
includes the presentation of viral antigens in the setting of direct viral infection 
of the cell. Endogenous or exogenous antigens processed in the endosomal 
compartment are presented in the context of MHC Class II. These may include 
endogenous components of the endocytic pathway or exogenous antigens 
captured through pinocytosis, phagocytosis or receptor mediated endocytosis.  
 
However, specific to some subsets of DC is the ability to ‘cross-present’ 
antigen, a mechanism whereby extracellular antigen is not presented in the 
context of MHC-Class II but is transferred to the MHC-Class I antigen 
presentation pathway (21) (Figure 1.2). This facilitates the activation of CD8+ T 
cells through stimulation by extracellular antigen. This route may be important 
for the induction of tolerance to self-antigen and immunity to viral and bacterial 
pathogens, where DC are not directly infected.  
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1.1.6 Role of DC in Tolerance 
As well as immunogenic responses, DC-T cell interactions can result in 
tolerance. This may occur either through the deletion or suppression of reactive 
T cells (22) or the induction of regulatory T cells (Treg).  
 
T cell deletion is seen particularly in the induction of central tolerance in the 
thymus. Here, apoptosis is induced in thymocytes that recognise self-antigen 
with high affinity and is mediated by thymic DC (23). Peripheral tolerance is also 
thought to be mediated by DC but the exact mechanism is debated. Some 
propose that immature DC mediate tolerance through T cell anergy, while 
mature DC stimulate immune responses (24). However, this has been revised 
to suggest that tolerance is induced by DC that are mature but quiescent where 
as immunity requires additional danger signals from pathogens (25). 
 
Naturally occurring Tregs not only prevent autoimmunity but also suppress a 
number of pathological immune responses to non-self antigens, such as allergy 
(26). Recently, an intimate association between the homeostasis of DC and 
Tregs has been seen in mice, linked to FMS-like tyrosine kinase 3 ligand (Flt3L) 
concentrations. Depletion of Tregs increases DC proliferation in a Flt3L-
dependent manner (27) (28), administration of exogenous FL induces Treg 
proliferation as a direct result of DC expansion, and DC depletion in Flt3L KO 
mice leads to reduced numbers of Treg, with autoimmune sequelae (29). The 
proliferation of Treg in vivo is dependent on MHC Class II expression on DC 
(30). This leads to a model proposed by Nussenzweig’s Group (Figure 1.3) 
whereby a feedback loop exists which allows reciprocal regulation of Treg and 
DC in a Flt3L and MHC Class-II dependent fashion.    
 
The homeostatic balance between DC, Treg and Flt3L has not been tested in 
humans. This is discussed in Chapter 5. 
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1.1.7 Classification of DC 
DC can be very broadly divided into two categories, relating to their tissue 
distribution (31): i) Migratory DC which act as sentinels of the immune system. 
In peripheral tissues they capture foreign- and self- antigen and migrate, via 
lymphatics, to lymph nodes (LN) where they communicate with T cells to initiate 
immunity or tolerance. They are particularly abundant at surfaces that interface 
with the environment, for example epidermal LC form a continuous network 
across the entire body. ii) lymphoid resident DC which present antigen 
encountered within the LN. An independent population of thymic DC is also 
described, which derive from thymic precursors and remain for their entire life 
within the thymus (32). 
 
There is a third group of DC which are not present in steady state but can be 
found after inflammation. These include ‘tumour-necrosis factor and inducible 
nitric-oxide synthase-producing DC’ (Tip DC). DC homeostasis in inflammation 
is discussed below. 
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1.1.8 Classification of Murine DC 
Murine DC can be similarly classified into migratory and lymphoid resident DC, 
reviewed in (33). Of these, the lymphoid resident cells are the most studied.  
These cells are peripheral blood-derived and can be divided into CD8+, CD4+ 
and CD8-CD4-subsets. These subsets vary in their anatomical location and 
antigen presenting capabilities. CD8+ DC are found in the T cell zone and are 
able to cross-present antigen, where CD4+ DC are mainly in the marginal zone 
and specialise in Class II dependent antigen presentation. Lymph node tissue 
contains similar populations but also those DC migrated from associated tissue. 
 
Most murine tissues, including dermis, lung, liver and kidney, contain at least 
two migratory DC subsets; CD103+Lang+CD11blow and CD11b++CD103-Lang- 
cells (34), (35). Again, these populations appear to have differing antigen 
presenting capabilities with CD103+ DC possessing the ability to cross-present 
antigen. Similarly to human, the murine epidermis contains a continuous 
network of Langerhans Cells. 
 
Table 1.1 summaries the currently recognised murine DC and monocyte 
subsets. Comparison of these subsets with human DC is discussed in the 
relevant sections below. 
 




1.2  Peripheral Blood Monocyte heterogeneity 
In order to study the homeostasis of human DC, a detailed knowledge of 
currently recognised subsets in peripheral blood (PB) and tissue is required. 
Human PB monocytes and DC are now well described (36), (37), (38) and 
include at least two subsets of monocytes based on CD14 (part of LPS 
receptor) and CD16 (Fc!RIII) expression, CD123+,BDCA2/CD303+, 
BDCA4/CD304+ plasmacytoid DC (pDC) and CD11c+ myeloid DC (mDC).  mDC 
can be further subdivided into CD141/BDCA3low,CD1c/BDCA1+ DC and 
CD141high,CD1c- DC (37). A recent consensus paper (39) has suggested the 
following nomenclature:   
Monocytes: Classical CD14++CD16-, Intermediate CD14++CD16+ and Non-
classical CD14+CD16+ Monocytes, The latter two groups are both included in 
the term CD16+ Monocyte. 
DC: plasmacytoid CD303+ DC, myeloid CD1c+DC and myeloid CD141highDC. 
 
However, despite attempts to harmonise nomenclature, controversy still 
remains, particularly as to the nature of the CD14+CD16+ cell, which shares 
properties in common with both CD14+monocytes and mDC and in the literature 
is variably classed with either cell type. For the purposes of this thesis, the 
nomenclature shown in figure 1.4 will be employed, based on the antigen 
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expression of cells in flow cytometric analysis, initially identified by negativity for 





The link between monocytes and macrophages was initially described following 
the observation that bone marrow precursors gave rise to circulating cells which 
were able to migrate to tissue to form macrophages (40). Monocytes were 
initially identified by their morphology and cytochemistry but more modern 
automated blood counters rely on their light scatter properties. The use of 
surface markers in flow cytometry, including CD14 and CD16, lead to the 
identification of monocyte subsets (41). CD14+monocytes constitute 
approximately 90% of total peripheral blood monocytes. 
 
1.2.2 CD16+monocytes 
CD16+monocytes express lower levels of CD14. Whether the CD16+monocyte 
is actually more closely related to a monocyte or a DC is debated (reviewed in 
(2)). Almeida et al (42) showed morphological, cytochemical, 
immunophenotypic and functional differences between the CD16+ cell and both 
the CD14+monocyte and mDC. Unlike CD14+monocytes CD16+ cells have 
cytoplasmic veils, are negative for myeloperoxidase staining and lack CD64 
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expression. They have higher HLA-DR, CD32 and CD86 expression. However, 
when compared to mDC they have lower HLA-DR and CD4 expression. 
Functionally, their Ig/complement mediated phagocytosis ability (as determined 
by E coli phagocytosis) was intermediary between CD14+monocytes (high 
phagocytosis) and mDC (low phagocytosis).  
 
In vitro, both CD14+monocytes and CD16+monocytes form DC-like cells when 
cultured with GM-CSF and IL-4 (43) (44) and both can become macrophage-
like with the addition of M-CSF to the culture medium (45) (46). However, 
Randolph et al (47) showed different migratory properties of CD14+monocytes 
and ‘CD16+DR+’ cells (equivalent to CD16+monocytes) in an in vitro 
transendothelial migration model, where CD16+DR+ cell was more likely to 
become DC-like as defined by reverse transmigration. In contrast, the 
CD14+monocyte, in this set up, was more likely to differentiate into a 
macrophage. More recently, Geissmann’s group demonstrated, through 
adoptive transfer experiments, the patrolling behaviour of the CD16+ human 
monocyte in murine vessels (48). 
 
Gene expression profiling (49) has shown the CD16+monocyte to be more 
closely related to CD14+monocyte and neutrophils, than to the lymph node 
resident DC, despite the possession of features in common with LN-DC and 
distinct from CD14+monocytes. However, direct comparison of 
CD14+monocytes and CD16+monocyte (50) has shown a more DC-like 
expression profile in the CD16+ cells. In vivo, numbers of CD16+monocytes can 
be expanded in acute inflammation (51) and reduced by corticosteroid therapy 
(52).  
 
1.2.3 SLAN DC 
A further subdivision of CD16+monocytes is by surface expression of 6-Sulfo 
LacNAc (53), so called ‘slanDC’. This population produces IL-12p70 on LPS 
stimulation via TLR4 signaling and may be critical in the programming of Th1 
cells and activation of NK cells. However, gene expression profiling has 
revealed no distinction other than SLAN expression between slan+ and slan- 
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CD16+monocytes (48). Higher numbers of slanDC have been seen in patients 
with psoriasis or rheumatoid arthritis. 
 
1.2.4 CD14+CD16+monocytes 
A third monocyte subset is identified in humans as CD14+CD16+ (54). In this 
study, CD14+CD16+ cells showed increased phagocytic activity and decreased 
antigen presentation compared to CD16+DR+(CD16+)monocytes. After LPS 
stimulation both CD16+ subsets produced TNF"  but only 
CD14+CD16+monocytes produced IL-10. Increased frequencies of this subset 
have been reported in patients with severe asthma (55) and in some with 
atherosclerosis (56). 
 
It remains to be seen whether the CD14+CD16+ subset is derived from the 
CD14+monocyte, the CD16+monocyte, or constitutes it’s own subpopulation 
with a physiological role distinct from these cells. However, it is conceivable that 
the fate and function of monocytes in vivo will depend on the physiological 
context. The remainder of this study considers only the CD14+monocytes and 
CD16+monocytes. 
 
1.2.5 Comparison with mouse monocyte subsets 
The CD14+monocyte and CD16+monocyte, by their CCR2 and CX3CR1 
expression, have been shown to be analogous to the two monocyte subsets 
described in the mouse; the Gr1+,Ly6Chigh,CCR2+,CX3CR1
low ‘inflammatory 
monocyte’ and Gr1-,Ly6Clow,CCR2-, CX3CR1
+ ‘patrolling monocyte’ respectively 
(57). More recently, genome wide expression analysis has confirmed this 
association (48). In the mouse, in inflammation, the Gr1+ monocyte can become 
a ‘TipDC’, producing TNF", nitrogen oxide and reactive oxygen species where 
the patrolling monocyte surveys the luminal side of vascular endothelium (58).  
 
1.3 Peripheral Blood DC 
PB DC, when freshly isolated, appear to be in an ‘immature’ state. They lack 
dendrites and the expression of maturation markers such as CD80 and CD83. 
Whether they have a specific function in blood is unknown, but it is unlikely that 
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they present antigen to T cells in this medium, as close cell-cell contact is 
required. It is therefore possible that these circulating cells represent a pool of 
immature DC, able to populate lymphoid or non-lymphoid tissues, where they 
may encounter antigens or maturation signals (59). 
 
1.3.1 Plasmacytoid DC 
This has been demonstrated in the case of plasmacytoid DC. They were initially 
identified as HLA-DR+ cells which, in response to virus, produce large amounts 
of IFN" (60), leading to the term ‘interferon-producing cells’ (IPC). After 
receiving maturation signals, they are able to enter LN directly from blood, 
through high endothelial venules, to prime T cells (61). However, they are either 
absent from, or found at only low levels in. healthy human peripheral tissues 
(62) (63). They can be positively distinguished from mDC by their expression of 
CD123, CD303 and CD304 and by their lack of CD11c, CD1c and myeloid 
markers CD13 and CD33. 
 
1.3.2 Myeloid DC 
Two mDC subsets circulate in blood; CD1c+DC and CD141high DC. In vitro, up-
regulation of maturation markers such as CMRF 44/56 and CD83 can be seen 
after incubation over night with serum, IL-3 and GM-CSF, and both subsets can 
induce T cell proliferation in an MLR (38) (64). However, they also show some 
features in keeping with a DC precursor status, such as the inability to mature in 
response to TNF"  (65), and the expression of early myeloid markers CD13 and 
CD33 (39).  
 
1.3.3 CD141high mDC as Cross-Presenter 
The CD141high mDC have recently been shown to be efficient at cross-
presenting antigen in response to TLR3 ligation (66) (67) (68) (69). This 
mechanism is thought to be specific to some DC subsets, including the murine 
CD8+ LN resident DC and dermal CD103+DC. A further similarity of these cross 
presenting cells is their expression of CLEC9A and XCR1. Whether a cell with 
cross presenting capacity exists in human tissues is unknown.  
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1.3.4 mDC as pre-tissue DC 
If PB DC are able to act as tissue pre-DC, it might be expected that cells of a 
similar phenotype would be found, even if transiently, in peripheral tissues. 
However, human tissue has never been examined in this way. As mouse 
counterparts to these circulating DC are less well recognised, comparison with 
mouse models may be misleading. The question as to whether cells analogous 
to circulating mDC can be found in normal human skin is addressed in Chapter 
3. 
 
1.3.5 Comparison with mouse blood DC 
Most studies of murine DC have concentrated on cells isolated in a relatively 
mature form from lymphoid tissues, due to the relative abundance of this tissue 
in comparison to mouse blood and non-lymphoid tissue. However, when blood 
was initially studied, two populations of immature DC were identified as 
CD11clowCD11b-CD45RAhigh cells resembling human pDC in morphology and 
production of type 1 interferons on stimulation, and CD11cintermediateCD45RA-
CD11b+ cells which developed DC-like morphology after 8hr culture and 
matured rapidly on contact with TNF", similarly to human mDC (70). In this 
paper, mouse ‘pDC’ and ‘mDC’ represented 0.025 and 0.07% of PBMC, 
respectively, in comparison with human 0.57% and 0.42% (unpublished). 
Another notable difference between species is the high expression of Class II 
on human PB DC but extremely low expression on these described mouse DC. 
CD11chighClass-IIhigh cells have not been found in mouse PB (31).  
 
1.4 Skin DC subsets 
Dissecting the DC subsets in human tissue has lagged behind studies in mice. 
Skin is the most easily and non-invasively accessible tissue from patients and 
relatively large quantities of normal material is available from that discarded at 
plastic surgery. For these reasons, skin is the chosen peripheral tissue for DC 
analysis in this work.  
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1.4.1 Langerhans Cells 
Epidermal Langerhans Cells (LC) were the first APC to be identified in 1868 by 
Paul Langerhans. Initially thought to be neuronal in origin, they were shown to 
be of haematopoietic origin in 1979 (8). They have a number of apparently 
distinguishing features including the expression of langerin, a C-type lectin and 
mannose receptor (71), and CD1a, a protein related structurally to MHC-Class I 
and involved in the presentation of lipid antigen (72). They contain Birbeck 
Granules, intracellular organelles associated with the endocytosis of langerin.  
 
1.4.2 Dermal Antigen Presenting Cells 
A recent paper from the laboratory describes three dermal myeloid APC when 
freshly isolated from digested tissue; CD1a+DC, CD14+DC and CD14+ 
macrophages (73). APC are identified as CD45+, HLA-DR+ and all express 
CD11c. The key to distinguishing between CD14+DC and macrophages in flow 
cytometry is the higher side scatter and inherent autofluorescence of 
macrophages, particularly in channels excited by the 488 laser, related to their 
ingestion of melanin. An important functional distinction between CD14+DC and 
macrophages is the ability of DC (including CD1a+DC) to migrate out of tissue 
in 40-72hr culture, while macrophages remain in the tissue ‘remnant’. Also 
present in digested dermis is a population of CD1abrightLang+ cells representing 
LC migrating from the epidermis, via the dermis, to draining LNs (74).  
 
1.4.3 Unidentified Dermal DC population 
When analyzing CD45+HLA-DR+AF- cells by CD14 and CD1a expression, 
populations of CD14-CD1a- and CD14+CD1a+ cells can always be seen. A 
similar phenomenon is observed in the differentiation of CD34+ progenitors to 
DC in vitro (75). Although the identity and physiological relevance of these 
populations are currently unknown, it is possible that division of skin DC by 
CD14 and CD1a alone may not be the most physiologically relevant system. 
This is particularly the case when considering the potential blood-borne cellular 
origin of these cells, where CD1a expression is not seen. 
Another complicating factor is the necessity for enzyme treatment and some 
time in culture to release the cells for analysis. Even with minimisation of both 
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parameters, it is possible that culture artifacts are introduced, such as 
alterations in antigen expression, particularly compared to PB that can be 
analyzed within an hour or so of sampling, with no enzyme treatment or culture 
steps. 
 
1.4.4 Mouse skin DC populations 
When mouse skin DC are selected as CD45+CD11c+Class-II+, two major 
subsets can then be identified as CD103+ and CD11b+. These populations are 
present in other peripheral tissues including lung, liver and kidney, but in all 
cases, cells negative for both CD103 and CD11b can be found (35). There are 
both functional and developmental distinctions between the two classified 
subsets as CD103+, but not CD11b+ DC, are able to cross present antigen and 
are dependent developmentally on Flt3L, inhibitor of DNA protein 2 (Id2) and 
IFN regulatory protein 8 (IRF8). How these subsets relate to the present 
classification of human skin DC and whether any as yet unidentified human 
functional counterparts to mouse DC exist is an area of intrigue. 
 
1.5 Langerin as a DC antigen 
The relationship between DC phenotype, function, origin, tissue location and 
species homology is one that continues to add complexity to the field. The idea 
that the expression of a specific marker may correlate to all of these may be 
misleading. Langerin expression, once considered to be specific to epidermal 
LC and preserved in mouse and man, is now recognised on additional and 
distinct murine populations of peripheral and lymphoid tissue DC.  
 
1.5.1 Langerin expression in murine tissues 
In the mouse, it was know that CD8-Langbright migratory LC could be found in 
skin draining lymph nodes. In addition, all lymph nodes, as well as spleen and 
thymus, contain a population of CD8+Langlow resident DC, distinct from 
migratory LC (76). This suggested that langerin expression was not specific to 
LC. In 2007 a number of groups published the description of murine CD8-Lang+ 
dermal DC (34) (77) (78), distinct from both epidermal LC and LC migrating 
through the dermis (79). Murine LC had previously been shown to self-renew 
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throughout life in steady-state (80) (81) but in transplant and parabiosis 
experiments CD8-Lang+ dermal DC were dependent on blood-borne precursors 
which traveled via the dermis to skin-draining LN where they formed a 
population of CD8-Langbright migratory DC. These cells were subsequently show 
to be CD103+ and of the same lineage derivation as CD8+Lang+ LN resident 
DC, by their reliance on IRF8 and Flt3 for differentiation and their ability to 
cross-present antigen (35). Whether Lang+DC, distinct from LC, exist in human 
tissue is unknown. 
 
1.5.2 Induction of Langerin expression in vitro 
Langerin expression can be induced on human CD34+ cells and PB monocytes 
in culture. Prior to the description of langerin, LC-like cells were identified by 
CD1a or E-Cadherin expression. Caux et al, cultured cord blood CD34+ 
progenitors cells for 12 days with GM-CSF and TNF" and found up to 50% 
CD1a+ cells, 20% of which were found to contain Birbeck Granules by electron 
microscopy (EM) conferring an LC-like phenotype (82). PB CD14+ monocytes 
cultured with GM-CSF, IL-4 and TGF# (83) develop LC-like characteristics of 
CD1a and E-Cadherin expression and the presence BGs. More recently 
Klechevsky examined langerin expression on in vitro derived LC-like cells; PB 
CD34+ cells cultured with GM-CSF, Flt3 and TNF" (75). A proportion of the 
resultant CD1a+ cells expressed langerin. However, in comparison to LC 
isolated from epidermis, both the CD1a and langerin expression were lower on 
the cultured cells. Similarly to isolated dermal CD1a+ DC and unlike LC, they 
had bright CD1c and CD11c expression and only very marginal expression of 
E-cadherin. These cultured cells, therefore, perhaps more closely resemble DC 
than LC, with the exception of langerin expression.  
 
1.6 The origin and homeostasis of tissue DC 
Understanding the origin of DC and how they are maintained in tissues, is 
critical to unraveling their role in disease and particularly to harnessing their 
therapeutic potential. The challenge is to map the ontogeny of migratory DC 
from the haematopoietic stem cell in BM, to circulating progenitors, to peripheral 
tissues and on to lymphoid organs. Understanding the conditions required for 
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these processes and how the steps are regulated will greatly increase the 
potential to manipulate DC for the purposes of immunotherapy. 
 
The study of human DC development is complicated by the scarcity of tissue 
available for study and the inability to perform specific manipulations in vivo. 
However, the development of several techniques has allowed the exponential 
expansion in the understanding of DC ontogeny and homeostasis over the last 
twenty years. 
 
1.6.1 Models of DC development 
Models of DC development that have enabled this process include: i) The 
discovery that bone marrow or peripheral blood CD34+ progenitors, and 
subsequently of human monocytes, can be differentiated into DC-like cells 
(moDC) in vitro (84) (43). This allowed not only the generation of large numbers 
of DC for functional or clinical studies, but also the initial mapping of cytokine 
requirements for DC differentiation. ii) The development of mouse models. 
Understanding of DC ontogeny at the cellular, cytosolic and genetic level has 
been hugely advanced by the use of genetic mouse models. Recombinant DNA 
technology facilitated the development of gene knock-out or knock-in models 
which have allowed the study of the effect of single genes on DC ontogeny (85). 
The ability to conditionally or constitutively ablate specific cell lineages has 
allowed studies of the kinetics of DC homeostasis (86) (76) (34) and genetic 
tagging has allowed tracking of cellular origins of APC (87). iii) Adoptive transfer 
of human progenitors to immune deficient mice allows the in vivo study of the 
differentiation of stem cells (88) (89) and more recent humanization of mouse 
models has increased the efficiency of this process (90).  
 
1.6.2 The Monocyte precept 
The precept that the monocyte is the immediate tissue DC precursor derived 
mainly from experiments showing the in vitro differentiation of monocytes to DC 
(43) (91). In vitro functional data showing phenotypic changes towards DC-like 
cells during reverse-transmigration (mimicking trafficking from tissue to 
lymphatic vessel) also lent weight to this argument (92).  
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Evidence to suggest that the monocyte may not be the immediate DC precursor 
was found through the bead-labeling of intracutaneous monocytes in a murine 
model. This showed that although labeled cells were found in draining lymph 
nodes they lacked some phenotypic features characteristic of classical 
lymphoid DC (93). Transfer experiments have shown that purified monocytes 
are unable to repopulate DC compartments in mice (94) (95). This inevitably 
leads to the questions; i) what is the tissue DC precursor? ii) at what point in 
haematopoiesis is it distinguishable from a monocyte precursor? 
 
1.6.3 Advances in murine biology 
Several observations in murine DC biology have suggested an alternative 
ontogeny of tissue DC. These include: 
1. The existence of committed DC precursors with separation of monocyte 
and DC lineages early in ontogeny. 
2. Differences in DC homeostatic mechanisms between steady-state and 
inflammatory conditions. 
3. Differential dependence of DC and monocytes/macrophages on growth 
factors. 
4. Selective effect of signaling molecule deficiencies on DC/monocyte 
subsets 
5. The seeding and maintenance of some macrophage populations directly 
from embryonic cells, prior to the development of the haematopoietic 
system. 
 
These observations suggest that steady-state DC homeostasis may be 
independent from the PB monocyte and that homeostatic mechanisms may 
vary between individual APC populations. They also highlight the necessity to 
distinguish between inflammatory and steady-state conditions in the study of 
DC ontogeny. How these observations relate to human DC biology is the focus 
of work presented here. 
 
1.7 DC ontogeny and the haematopoietic stem cell compartment 
In order to study haematopoietic lineage relationships, DC ontogeny may be 
traced back to the stem cell compartment. Studies of DC potential in mutant 
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mice have provided valuable insights into lineage dependence on, for example, 
transcription factors (33). However, the isolation of clonogenic precursors 
allows the direct identification of lineage relationships (96). These studies have 
challenged the basic concept of early segregation of myeloid and lymphoid 
lineages and allowed the mapping of populations with DC potential. 
 
1.7.1 Lymphoid versus myeloid DC development 
The categorization of human DC into myeloid and lymphoid subsets occurred 
early in attempts to classify these cells. Human plasmacytoid DC (pDC) were 
recognised as interferon producing cells (IPC) before their mouse counterparts 
were identified (97). They were labeled as plasmacytoid due to their 
morphological appearance and the presence of characteristic immunoglobulin 
rearrangements in a proportion of cells (98) and presumed to arise solely from 
lymphoid progenitors. The myeloid/lymphoid division of DC subsets was 
encouraged by in vitro culture experiments which revealed the myeloid DC 
potential of CD34+ progenitors and monocytes. IPC were not found in these 
cultures. This concept was in keeping with the classical description of 
haematopoiesis involving an early and irreversible division of myeloid and 
lymphoid lineages (Figure 1.5). 
 





Subsequently, murine studies have led to the questioning of this early 
myeloid/lymphoid divide in haematopoiesis (99), and, through the study of 
individual precursor populations, murine plasmacytoid DC were found to arise 
from apparently committed myeloid precursors (100) (101). A new model was 
therefore proposed whereby a myeloid progenitor (MP) gives rise to a 
macrophage dendritic cell progenitor (MDP) which gives rise to a common 
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dendritic cell precursor (CDP) and monocyte (102). The CDP may then produce 





However, the earliest murine precursors apparently committed to the lymphoid 
lineage (common lymphoid progenitors, CLP) have been found to have some 
myeloid potential and the ability to differentiate in mice to both myeloid and 
plasmacytoid DC subsets (104) (105). A link was made between lymphoid and 
DC ontogeny in humans cells as early as 1995 (106) when CD34+CD38+CD10+ 
cells with B, T and NK cell potential were also seen to differentiate to 
CD33+HLA-DR+ cells with DC-like morphology in liquid culture.  A second 
paper described the differentiation of DC, B and NK cells from a CD34+Lin-
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CD38- population (107). Here it was shown that 2% of single cells from this 
population could give rise to all three lineages in vitro. 
 
Authors of a more recent paper (89) have demonstrated the existence of a 
CD34+CD38-CD90-CD45RA+ MLP and shown that it can give rise to T, B, NK 
and CD33+CD11b+ myeloid cells, either CD14+ monocyte/macrophages when 
cultured with M-CSF, or DC-like cells if cultured with GM-CSF and IL-4. MLP 
were also able to give rise, albeit transiently, to B, NK cells and monocytes 
when transferred into a NOD-SCID mouse. In contrast to the MLP, a 
granulocyte macrophage progenitor (GMP) gives rise exclusively to myeloid 
(granulocyte and CD14+ monocyte/macrophage) colonies. From this, and in 
keeping with mouse models, was formed the hypothesis that there may be two 
routes of differentiation to monocyte or DC; the first via GMP and the second 
via MLP. Whether MLP plays a role in adult human monocyte or DC 
homeostasis, and in what relationship to GMP, is entirely unknown. (Figure 
1.7). 
 




The physiological relevance of the lineage derivation of mouse or human DC, 
differences in developmental mechanisms and functions, and implications for 
human disease are not yet clear.  
 
1.7.2 DC precursors in blood 
Although it is generally accepted that BM derived DC precursors enter tissues 
via blood in some form, the identification of these circulating pre-DC in mouse  
has caused some debate. These have most recently been identified as 
CD11c+MHC-Class-II-Flt3+ cells (28), representing 0.03% of PB cells and also 
present in mouse bone marrow, spleen and lymph node. However, previous 
study identified two mouse PB pre-DC populations, analogous to human pDC 
and mDC (70), discussed in 1.3.5. There is also discrepancy in the findings of 
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circulating early progenitor cells in mice. Despite the identification of 
haematopoietic stem and progenitor cells in mouse blood (108), circulating 
MDP and CDP were not specifically identifiable by Liu et al.. It is possible that 
the ability to identify small numbers of circulating progenitors is dependent on 
factors such as mouse strain, age or condition and also the kinetics of transfer 
of cells from bone marrow to peripheral tissue and half life of these cells in 
blood. 
 
Human tissue DC precursors are known to be bone marrow derived and blood 
borne from human allogeneic bone marrow transplant recipient studies (109) 
(73). However, which circulating cell population is responsible for repopulating 
tissues in this setting is not known. Candidates include PB monocytes or DC. 
However, unlike the mouse, circulating CD34+ progenitors are consistently 
found in resting human PB and it is known that culture of these cells can give 
rise to DC-like populations in vitro. The constituent subsets of this CD34+ 
population and whether these cells contribute to steady-state DC homeostasis 
in vivo is currently unknown. 
 
1.8 Inflammatory versus steady state DC precursors 
The observations that monocytes were not necessarily DC precursors in the 
steady-state, but that activated monocytes share many features with DC, such 
as high class II expression, the up-regulation of co-stimulatory factors (CD80, 
CD83, CD86) and the ability to stimulate an MLR, led to a re-examination of the 
derivation of DC in inflammatory conditions. 
 
1.8.1 Murine LC 
The concept that a different homeostatic mechanism for DC maintenance may 
be required during inflammation, as opposed to the steady-state, has been 
illustrated most effectively for the murine LC.  With the use of minimally 
perturbed bone marrow transplant and parabiosis models it has been shown 
that LC can be maintained through self-renewal in the steady-state (80). 
However, following depletion by uv irradiation, the epidermis is repopulated with 
LC derived from Gr-1highmonocytes (110). 
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1.8.2 Monocyte as an inflammatory-DC precursor 
Similarly to the monocyte dependence of LC repopulation following 
inflammation, there is evidence to suggest that monocytes play a role in DC 
differentiation in inflammatory conditions (111), reviewed in (112) and (31). One 
clear example is the murine Gr1high monocyte which can become a ‘TipDC’, 
producing TNF", nitrogen oxide and reactive oxygen species, and found only in 
inflammatory tissue, typically in response to Listeria monocytogenes infection 
(113). The development of TipDC is thought to be dependent on GM-CSF (31). 
For this reason, although it is unknown whether a similar inflammatory 
monocyte-derived DC exists in vivo in humans, parallels are drawn with in vitro 
derived moDC differentiated from CD14+monocytes in the presence of GM-CSF 
and IL-4. 
 
1.9 Growth factor requirement for DC differentiation 
The selective effect of a number of cytokines on DC or monocyte/macrophage 
differentiation and homeostasis is a further line of evidence that these two 
lineages are independently developed and regulated. Although this has mainly 
been examined in vitro for human cells, the therapeutic use of some growth 
factors, such as Flt3L and GM-CSF has allowed limited studies of APC 
following administration of these factors in vivo. Murine knock-out models have 
facilitated the in vivo study of the effects of single cytokine or cytokine-receptor 
deficiency. Several cytokines of key importance have been identified in this 




The initial observation that GM-CSF was required for differentiation of both 
human and mouse monocytes to moDC in culture (43) (114), suggested the 
dependence of DC on this cytokine. More recently it has been thought to have a 
prominent role in development of inflammatory DC (reviewed in (115), but may 
not be required for steady-state homeostasis. This is supported by the fact that 
mice lacking GM-CSF or its receptor have normal levels of DC in lymphoid 
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organs (116). GM-CSF administration to humans increases the number and 
cytotoxicity of monocytes (117) but DC have not been studied.  
 
1.9.2 Flt3 Ligand 
The dependence of DC on Flt3 and its ligand, in vivo and in vitro, is now well 
recognised. Mice devoid of Flt3 or Flt3L have low levels of pDC and mDC, 
despite normal monocyte numbers (118). The treatment of mice and humans 
with Flt3L leads to increased numbers of DC as well as monocytes and 
granulocytes (119) (120). This suggests the dependence of both plasmacytoid 
and myeloid DC on Flt3 signaling. Although monocyte expansion can be 
induced by Flt3L, this is in the context of a general myeloproliferation and these 
cells appear not to be dependent on Flt3 signaling for differentiation or survival. 
 
1.9.3 M-CSF 
In contrast, mononuclear phagocytes, including  monocytes, macrophages and 
osteoclasts, but not DC, are dependent on M-CSF (CSF-1) signaling. CSF-1-/- 
(Csf1op/Csf1op), and CSF-1-R-/- mice, among other abnormalities, have 
osteopetrosis and reduced numbers of monocytes and tissue macrophages 
(121). They also have reduced numbers of LC, but not lymphoid DC (110) 
(122). The presence of M-CSF in culture skews the differentiation of CD34+ 
cells and monocytes towards macrophages. 
 
1.9.4 Additional cytokines 
TGF# null mice show a selective deficiency of LC suggesting the dependence 
of this cell, but no other monocyte or DC subset, on TGF# signalling (123). A 
number of other cytokines, such as IL-4, TNF" and G-CSF may well have more 
subtle roles in DC homeostasis in vivo (33). 
 
1.10 Genetic control of DC development and homeostasis 
Cytokines mediated their effects through cytosolic signaling molecules and 
activation of transcription factors (TFs) which orchestrate gene transcription. 
Several TFs have been identified, mainly through the study of knock-out mice, 
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with importance in murine DC differentiation (reviewed in (33). Many of these 
are required for global DC development, such as STAT3 (124) but some have 
more subtle effects on specific DC subsets, including RelB, deficiency of which 
leads to massive reduction of CD8"-DC. Figure 1.8 summarises the effect of a 
number of knockout genes on bone marrow progenitors, DC subsets, 
monocytes and macrophages where known (125) (33). Rarely is information on 
all these APC compartments available.   Due to the dependence of steady-state 
and inflammatory DC development on Flt3L and GM-CSF signaling 




1.10.1 Flt3L and GM-CSF signaling pathways 
Flt3L and GM-CSF drive DC differentiation through STAT3 and STAT5 
signaling, respectively. Deletion of STAT3 in the haematopoietic compartment 
blocks Flt3L mediated DC differentiation, but not GM-CSF driven development 
(126). STAT5 directly inhibits IRF8 (and IRF7, SpiB and PU.1) and reduces 
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pDC development (127). Inhibition by STAT5 is hypothesised to control the 
balance between pDC and mDC. STAT5 will also activate IRF4 and this is 
shown to be the predominant route to GM-CSF stimulated DC differentiation in 
vitro, whereas Flt3L signaling relies predominantly on IRF8 (128). Another key 
TF in the signaling of these cytokines is PU.1. GM-CSF is unable to trigger DC 
differentiation in progenitors rendered PU.1 deficient (129) and Flt3L signaling 
up-regulates PU.1 expression (124), suggesting PU.1 is a critical TF for both 
GM-CSF-driven inflammatory and Flt3L-mediated steady-state DC 
differentiation (130).  
 
1.10.2 Integration of signaling pathways 
As can be seen in the case of Flt3L and GM-CSF signaling pathways, the 
physiological result of activation of a signaling receptor depends on the 
integration of intracellular signals with those of other pathways. The relative 
level of expression of a TF, for example compared to an antagonistic TF, may 
be as physiologically relevant as whether or not it is present or absent. Another 
example is seen in monocyte differentiation to either DC or macrophage, where 
a high expression level of PU.1, compared to a macrophage-driving TF (MafB) 
is required to induce a DC as opposed to macrophage fate (131). For this 
reason, results of knockout models may not be subtle enough to reflect true in 
vivo influences.  
 
This concept may also be relevant when considering signaling molecules as 
haematopoietic stem cell factors and differentiation factors. Early 
haematopoietic stem cells express Flt3 and it is becoming clear that progenitors 
previously described as early myeloid or lymphoid can both give rise to DC, yet 
not every early progenitor follows a DC differentiation path. Over-expression of 
Flt3, even in progenitors without inherent DC potential (such as MEP), leads to 
activation of down stream Flt3-associated genes such as STAT3, PU.1 and G-, 
M- and GM-CSF receptors and differentiation to mDC, pDC and 
myelomonocytic cells (124). Again, the differentiation outcome of Flt3 signaling 
may depend on the balance of signals received, PU.1 reduces the DNA binding 
capacity of GATA-1, a TF critical for megakaryocyte and erythroid development 
(132), and GATA-1 inhibits the binding of PU.1 to c-jun, a critical PU.1 cofactor 
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(133). It is therefore possible that physiological expression of Flt3 in 
haematopoietic progenitors permits differentiation of these cells to DC but the 
differentiation route taken depends on a balance of signaling from Flt3L and 
other lineage determining cytokines. 
 
1.10.3 DC-related TF mutations in human disease 
A few DC-related TF genes have been found to be mutated in human disease, 
usually in relation to malignancy. PU.1 and Flt3 mutations have been described 
in human AML (134) (135) and the involvement of the IKAROS gene in adult 
and childhood ALL is also recognised (136) (137).  
 
A small number of human germ line mutations affecting DC lineages have been 
recognised. Pitt-Hopkins syndrome is an autosomal dominant condition 
associated with mono-allelic loss of function mutations in E2-2, severe mental 
and motor dysfunction and abnormal craniofacial development. Analysis of pDC 
in this condition showed normal numbers of cells but abnormal phenotype with 
reduced CD303 expression and impaired IFN" production in response to CpG 
in vitro.  A similar phenotype was seen in E2-2+/- mice (138). 
Heterozygous STAT3 mutations are found in the majority of patients with 
Hyper-IgE syndrome, a rare disorder characterised by recurrent severe 
bacterial infections, eczema and variably with spontaneous fractures (139). 
However, the DC profile of patients with this condition has not be examined.  
 
1.11 Embryological origin of some macrophage populations 
One further potential ontogenic pathway for APC, specifically long-lived tissue 
macrophages, has its routes in embryogenesis. Prior to the development of 
definitive bone marrow haematopoiesis, fetal liver haematopoiesis or even the 
establishment of a circulatory system, haematopoietic cells can be found in the 
yolk sac. Yolk sac macrophages may migrate to tissues directly, or via blood 
once the circulatory system is established. 
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1.11.1 Microglia 
It has recently been shown in mice that microglia, the central nervous system 
resident macrophages, derive from yolk sac primitive myeloid progenitors that 
arise before the development of haematopoiesis, and can be maintained 
throughout life independently of blood-borne precursors (87). 
 
1.11.2 LC 
A similar concept has been proposed for epidermal LC (140). HLA-DR+ cells 
can be detected in embryological developing human epidermis as early as 6-7 
weeks gestation (141), and langerin expression detected after week 11 (142). In 
mice, ATPase+ LC-like cells are present in the subectodermal mesenchyme 
(future dermis) from as early as E10.5 and will migrate to the epidermis as soon 
as E16.5, prior to the development of bone marrow haematopoiesis, and show 
a similar phenotype to yolk-sac derived macrophages with a high proliferative 
index. They only acquire class II and langerin expression after birth. The 
contribution of fetal liver monocytes to this process is not clear. The hypothesis 
that the initial seeding of epidermis is with self-renewing, embryologicaly 
derived yolk sac cells which may then be supported by blood borne precursors 
during inflammation and/or in adult tissue, is yet to be proven.  
Whether this hypothesis holds true for any other tissue macrophage populations 
is also not known. 
 
1.12 Primary DC diseases in humans 
Disordered DC ontogeny or homeostasis as a primary human disease is 
recognised in only a few conditions.  These include two DC neoplasms, 
interdigitating DC sarcoma and pDC leukaemia/haematodermic neoplasm, and 
one condition of disordered DC homeostasis, Langerhans cell histiocytosis 
(LCH), the malignant nature of which is debated. Of these rare disorders, LCH 
is the most common and so is considered further. 
 
1.12.1 LCH 
LCH presents mainly in children but is also seen in adults. It is characterised by 
accumulations of Lang+ dendritic-like cells in single or multiple organs. These 
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‘LCH Cells’ are found in an inflammatory environment admixed with T cells, 
eosinophils, macrophages and neutrophils. It commonly affects skin, pituitary 
gland, bone, liver, lung and brain but may be found in any organ. The natural 
history ranges from a mild, single-organ, self-limiting disorder to a multi-systems 
potentially fatal disease. Treatment, when necessary, is with 
immunosuppressive, immunomodulatory or chemotherapeutic agents and may 
be required for a number of years. Late sequaelae, directly attributable to the 
disease, in addition to the side effects of treatment, may be seen particularly in 
the neurological system.  
 
Due to their langerin expression, it has been generally accepted that LCH cells 
derive from LC, despite their appearance in tissues where LC are not normally 
found. However, the discovery of Lang+ non-LC cells in mice, raises the 
question of the exact origin of LCH cells, particularly if langerin expression were 
found not to be specific to human LC. A number of critical questions remain 
unanswered in LCH: are LCH cells present as the cause or consequence of the 
LCH lesion?; how or why do they accumulate?; how do they interact with other 
cells in the lesion? Determining the origin of these cells is a critical step in the 
understanding of LCH pathogenesis and may potentially guide treatment 
strategies. 
 
1.13 Scope of the Thesis 
The primary aim of this work is to develop an integrated model of human DC 
ontogeny and homeostasis through the examination of BM, PB and tissue in 
health and disease. The key questions considered are: i) Is the homeostasis of 
peripheral tissue (skin) DC reliant on blood borne precursors in the steady-
state? ii) Which circulating cells are capable of supporting tissue DC 
populations? iii) Are human DC populations capable of self-renewal in steady-
state? iv) Can DC progenitors be traced back to the BM? v) What is the lineage 
derivation of DC and monocytes/macrophages? vi) How is DC development 
controlled genetically in humans? 
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1.13.1 Limitations of studies in humans 
The understanding of human DC biology lags behind that of the mouse and 
many hypotheses generated from murine studies have been difficult to test in 
vivo in humans, particularly under steady-state conditions. 
 
Studies of human DC are limited by material resources and the obvious inability 
to proactively manipulate physiology in vivo. However, comparisons between 
healthy and diseased tissue can allow inferences to be drawn and the study of 
DC homeostasis during specific treatments, such as haematopoietic stem cell 
transplantation, growth factor administration or treatment with small molecule 
inhibitors, are invaluable. 
 
Relevant particularly to DC ontogeny is the difficulty in humans of tracking 
cellular changes with time, as methods such as bead or fluorescent protein 
labeling of cells are not possible. Sampling tissues only gives a snap-shot 
impression and while serial sampling can give a broader picture, it requires 
more committed subject participation and still requires assumptions of cellular 
behaviour between sample times. The use of humanised mouse models to 
study human DC populations in vivo goes some way to overcoming these 
problems but cannot take into account the genetic variation encountered in the 
human populations, nor the range of environmental stimuli experienced. 
 
Much is yet to be learned about DC and progenitor populations in ex vivo, 
healthy, human tissues and the study of these cells in human diseases.  
 
1.13.2 The study of DC in Healthy human tissue 
Work in this thesis examines BM, PB and skin from healthy volunteers. This 
provides a snap-shot of cellular profiles in steady-state. Studies include the 
phenotyping and quantification of APC, and analysis of growth factor receptor 
expression, cell cycle, and mRNA expression patterns.  
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1.13.3 The study of DC in human disease 
In order to specifically probe the relationship between BM progenitors, human 
PB monocytes/DC and tissue APC populations, new human models, akin to 
mouse steady-state models, are required. A search was undertaken for 
subjects with spontaneous and prolonged monocyte or DC deficiency and a 
thorough analysis of BM, PB and tissue DC and their precursors was 
undertaken, together with investigation of immune regulatory mechanisms and 
a search for genetic mutations responsible for the phenotypes. 
 
Finally, following the identification of Lang+DC, distinct from LC in mice, a 
survey of langerin expression in human tissues is performed. Findings are 
extended to a study of Langerhans Cell histiocytosis (LCH) lesions. The identity 
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Chapter 2. Materials and Methods 
2.1 Cell isolation  
Human samples were obtained following informed consent and in accordance 
with a favorable ethical opinion from North Tyneside and North London 
Research Ethics Committees. 
 
2.1.1 PB and BM mononuclear cells and neutrophils 
Mononuclear cells from fresh blood were isolated according to standard 
protocols. Briefly, PB (in EDTA: Ethylenediaminetetra-acetic, or heparin) or BM 
(in EDTA) were diluted 1:2 and 1:4, respectively, Dulbeccos Phosphate 
Buffered Saline (DPBS) and layered over Lymphoprep (Axis-Shield Diagnostics 
Ltd.; www.axis-shield.com) then separated by density centrifugation, room 
temperature at 800g for 15 mins. Cells at the interface of lymphoprep and 
supernatant were removed and washed in DPBS (500g for 5mins) then again to 
remove platelets (200g 7.5mins). Cells were counted on Improved Neubauer 
Haemocytometer and viability assessed by trypan blue (Invitrogen; 
www.invitrogen.com) staining.  
 
Leukoreduction system filters were obtained in place of buffy coats from 
NHSBTS. These ‘cones’ contain white cells which are not returned to the 
subject after platelet apheresis. They contain up to 2 x109 total cells in 5-10ml 
volume, allowing the isolation of approximately 1.5 x 109 PMBC (143). To 
extract the cells, the cone is clamped above a 50ml falcon tube and the bottom 
tube of the cone is cut, allowing the contents to flow into the falcon. The cone is 
then flushed from the top with RT DPBS to a total volume of 40ml. The sample 
is then diluted 1:4 with DPBS and layered over lymphoprep before 
centrifugation and extraction of PBMC in the same way as for fresh blood 
(above).  
 
PB Neutrophils for DNA were isolated from the red blood cell (RBC) pellet. The 
majority of the red cell pellet, particularly the upper portion, was pipetted from 
underneath the lymphoprep and diluted 1:4 with DPBS. This was mixed with 
half the volume of 6% Dextran/0.9% NaCl, alliqoted into 15ml tubes and left to 
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stand for 1hr. The supernatant was then removed and spun, 40C at 500g for 12 
mins with slow brake. Supernatant was discarded and cells resuspended in 
12ml ice-cold distilled water for lysis of remaining RBC. After 20secs 4ml of 
0.6M KCL was added and then the solution diluted to 50ml with DPBS. This 
was spun at 600g for 6mins (40C). Lysis steps were repeated if RBC remained. 
Cells were then pelleted and frozen for later DNA extraction. 
 
2.1.2 Skin 
Control skin DC were isolated from 300µm dermatome sections of skin 
recovered from mammoplasty surgery. 4mm punch or shave biopsies were 
taken from subjects. Where necessary, epidermal and dermal sheets were 
prepared by digestion at 370C for 1hr with 1mg/ml dispase (Invitrogen; 
www.invitrogen.com) in RPMI (Roswell Park Memorial Institute; RPMI-1640; 
Sigma-Aldrich; www.sigmaaldrich.com). Sheets were then separated with 
forceps and washed in cold RPMI. Single cell suspensions were obtained by 
the digestion of dermal sheets or whole skin at 370C with 0.8mg/ml collagenase 
(Type IV, Worthington) and epidermal sheets with 0.6mg/ml collagenase, in 
RPMI with 10% Fetal Calf Serum (FCS) for 8 hours in a bacterial petri dish to 
prevent adherence of leukocytes. Alternatively, whole skin or dermal sheets 
were cultured at 370C, 5% CO2, in RPMI or X-Vivo 10, (BioWhittaker™; 
www.fishersci.com), or epidermal sheets in the same medium supplemented 
with 500U/ml GM-CSF (SagramostinTM) for collection of migrating DC. Viability 
of digested cells was usually >95% and of migrated cells >90% by DAPI (4,6-
diamidino-2-phenylindole; Partec; www.partec.com) or LIVE/DEAD® dead cell 
stain (Invitrogen; www.invitrogen.com) exclusion. 
 
For enumeration of LC by whole mount microscopy, epidermal sheets were 
fixed in acetone for 30mins and then rehydrated in DPBS for 20mins and stored 
at 40C. 
 
2.1.3 Cell sorting 
Fluorescence activated cell sorting (FACS) was performed using a BD FACS 
Aria (custom 100 mW 488 sapphire, 60mW 355 UV, 40 mW 640 red, 50 mW 
407 violet, 100 µm nozzle and 20 psi). Cells were stained as for flow cytometry, 
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washed and suspended in buffer (DPBS + 0.1% FCS + 2mM EDTA). Cells were 
collected in flow tubes or 1.5ml eppendorfs containing small volumes of RPMI, 
at 40C. Alternatively, skin DC from patient samples were sorted directly onto 
Shandon Cytoslides® (Thermo scientific; www.thermo.com), into a small drop 
of buffer for subsequent air-drying, fixation and FISH analysis. 
Cells for mRNA analysis were pelleted, lysed and stored at -800C in 350µl lysis 




Dermal fibroblasts (Fb) were isolated from punch or shave biopsies of skin. 
Deep dermis was digested for 12 hours in RPMI (Invitrogen; 
www.invitrogen.com), supplemented with glutamine, penicillin and streptomycin 
+ 10% FCS, with collagenase (0.8mg/ml collagenase D Roche; www.roche-
aplied-sciences.com). A single cell suspension was obtained by pipetting and 
was then washed in DPBS. Cells were resuspended in 500µl of RPMI + 20% 
FCS and transferred to a single well in a 24 well plate. This was incubated for 2-
4hrs at 370C then the medium replaced with fresh RPMI + 20% FCS. This step 
was repeated after incubation at  370C overnight and then cells left to grow with 
twice weekly replacement of medium. Once 80% confluence was reached, cells 
were sub-cultured to bigger tissue culture vessels.  
To sub-culture fibroblasts, medium was removed and cells rinsed with DPBS. 
Cells were covered with Trypsin/EDTA (Trypsin Versene Mixture, Lonza 
BioWhittaker; www.fishersci.com) for 5 minutes at 370C and then FCS, 1/3 the 
volume of Trypsin/EDTA, added to neutralise the trypsin. Cells were transferred 
to a universal container and washed with DPBS and re-plated at 2x105 cells in a 
25ml tissue culture flask, or 6x105 cells in a 75ml flask, in RPMI + 20% FCS. 
 
2.2 Phenotype analysis 
2.2.1 Flow cytometry and FACS sorting 
Multiparamater flow cytometry allows rapid and simultaneous analysis of 
differential antigen expression and physical properties to define populations of 
cells in suspension. Surface, intracytoplasmic and intranuclear antigens may be 
   
 47 
detected, in addition to quantitative assessment of DNA content. Modern 
instrumentation provides twelve or more fluorescent channels allowing the 
analysis of a corresponding number of antigens in a single tube. A panel was 
developed to identify, enumerate and analyse specifically monocytes, DC and 
CD34+ progenitors and allow comparison with peripheral tissue DC. A second 
panel catered for the analysis of lymphocytic cells.  
 
PBMC, BM and normal skin preparations, were stained in aliquots of 1x106 cells 
in 50µl of buffer (DPBS + 2% FCS+ 2mM EDTA; AnalaR®) according to 
standard protocols. For subject skin biopsies, all available cells were prepared.  
Flow cytometry was performed on LSRII cytometer (Becton Dickinson; BD) and 
data analyzed with FlowJo (Treestar).  
 
Antibodies were from BD unless stated otherwise and are denoted as: antigen 
fluorochrome (clone). CD1a FITC (NA1/34; Dako; www.dako.com); CD1a APC 
(HI 149); CD1c PE APC (AD5-8E7; MACS/Miltenyi Biotec), CD3 FITC PE APC 
(UCHT1) PerCPCy5.5 (SK7); CD4 FITC (SK3); CD8 APCCy7 (SK1); CD10 
APC (HI10a); CD11c APC V450 (B-ly6); CD14 PE PECy7 (M5E2) and 
QDOT605 (TuK4; Invitrogen); CD16 FITC PE PECy7 (3G8); CD19 FITC PE 
PECy7 (SJ25C1); CD25 PE PECy7 (2A3); CD34 APC (8G12) and APCCy7 
(581; Biolegend); CD38 PE-Cy7 (HB7); CD45 APCCy7 V450 (2D1); CD45RA 
FITC (L48) PE (HI100); CD56 FITC PE (NCAM16.2); CD90 Qdot605 (5E10; 
eBioscience); CD115 PE (61708; R&D Systems), CD117 PE (104D2), CD123 
PE (9F5); CD135 PE (4G8); CD141 PE (1A4), CD141 APC (AD5-14H12; 
MACS/Miltenyi Biotec), HLA-DR PerCP Cy5.5 (L243); Langerin PE (DCGM4; 
Beckman Coulter).  Intracellular staining with FoxP3 APC (PCH101; 
eBioscience) and Ki-67 PE FITC (B56) and corresponding isotypes, was 
performed with 2x106 cells/tube after fixation and permeabilisation with BD 
Cytofix/Cytoperm and Permwash reagents, according to manufacturer’s 
protocols. Absolute counting was performed using 50µl whole blood in BD 
Trucount™ Tubes according to manufacturer’s protocol. Dead cells were 
excluded by DAPI (4,6-diamidino-2-phenylindole; Partec; www.partec.com) or 
LIVE/DEAD® dead cell (Invitrogen; www.invitrogen.com) staining. True positive 
staining was confirmed with the use of isotype controls in a ‘fluorescence minus 
one’ system. 
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Antibody panels are shown in table 2.1 including PB DC panels, PB lymphoid 
panel, Skin DC and BM analysis panels. The blue series demonstrates the 




2.2.2 Immunofluorescence microscopy 
Modern epifluorescence microscopy with Z-stack capability can be used to 
determine accurately the absolute number of cells in small volumes of fixed 
tissue, giving additional valuable topographical information. The cellular 
distribution of antigen expression can also be observed. The combination of 
flow cytometry and fluorescence microscopy allows powerful analysis of small 
amounts of tissue. 
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Fluorescence microscopy was performed using a Leica TCS SP2 confocal 
microscope with HCX Plan Apo x40 NA 0.85 lens and PMTs running Leica LCS 
v2.61 software (www.leica-microsystems.com) or Zeiss Axioplan 2 microscope 
EC Plan-neofluar x40 NA 0.75 lens and Axiocam with running Ziess Axiovision 
v2.8 software (www.zeiss.com).  Separated epidermal sheets were fixed in 
acetone for 20mins and rehydrated in PBS for 20mins before staining.  The 
following primary or directly labeled antibodies were used: anti-CD1a FITC 
(NA1/34; Dako); anti-HLA-DR FITC (L243 or G46-6; BD), anti-Ki-67 (rabbit 
monoclonal SP6; Vector Laboratories) followed by Alexa fluor 555 conjugated 
goat-anti-rabbit IgG (H+L) (Invitrogen). Specimens were mounted in 
VectaShield containing DAPI (Vector Laboratories). 
 
2.2.3 FISH 
Cytospin slides of sorted PB populations at 10-20 thousand cells/slide were 
made and air-dried. These, or slides supporting directly sorted skin cells were 
fixed in Carnoy’s (methanol:acetic acid 3:1): 100µl of Carnoy’s pipetted onto 
slide and fluid contained by a circle drawn around the cells with ImmEdge 
Hydrophobic Barrier Pen (Vector Labs; www.vectorlabs.com). Slides were then 
air-dried before fixing again in Carnoys for 2mins in a coplin jar and again air-
drying. XY probe mix (Vysis CEP X SpectrumOrange and CEP X 
SpectrumGreen DNA probe kit; www.abbottmolecular.com) was combined with 
CEP buffer at 1:4 and 8µl of this was pipetted onto each slide and a 20x20cm 
coverslip applied. The edges of the coverslip were sealed with rubber glue. 
Denaturation (2mins at 730C) and hybridization (over night at 370C) was 
performed on a ThermoBrite Statspin Slide Hybridiser. After hybridization, 
coverslips were removed and slides placed in 2x SSC prior to 2mins at 730C in 
0.4x SSC. Slides were replaced in 2x SSC at RT for 1 minute before air-drying.  
Fluorescence was preserved with Vectashield + DAPI, coverslip applied and 
edges sealed with clear nail varnish. Slides were stored at 40C until analysis 
within 24-48hrs. Subsequently they were stored at -200C. 
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2.3 Molecular biology 
2.3.1 DNA preparation for neutrophils and fibroblasts 
Cell pellets (5x106-1x107 cells) were resuspended with 2ml of nuclear lysis 
buffer (400mM Tris – HCl, 60mM EDTA, 150mM NaCl, 1% SDS, in distilled 
water) and transferred to 15ml tubes. 0.5ml of 5M sodium perchlorate was 
added to each tube then rotary mixed at room temperature for 15 min to fully 
dissolve the pellet. Tubes were then incubated at 65ºC for 30mins prior to the 
addition of 2ml Chloroform. The resulting solutions were mixed for 10mins then 
cetrifuged to break the emulsion. The DNA containing phase (top layer) was 
transferred to a fresh 15ml tube and 2 volumes of pure ethanol were added 
down the side of the tube.  After gentle mixing the DNA was spooled onto a 
disposable microbiology loop and air-dried for 10mins. DNA was then dissolved 
off the loop in 0.2ml TE buffer (10mM Tris, 0.5mM EDTA) at 60ºC overnight. 
 
2.3.2 RNA and cDNA prep (CD34s) 
RNA was extracted using the Qiagen Micro kit (for <1x106 cells) as per 
manufacturer’s instructions. Briefly, 350µl of 70% ethanol was added to cells 
which had been lysed and stored in 350µl lysis buffer, mixed and pipetted onto 
RNeasy micro column (Qiagen RNeasy Plus Micro Kit; www.qiagen.com) in a 
2ml collecting tube, then centrifuged at 8000g for 15secs. 350µl of RW1 buffer 
was added to column and centrifuged for 15secs at 8000g. DNase in RDD 
buffer was placed directly onto the silica-gel membrane and incubated at RT for 
15mins. This was washed with RW1 buffer and then RPE buffer, centrifuging 
between each wash. 500µl 80% ethanol was added, followed by centrifugation 
for 2mins at 8000g then the membrane dried by further centrifugation. RNA was 
eluted from the membrane  with RNase-free water and RNA yield determined 
spectrophotometrically using a Nanodrop ND-1000 machine (Thermo Scientific; 
www.nanodrop.com).  
Single stranded cDNA was generated: RNA was denatured at 650C for 5 mins. 
cDNA mix was made: 5 x buffer from MMVRT kit (invitrogen, 
www.invitrogen.com) 166.25µl, deoxyribonucleotide triphosphate (dNTP) 
(Roche; www.roche.com) 50µl of each in 300µl RNase free water, Random 
Hexamers (Pharmacia, www.pfizer.com) 105µl, dithiothreitol (DTT) (from 
   
 51 
MMVRT kit). To each 10µl sample of RNA was added 11µl cDNA mix, 0.75µl 
moloney murine leukemia virus (M-MLV) reverse transcriptase (RT) enzyme 
(Invitrogen) and 0.38µl RNasin (Promega, www.promega.com). This was 
incubated at 37oC for 2hrs then denatured at 650C for 10mins. cDNA was 
stored at -200C until used. 
 
2.3.3 Quantitative real-time PCR 
QPCR was performed with TaqMan® Gene Expression Assays (Applied 
Biosciences; www.appliedbiosystems.com) according to manufacturer’s 
instructions. These assays contain a mix of two unlabeled PCR primers and 
one FAM dye-labeled TaqMan MGB Probe. Briefly, 2-5µl of cDNA was diluted 
with water to total volume of 9µl. 10µl of TaqMan Universal PCR Master Mix 
and 1µl of gene specific TaqMan Primer/Probe Mix were added to each sample. 
Each 20µl reaction was pipetted into a well of the MicroAmp® optical 96-well 
reaction plate (Applied Biosciences), sealed with an optical lid and run on 
7900HT Fast Real-Time PCR system (Applied Biosciences).  Each gene 
expression assay was plated in duplicate for each sample. Relative mRNA 
levels were determined using standard !! Ct calculations with expression 
levels of experimental samples normalised to GAPDH. 
 
Quantitative real-time PCR on LCH samples, langerin+ DC and LC (Chapter 7) 
was performed by Carl Allen in Texas (Dept of pediatrics, Texas Children’s 
Cancer Center and Hematology Service, Baylor College of Medicine, Houston 
TX 77030). Cells were isolated and stored RNA lysis buffer by the author, prior 
to dispatch to Texas. 
RT Q-PCR discussed in Chapter 6 was performed by the author and members 
of the laboratory (Naomi McGovern and Sarah Pagan). 
 
2.3.4 ELISA 
Quantikine® immunoassays (R&D Systems, www.rndsystems.com) were used 
for all cytokine ELISA tests (Flt3L, M-CSF, SCF). The assay employs a 
quantitative sandwich enzyme immunoassay technique whereby a monoclonal 
antibody specific for the cytokine is pre-coated onto a microplate. Samples are 
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added and any cytokine present is bound by the immobilised antibody. This is 
detected by adding an enzyme-linked polyclonal antibody specific for the 
cytokine, followed by a substrate solution which triggers a colour change in the 
presence of any cytokine. Tests were run according to manufacturer’s 
instructions. Briefly, standard curves were prepared using manufacturer’s 
supplied standard reagent for each kit. 10 control serums (from healthy 
volunteers) were used to determine normal ranges for each cytokine. Samples 
were tested neat and at 1:2, 1:10, 1:20 and 1:40 dilutions. Each sample was run 
in duplicate in 2 separate experiments.  
 
ELISA results discussed in Chapter 5 were obtained by the author and 
members of the laboratory (Naomi McGovern and Sarah Pagan). 
 
2.4 Statistical analysis 
Graphs were plotted with Prism Version 5.0a (GraphPad Software, Inc.). Mean 
and SD calculation, paired t tests and linear regression analysis were 
performed within the graphing software. All p values were two-tailed. 
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Chapter 3. DC profiling 
3.1 Introduction  
In order to study the homeostasis of human dendritic cells (DC) in health and 
disease, it was necessary to be able to identify and quantify, in absolute or 
relative terms, the DC and monocyte/macrophage subsets in human tissues. 
The most accessible human tissues included peripheral blood and skin.  
 
Methods were required that could i) positively identify monocytes and DC in 
peripheral blood (PB) and exclude cells extraneous to the analysis, ii) assess 
the potential of PB cells as pre-tissue DC, iii) enable the examination of 
peripheral tissue (skin) for the presence of cells analogous to blood 
components, iv) determine ‘normal ranges’ for PB and skin monocyte and DC 
subsets, against which to compare clinical samples, v) lend themselves to the 
analysis of limited clinical material. 
 
3.1.1 The necessity of lineage staining 
In the flow cytometric analysis of human peripheral blood DC, prior to the 
identification of specific DC markers, such as blood DC antigens (BDCA) 1-4 
(37), the exclusion of cells which could express HLA-DR was necessary. This 
was achieved by labeling surface antigens of these cells with the same 
fluorochrome so they could be excluded in a single fluorescence channel. Even 
with the advent of specific DC markers, the proportions of DC in peripheral 
blood mononuclear cells (PBMC) are so small (<1%), that exclusion of other 
cells prior to analysis greatly aids accuracy. Additionally, other cells may 
express DC markers, such as CD1c (BDCA-1) on approximately 50% of B cells 
(144) and CD304 (BDCA-4) on some activated T cells (145) and also reported 
on a subset of lymph node (LN) Treg cells (146). 
 
3.1.2 Lineage options 
The ‘lineage cocktail’ applied to exclude non-DC from the lineage-HLA-DR+ (Lin-
DR+) gate, and so the nature of the cells excluded, varies between publications 
(37) (38). B cell markers may include CD19 or CD20, NK and T cell markers 
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CD56, CD3, CD7, CD16 and the inclusion of CD34 is variable. Circulating 
CD34+ progenitors express medium levels of HLA-DR (at least equivalent to 
CD14+ monocytes) and so will be included in the DC gate unless specifically 
removed. In addition, most DC studies exclude monocytes from analysis with 
the addition of CD14 and CD16 in lineage. Although much attention has been 
directed at the necessity to exclude cells from DC analysis, less focus has been 
given to Monocytes/DC which could potentially be excluded from the Lin-DR+ 
gate due to positive lineage staining.  
 
3.1.3 Reports of myeloid cells in NK gates 
One group noted that myeloid cells could be found in NK cell gates when using 
CD16, CD56 and CD7 for NK cell identification (147). Lin(CD3/14/19)-CD56+ 
PBMC contained CD7+ NK cells and CD7- monocyte/DC, the identity of which 
remained unexplained. The expression of DC antigens on NK cells, particularly 
when activated, has been previously described and includes CD80, CD86, 
HLA-DR and CD4, reviewed in (148).  However, the expression of NK cell 
antigens on cells gated from a DC perspective has not. This analysis may 
reveal the identity of these mystery myeloid cells, without having to redefine 
them  phenotypically or functionally. 
 
3.1.4 Lin-DR- cells 
In the analysis of Lin-DR+ PB DC, the nature of cells which stain positively for 
lineage is well documented but cells which remain negative for lineage markers 
and are also HLA-DR- have not been characterised. As Lin-DR+ cells show a 
spectrum of HLA-DR expression, it is important to know what cells may be 
inadvertently included in the lower end of the gate and whether they express 
any DC-associated antigens which would be included in DC analysis. Also, this 
population, present in normal PB and not removed by Ficoll treatment, may be 
important in the analysis of PBMC in disease but without identifying these cells, 
this information would be lost. 
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3.1.5 Skin DC 
One of the aims of this work was to explore the relationship between blood and 
skin DC. No simple relationship was apparent with previous analytical methods.  
 
The markers used to classify skin DC, primarily CD1a and CD14, do not related 
to PB DC as there is no CD1a expression in PB. Conversely, the expression of 
BDCA markers in skin has not been investigated. Even with more advanced 
skin DC analysis (73), unclassified populations can be found, such as 
CD1a+CD14+ and CD1a-CD14- (double negative, DN) cells. In vitro culture 
reveals that both markers are inducible on monocytes and CD34+ progenitors, 
further complicating the direct comparison of PB and peripheral tissue 
leukocytes. In addition, extraction of single cell suspensions from skin requires 
greater tissue processing than extraction of cells from blood. Skin preparation 
requires either digestion of tissue, introducing enzyme-related artifacts, or 
migration of cells, introducing potential in vitro culture artifacts. Whilst these 
problems are impossible to eliminate, they must be taken into account in the 
analysis of results. 
 
3.1.6 Cross-presenting DC in blood and skin 
Recent interest in the PB CD141high mDC as a cross-presenting DC (149), 
analogous to the CD8"+ murine LN DC (66), and the identification of a 
functionally similar cell in mouse skin (35), begs the question of whether such a 
cell exists in human skin. Not only are these cells potent DC with the potential 
to control autoimmunity and protect against viral infection, but their distinct 
function and antigen expression profile may further the understanding of 
mouse/human DC homology. 
 
Elucidating the relationships between PB and tissue DC is a critical step 
towards explaining DC ontogeny and homeostasis. 
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3.2 Materials and Methods for Chapter 3 
3.2.1 Flow cytometry set up 
Using LSRII or FACSAriaII, PMT voltages were set on cells stained with single 
fluorochromes. Compensation was then performed using individual 
fluorochrome staining of compensation beads (BD CompBead anti-mouse Ig $) 
and adjusted manually using BD Diva software. Positive staining was confirmed 
with isotype controls for all tissues. 
 
3.2.2 Trucount Analysis 
To determine the absolute counts of leucocytes in blood (cells/µl), BD 
TruCOUNT Tubes were used. Each tube contains a known number of 
fluorescent beads in a lyophilised pellet which dissolves on contact with liquid. 
A known volume of whole blood is added accurately and leukocytes are 
identified by staining with conjugated antibodies. The resulting mixture is run on 
a flow cytometer after a red cell lysis step and thorough mixing. As the number 
of beads and cells analyzed can be counted, the corresponding volume of blood 
analyzed can be calculated and the number of cells/µl determined: 
 
(# cells counted/# beads counted) x (# beads in tube/test volume) = 
absolute count of cell (cells/µ l whole blood) 
 
Trucount tubes were stained with CD45, CD3, CD34 and CD14. CD45 was 
necessary in order to threshold on positively stained cells. Normally FSC 
parameter would be used for this purpose (to reduce the amount of noise or 
debris recorded by the flow cytometer as events) but as the beads are smaller 
than cells, a fluorescence channel is used for trucount tubes. CD3 allowed 
calculation of T cell numbers, CD14 of CD14+monocytes and CD34 of 
circulating progenitors. The relative proportions of PBMC cells analyzed in 
tubes containing any of these antigens could then be used to determine the 
absolute numbers of all cell populations. 
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3.2.3 PBSC processing 
PBSC from donors harvested after G-CSF administration was generally 
analyzed directly with no further processing steps. Where red cell contamination 
was evident, a red cell lysis step was performed using BD FACS lysing solution 
(10x) diluted with cold distilled water. This was applied to cells using 
approximately 1ml of diluted lysis solution per 1x107cells for 10mins at RT, 
followed by a wash in DPBS and subsequent staining in flow buffer. 
 
3.2.4 Skin Digestion at 40C 
Where described, dermis was digested at 40C. Skin was processed as 
described in Chapter 2 except that after addition of collagenase, it was left at 
40C overnight. Subsequently, it was placed at 370C for 3hrs to complete the 
digestion. The resulting cell suspension was treated the same way as 
previously described. 
 
3.3 Results I: PB Analysis 
3.3.1 PB APCs 
A 12 channel flow protocol was developed to allow, in a single flow cytometry 
tube, the identification and relative quantification of all DC subsets from PBMC 
(Figure 3.1, A), collected in a single ‘APC’ gate. Firstly, a gate was set on FSC 
and SSC to include PBMC and exclude residual red cells, platelets, neutrophils 
or debris (plot i) and doublets excluded using SSC-A v SSC-H (ii). A Lineage 
channel was used to stain T-cells (CD3), B-cells (CD19 and CD20) and NK cells 
(CD56). Cells within a Lin-DR+ gate were then selected (iii). From this classical 
(Gate 1), intermediate (Gate 2) and non-classical (Gate 3) monocytes were 
separated with CD14 and CD16 staining (iv). Cells negative for both these 
antigens (double negatives ‘DN’) include PB DC and CD34+ progenitors. pDC 
(Gate 4) and mDC were identified by their CD123 and CD11c expression 
respectively (v). mDC were then further split by CD141 (Gate 5) and CD1c 
(Gate 6) staining (vi). CD141high cells had slightly lower CD11c expression than 
CD1c+ cells (vii). Circulating progenitors were negative for both these markers 
and positive for CD34 (viii, Gate 7).  
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Further analysis of Lin-DR+CD34+ cells (Figure 3.1, B, ii) showed they were 
consistently CD45dim (red dots in iii) and, although HLA-DR+, they expressed 
lower levels of Class-II than PB DC (red dots in iv, compared to grey cells in Lin-
DR+ area of the plot).  Interestingly, when examining all CD34+ cells found in 
PBMC (i) small numbers of Lin+CD34+CD45bright cells were observed (black dots 
in iii and iv). Variability was noted in the proportion of CD34+ cells that were Lin+ 
but these cells could be found in all Lin+ areas of the Lin v DR plot and in all 
samples. 
 
In order to be able to identify all cells in the Lin v DR plot, the Lin-DR- gate 
(Figure 3.1, A, iii, gate 8) was analyzed. This contained a population of CD123+ 
cells with low FSC and SSC, negative for CD14, CD16, CD1c, CD11c, CD304, 
CD7 and CD10, but positive for CD33, CD13 and CD31 (Figure 3.1, C). 
Cytospin of these sorted cells showed lobulated nuclei with basophilic 
cytoplasm. These findings were consistent with the phenotype and 
morphological appearance of basophils. By FACs, cytospin and giemsa 
staining, the Lin-DR-CD123- material was found to be a combination of debris, 
small platelet clumps and red blood cells which had not been excluded by the 
initial ‘Cells’ gate. This material showed the lowest SSC and FSC profile of all 
events in the cells gate.  
 
The viability of freshly isolated PBMC was always >99% so a dead cell 
exclusion dye was not routinely included for this material. However, there was 
the flexibility to allow its inclusion for previously frozen material; either DAPI in 
the V450 channel (with CD11c in APC) or amine dye in the V500 channel (with 
HLA-DR in PERCPCy5.5 and CD123 in PE). 
 





True positive staining of antigens on all APC subsets in all tissues examined 
was confirmed with specific isotype controls. This is particularly necessary in 
the case of APC as non-specific and Fc-receptor binding can lead to false 
positive results if compared to other cell types and not isotype controls. Figure 
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3.2 shows the use of isotype controls in PB DC analysis. Here, one conjugated 
antibody per tube is switched for its relevant isotype whilst the remaining 
antibodies are unchanged, in a fluorescence minus one (FMO) system (Table 
2.1). This negates issues related to compensation when more than one 




3.3.3 Lineage delineation  
The use of Lin-DR+ gate to identify monocytes/DC relies on good separation of 
Lin+ and HLA-DR- cells from the gate, in order to exclude HLA-DR expressing 
lymphocytes and Lin-DR- basophils. A bright HLA-DR stain was the first step 
and although V500 (BD Horizon) was found to give the best separation this was 
only available in the last few months of work. Up to this point, and for the 
majority of work PERCPCy5.5 conjugated antibody was used. This ensured 
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sufficient distinction of HLA-DRbright CD123+ pDC from HLA-DR- CD123+ 
basophils. 
 
Staining of B, T and NK cells with specific markers not included in lineage 
allowed the identification of the position of these cells on the Lineage versus 
HLA-DR plot (Figure 3.3, A). CD19+ B cells, gated from total PBMC, stained 
brightly with lineage containing CD20 (black dots) which increased the 
separation of these cells from HLA-DR+ monocytes/DC (Figure 3.3, A). Note 
the comparison with the third plot in panel A (showing blue dots) where CD20 is 
not included in lineage. Here there is a cloud of DR+ cells in the centre of the 
plot which are B cells stained only with CD19. CD7 identified both NK and T 
cells (red dots), showing them to sit in the Lin+DR- area. Blue dots represent 
CD56+ cells gated from total PBMC. The CD56+ cells with the brightest lineage 
fluorescence are likely to represent a mixture of CD56+ T cells and CD56bright 
NK cells, and the Lin-CD56+ cells may be CD16- NK cells. The bulk of the 
CD56+ population shows lineage fluorescence in the middle of the axis. 
A proportion of both T and NK cells could express HLA-DR when activated. 
Populations of cells positive for CD7 or CD56 was also noted in the Lin-DR+ 
area, discussed below. 
 
In order to identify myeloid cells that may fall into NK cell gates when CD56 and 
CD7 were used as NK cell markers, the expression of these antigens on cells in 
the Lin-DR+ gate was examined. It was found that a proportion of CD11c+mDC 
(14% mean of n=3) and a small proportion (1.6% mean of n=3) of 
CD14+monocytes expressed CD56 compared to isotype control. In addition, 
17% (mean of n=3) of pDC and 11% (mean of n=3) of circulating CD34+ 
progenitors expressed CD7 (Figure 3.3, B). The addition of CD7 and CD56 to 
lineage cocktail increased the brightness of NK cells in the lineage channel and 
increased the separation from the Lin-DR+ gate (Figure 3.3, C) but lead to the 
exclusion of some DC from the Lin- gate. The variation in the shape of the Lin-
DR+ cell cloud in C compared to A is due to the respective presence and 
absence of monocytes in this population.  
 




3.3.4 Normal range of PB monocytes/DC relative to Number of cells 
analyzed 
In order to develop a normal range of monocytes/DC in PBMC, blood from 
twenty-six healthy adult volunteers (age range 24-55yrs) was analyzed. APC 
populations were expressed in relative terms as the percent of mononuclear 
cells (Figure 3.4). Mononuclear cells were defined as cells falling within both 
the initial ‘Cells’ gate (Figure 3.1, Plot A) and the subsequent ‘singlets’ gate 
(Figure 3.1, Plot B).  
 




3.3.5 Normal range of PB monocytes/DC in absolute terms 
Although a SSC v FSC gate is often used as an initial step in lymphocyte 
analysis, this is not possible for DC analysis as DC and monocyte subsets have 
a range of SSC and FSC profiles from the largest CD14+monocytes to the 
smallest CD34+progenitors (Figure 3.5, A). Therefore all cells must be included 
in the analysis of DC. 
 
In order to derive a normal range of absolute counts (cells/ml whole blood) for 
monocyte/DC subsets, an additional BD Trucount%tube of whole blood was run 
and analyzed alongside twenty-one normal samples. CD45 was included to set 
a threshold for flow cytometric data recording (only events falling in the CD45+ 
gate were counted). The inclusion of CD14 and CD34 allowed the proportions 
of cells in the DC tube to be derived and CD3 was required for quantification of 
lymphocytes as discussed below. As described in material and methods this 
allowed the determination of the absolute number of cells in each population 
(Figure 3.5, B). 
 





A second panel of conjugated antibodies was designed to quantify, by direct 
staining, the lineage positive fraction of PBMC (Figure 3.6, A), including CD19+ 
B cells (Gate 1), CD3+ T cells (Gate 2) and CD56+NK cells (Gate 3). CD4 and 
CD8 were included to differentiate T cell subsets (T cell Plot). In addition to 
identifying two populations of NK cells (CD56bright, Gate 3a, and CD56+) CD56 
could be used to identify activated CD56+ T-cells (Gate 4). CD45 was used to 
exclude debris as the initial ‘cells gate’ was close to where this material fell at 
the origin of SSC versus FSC plot. Also, unlike the analysis of DC where there 
is an additional positive (Lin-DR+) gating step to exclude other cells and debris 
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prior to quantification, without CD45, the cells gate would be the only gate 
before lymphocyte quantification.  
 
Again, populations were expressed both as percent of singlet cells in the 
lymphocyte gate (Figure 3.6, B), and as number of cells/ml whole blood 
through the BD Trucount%method (Figure 3.6, C). Inclusion of CD3 in the 
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3.4 Results II: Skin APC analysis 
3.4.1 Flow cytometric analysis of digested and migrated skin APC 
Figure 3.7 shows flow cytometric evaluation of APC populations digested and 
migrated from whole skin, dermis and epidermis. It was found that digesting or 
migrating thin sections of whole skin allowed isolation of all described 
populations of both dermal and epidermal APC, which could be then 
distinguished by flow cytometry.  
 
 
Leukocytes were identified by positive CD45 staining and APC by their 
expression of HLA-DR. Dermal macrophages containing melanin granules 
could be separated from DC by their autofluorescence (AF) in the FITC 
channel, without additional surface markers. This autofluorescence could also 
be seen in the other fluorescence channels. These cells were not capable of 
migration in vitro and so were not present in the cells of migrated preparations. 
From the non-autofluorescent populations several subsets of DC could be 
identified, including a population of dermal DC (DDC) expressing CD14 but 
lacking CD1a (Gate 1) and a population expressing CD1a but lacking CD14, 
CD14+DC (Gate 2). From whole skin a population of CD1abright, 
langerin/CD207+ (Lang+) cells could be found (Gate 3), representing epidermal 
LC. The autofluorescent macrophages from digested preps were CD14+CD1a- 
(Gate 4). A small number of CD1abrightLang+ cells could always be found in 
digested dermis and represented LC migrating through the dermis. 
 
It was found that digesting epidermis alone with the same concentration of 
collagenase as for whole skin or dermis resulted in unnecessary disruption of 
the epidermal architecture causing release of large numbers of keratinocytes 
into the medium, without increasing the numbers of available LC. Keratinocytes 
were found to non-specifically bind antibodies and complicate the flow 
cytometric analysis of LC. A similar problem was observed with the digestion of 
whole skin if the epidermis remaining after digestion was disrupted through 
pipetting. A reduction in collagenase concentration (to 0.5mg/ml) for digesting 
epidermis and care extracting cells from whole skin digests was found to solve 
the problems. 




3.4.2 Relative quantification of dermal APC 
For the study of DC from patient biopsies, the interest was primarily in 
quantifying the DC subsets. As dermis and epidermis from these samples 
would be analyzed separately, the dermis from twenty two controls was used to 
determine a normal range of APC populations expressed as the percent of live 
cells in the digested dermis (Figure 3.8). 
 




Initially attempts were made to quantify APC relative to fibroblasts present in 
the digested preps, using CD73 as a fibroblast marker. However, quantifying 
APC relative to total live cells gave comparative ratios and released a 
fluorescent channel for additional phenotype analysis. The use of shave 
biopsies, as opposed to punch biopsies, for clinical samples created a similar 
thickness of  sample to that of the normal skin preparations, so controlling for 
variations in APC density through the thickness of the dermis. 
 
3.4.3 Quantification of absolute numbers of LC in epidermal sheets 
In the epidermis, it was possible to quantify the absolute number of LC/mm2 by 
fluorescence microscopy (sections 2.1.2 and 2.2.2). Twelve Controls were 
analyzed to determine a normal range against which to compare patient 
samples (Figure 3.9). LCs within a minimum area of 0.3mm2 were included in 
each count. This equated to approximately three fields at x10 magnification. 
 




3.4.4 CD141high cells in skin 
In order to determine whether any cells with phenotypic similarities to PB mDC 
could be found in skin, CD141 and CD11c expression on skin DC was 
examined. A population of CD141highCD11clow cells was found in the DC gate 
(CD45+HLA-DR+AF-) of both digested whole skin and dermis (Figure 3.10, A, i). 
These cells represented 0.8-1% of all live cells analyzed (n=3 dermis; n=4 
whole skin) (B). Within this population there was a spectrum of CD1c and CD1a 
expression (A, ii, blue dots) up to the level of antigen expression seen in DDC 
(background grey dots). All 141high cells expressing CD1a also expressed CD1c 
while some CD1clowCD1a- cells were present. None of the CD141high cells 
expressed CD14 or fell in the CD1abright LC gate (A, iii). There was no langerin 
expression in this population, compared to isotype control (A, blue histogram 
Gate 1). Conversely, the population of CD11clowCD141low cells (A, Gate 2) 
expressed high levels of langerin and fell in the CD1abright gate (A, green 
histogram, Gate 2), identifying them as LC. The same populations were found 
in digested dermis, suggesting that these cells were not epidermal in origin. The 
only difference was the smaller number of LC in this preparation, as seen in all 
digested dermal preps. 
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CD141high cells were also found among DC migrated from skin, (shown in C 
plotted against CD1a) and displayed a similar spectrum of CD1a expression as 
cells from digested skin (C). However, in the migrated prep, CD14+ cells had to 
be excluded from the analysis (C, ii) as they expressed levels of CD141 akin to 
the CD141high cells (C, blue histogram, Gate 3a). This is examined further in 
section 3.4.6. Once these cells were removed, CD14-CD141high cells could still 




3.4.5 Comparison of CD141 expression in Skin and Blood DC 
If PB mDC can contribute to skin DC homeostasis, it is likely that cells 
phenotypically comparable to PB mDC would be found in skin. As CD141high 
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cells have been identified in skin, a direct flow cytometric comparison of CD141, 
CD11c, and CD1c expression was made between blood mDC and skin DDC 
(Figure 3.11). As there was no CD16 or CD123 expression in skin, cells 
expressing these markers in blood (CD16+monocytes and CD123+pDC) were 
excluded from the PB analysis. CD11c+CD141highCD1c- and 
CD11c+CD141neg/lowCD1c+ cells could be found in both tissues. When 
CD1a+cells were excluded from the skin analysis (DN DC were gated), the 
proportions of the two mDC populations in skin became very close to the 
proportions found in PB. As there is no CD1a expression on PB mDC, this 
comparison is perhaps more relevant to identifying cells which may have 
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3.4.6 CD141 up-regulation in blood and skin 
As CD141 appears to be a critical marker in the identification of a specific 
subset of cross-presenting DC, it’s expression by other cells in PB and skin was 
important to examine. In addition, during the preparation of skin, enzyme 
digestion may remove sensitive antigens and the short culture step (overnight 
at 370C) may be sufficient to induce expression of some antigens. 
 
In blood, all monocyte/DC subsets were found to express CD141 at a lower 
level to CD141highmDC. (Figure 3.12, A, black histograms compared to grey 
isotype control). However, it was noted that PB cells that had been left 
overnight in EDTA at room temperature before PBMC isolation, for example 
during transport, expressed higher levels of CD141 (A, red histograms). Neither 
the proportion of CD141highmDC, nor the level of their CD141 expression was 
altered under these conditions. 
 
Similarly, in skin, all APC, including dermal macrophages, showed some 
expression of CD141 compared to isotype control after overnight collagenase 
digestion at 370C (B, red histograms). To determine whether preparation 
conditions affected the level of CD141 expression, half of the same skin 
preparation was collagenase digested overnight at 40C, followed by 3hrs at 
370C to complete the digestion (B, black histograms). The level of CD141 
expression on DC and macrophages was lower after digestion at 40C than 
370C.  However, the expression of CD141 by the CD11clow cells was reduced in 
the dermal preparation digested at 370C. This resulted in the histogram of 
CD141 expression for these populations showing only one peak. However, the 
cells could still be distinguished by their level of CD11c expression (C) 
Interestingly, preservation of CD141 expression on these cells was observed in 
skin digested whole at 370C, possibly due to protection by the epidermis.  
 





Through the development of techniques to enable the profiling of PB and skin 
DC a number of important biological observations have been made. These are 
critical not only to the ability to accurately identify DC but they also have direct 
relevance to the study of DC ontogeny and homeostasis. Most important of 
these is the observation that cells analogous to PB mDC can be found in skin. 
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3.5. Identification of PB DC  
In practice, the DC profile panel was developed over the course of the project 
as issues, such as the brightness of HLA-DR, came to light. The necessity to 
have a bright channel (PE or APC) available for the staining of other antigens of 
interest, whilst conserving the ability to positively identify all PB DC subsets, 
lead to the omission of CD1c when necessary. An additional advantage of the 
final set-up is the common use of PE and APC as commercially available 
conjugates for antigen specific antibodies. In fact, a recent paper (36), 
published after development of the PB flow cytometry panels used in this study, 
shows an example of how flow cytometry panels can be expanded to include 
the simultaneous analysis of up to 12 different antigens. 
 
However, as well as allowing the creation of normal ranges specific to the 
reagents and techniques used here, enabling direct comparison of clinical 
samples and controls, the development of the panel has facilitated in a number 
of key observations, discussed below.  
 
3.5.2 Identification of myeloid cells expressing NK cell markers. 
CD7 is an antigen present on NK and T cells. In the recent paper by Milush et 
al., (147) it was used to distinguish between CD56+ NK cells and CD56+ 
‘myeloid cells’, This was necessary as activated NK cells can also express DC-
associated markers such as HLA-DR, CD4, CD80 and CD86. This group 
showed that CD56+CD7- cells had myeloid characteristics including CD33 and 
CD13 expression, and the FSC and SSC profile of lymphocytes in flow 
cytometric analysis. Examining the expression of CD56 cells from a DC 
perspective revealed that these cells are CD11c+mDC, approximately 15% of 
which express CD56.  In keeping with previous reports of CD56 expression on 
small numbers of both freshly isolated CD14+monocytes and those in culture 
(150) (151), CD56 expression was identified on 1.6% of CD14+monocytes. In 
addition the data show that CD34 and CD123 should also be included in 
lineage for NK cell analysis which relies on NK expression of CD7 as a 
proportion of both these cell populations also express CD7. 
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From a DC analysis perspective, although the addition of CD7 to the lineage 
cocktail increases the separation of NK cells from the Lin-DR+ APC gate, and 
therefore reduces the likelihood of CD16+DR+ NK cells falling in the 
monocyte/DC gate, the loss of CD7+pDC to the Lin+ area of the plot precludes 
it’s routine use as a lineage marker. Although some mDC express CD56, this 
expression is relatively dim and so it was still possible to include these cells in 
the Lin-DR+ gate with CD56 in lineage. Compared to other NK cell markers, 
CD56 in lineage was the least disruptive to monocyte/DC analysis, as the 
inclusion of CD16 would have largely prevented analysis of CD16+DR+ cells. 
 
The observation that some NK cells, as well as B cells, share antigens (for 
example CD11c) in common with DC is of interest. Functionally, DC and B cells 
are both professional APC. NK cells have been shown to have the ability to 
present antigen in the context of MHC-Class II (152). Although not without 
controversy, a mouse cell co-expressing markers associated with DC and NK 
cells has been designated as an interferon producing killer dendritic cell (IKDC) 
(153). Whether human DC expressing NK markers might have a similar role is 
not known. In order to determine whether these cells have a specific 
physiological role, further phenotypic and functional work is required. 
 
The reports of DC arising from a common lymphoid progenitor suggest that at 
least some of these cells may share an origin with NK and B cells. This will be 
discussed further in Chapter 5. 
 
3.5.3 Normal ranges 
Normal ranges for PB subsets were developed to allow the comparison of 
clinical samples with normal controls, with the specific techniques and materials 
used in this work. Whilst quantifying cells populations, as a proportion of cells 
analyzed is sufficiently accurate for normal controls, as soon as numbers of 
specific populations become altered in clinical samples, the comparisons 
become less valid. 
 
In terms of DC analysis, this is particularly the case if the number of 
lymphocytes changes, as this affects the denominator. Although it can be 
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argued that this form of analysis still reflects important quantitative relationships 
between immune cell types, to negate the problems encountered in relative 
values, a normal range based on actual cell counts per ml of blood was also 
derived. 
 
However, when analyzing small populations in PB, it is not practical to work with 
whole blood as there are so many cells extraneous to the analysis. For this 
reason the Trucount™ method was used to convert counts in whole blood to 
counts in PBMC. The assumption, inherent in the use of the Trucount™ 
method, is that Ficoll treatment results in isolation of PBMC populations in 
equivalent proportions to whole blood. This allows the absolute count of one cell 
type in the Trucount™ tube to be used to determine the absolute count of all 
others cells in PBMC according to their compositional proportions. However, 
providing patient samples are processed in the same way as control samples, 
both the relative and absolute normal ranges will be valid for comparison 
between the two. 
 
3.5.7 The identification of novel DC subsets in skin 
The novel finding of CD141highCD11clow cells, comparable to PB 
CD141highmDC, has been described in digested and migrated skin and is of 
particular interest in relation to peripheral tissue DC homeostasis. Unlike the PB 
CD141highmDC, the skin population includes cells with a spectrum of dual 
expression of CD1c and CD1a. As CD1c-CD1a- cells are also present within 
this population, and the staining pattern of both antigens is a spectrum from 
negative to positive, it is tempting to speculate that these could be blood 
derived mDC which acquire CD1c and CD1a on entry to the skin compartment. 
Without longitudinal studies to examine the acquisition or loss of antigen 
expression, it is impossible to be sure whether CD141high cells are gaining or 
loosing CD1a and CD1c expression, but the presence of these antigens on the 
majority of dermal DC makes the latter less likely. Further work is needed to 
characterise these cells, in particular whether, like their potential PB 
counterparts, they express CLEC9A and XCR1 and are capable of antigen 
cross-presentation (68) (66).  
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What has not been formally excluded in this analysis is whether the cells 
identified in digested skin preparations could be from PB contamination. 
However, this is unlikely, at least as a non-physiological process, as other 
constituents found in PB, such as B cells and pDC, which represent greater 
proportions of PBMC than mDC, are not found in these skin preps. 
 
3.5.8 Level of CD141 expression on skin DC subsets 
Although the CD141highCD11clow cells can be detected in digested dermis and 
whole skin, the level of CD141 expression on these cells is lower in dermis 
digested alone, even though CD141 is still expressed up to a similar brightness 
on the other DC subsets. A possible explanation for this is that there are two 
competing forces determining CD141 expression in this setup: firstly, the 
overnight culture at 370C allows up-regulation of CD141 on DDC; secondly, 
there is some collagenase sensitivity of CD141 expression on the CD11clow 
cells. The presence of the epidermis in the whole skin digest may provide 
protection against collagenase digestion of the CD141 antigen on the CD11clow 
cells, either physically or through cell-cell or soluble factor communication.  
 
CD141/BDCA-3 is also known as thrombomodulin. In the clotting cascade, this 
protein acts as an anti-coagulant through its action as a cofactor in the thrombin 
induced activation of protein C. However, its role in DC biology is completely 
unknown. As such, the physiological relevance of this marker on cross 
presenting DC and the mechanism and consequence of CD141 up-regulation 
either in cultured skin or older PB cells remains to be determined. 
 
3.6. Further work 
3.6.1 PB DC and NK cell biology 
The functional relationship between DC and NK cells, particularly those DC 
expressing NK cell markers, is of interest. Whether these cells express other 
‘NK cell specific’ markers, such as Killer-cell immunoglobulin-like receptors 
(KIRs), NKp46, NKG2 and NKG2D will be explored. Whether these cells have 
any specific physiological role, or any similarities with mouse IKDC, such as 
type 1-IFN or IFN! production can be investigated. 
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3.6.2. Characterization of skin DN DC 
Work will aim to further characterise the skin DN DC including the CD141high 
and CD11c+ cells. As this DN population potentially houses the blood-derived 
DDC ‘precursors’, phenotypical and functional comparisons will be made 
between these cells and PB DC through the examination of mRNA and antigen 
expression levels, including TLRs, CLEC9A, XCR1 and GFRs. In addition, their 
anatomical positioning within the dermis, their ability to enter the cell cycle and 
to cross present antigen will be explored. 
 
   
 79 
Chapter 4. DC ontogeny and Homeostasis in Health 
4.1 Introduction 
There are three distinct but overlapping potential compartments of steady-state 
DC development. These have not been clearly mapped in vivo in humans. 
1. The bone marrow haematopoietic progenitor compartment 
2. Circulating ‘pre-tissue DC’ progenitors 
3. Progenitors which replenish DC from within tissues 
4.1.1 DC Precursors in BM 
As discussed in Chapter 1, there has been some progress in mapping steps in 
murine DC haematopoiesis, but fewer successful attempts to dissect the human 
CD34+ DC progenitor compartment. 
 
The study of haematopoietic progenitors is a massive field, which is 
approached from every angle of biology, including work ranging from 
inflammatory disease and malignancy to aging and regenerative medicine. 
Even studies specific to DC ontogeny show some conflicting or at least 
incompatible results, due in part to lack of common nomenclature, varying in 
vitro and in vivo techniques and different cellular endpoints. Most recently, the 
description of a myeloid/lymphoid split later in haematopoiesis than originally 
thought has allowed a paradigm shift of understanding of potential routes of DC 
development (100) (104). The identification of TF important in DC differentiation 
in mice has fueled an expansion in the understanding of signaling pathways 
necessary for DC development and expanded the options for identifying DC 
precursors (33).  
 
As studies in human DC ontogeny are not as far advanced, it was necessary to 
find a starting point from which to develop the analysis of human CD34+ DC 
progenitors in health and disease. The recent study by Doulatov et al., (89) 
provided a manageable protocol, applicable to small clinical samples, and had 
the advantage of an accompanying in vitro functional analysis of each CD34+ 
progenitor subset, establishing which subsets had monocyte/DC potential. This 
study identified in human cord blood and adult bone marrow of two CD34+ 
populations able to give rise to DC; the MLP (multilymphoid progenitor) and the 
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GMP (Granulocyte monocyte progenitor). Whether these cells play a role in 
human DC homeostasis in vivo, and in what relationship to each other, is 
unexplored. 
 
4.1.2 Circulating pre-tissue DC progenitors 
Whilst it is assumed that tissue DC rely on blood-borne precursors to maintain 
their numbers, the identity of these precursors is unclear. The monocyte has 
previously been considered the most likely candidate in part due to its ability to 
differentiate into DC-like cells in vitro (43).  However, it is becoming more 
generally accepted that its role as a DC-precursor in vivo may relate only to 
inflammatory environments, possibly under the control of GM-CSF (112).  
 
Identifying the steady-state circulating DC precursor is therefore critical. Exactly 
which PB cells have the potential to become tissue DC, and under what 
conditions, remains undetermined. Either or both mDC subsets (CD141high or 
CD1c+) could reasonably be proposed as tissue DC precursors. Data from the 
previous chapter showed the presence of phenotypically similar cells in human 
skin. mDC have the ability to migrate across endothelium in vitro, without any 
chemotactic stimuli (154) and they express CLA (cutaneous lymphocyte 
antigen), a molecule responsible for T cell homing to skin via interaction with 
ELAM-1 on endothelial cells (155). In comparison, pDC, although they express 
CLA, require chemokine stimulation for migration across endothelium and have 
not been identified in non-lymphoid healthy peripheral tissues.  
 
CD34+ progenitors circulate in human PB in steady-state. They are HLA-DR+ 
and known to have DC differentiation potential from in vitro culture systems. It 
has also been noted that a subset of these cells express CLA (156). Whether 
this population contains cells with the capacity to replenish tissue DC in vivo is 
unknown. However, the observation in mice that CD34+ cells circulate from BM 
via blood to extramedullary tissues, where they are able to proliferate within 
tissues and differentiate into myeloid cells, including DC (108), suggests that 
the DC potential of circulating human CD34+ progenitors is worth examining.  
 
   
 81 
The phenotyping of these cells in a comparative fashion to BM CD34+ 
progenitors, in un-stimulated, steady-state PB, has not been undertaken but 
would go some way to assessing their potential as pre-tissue DC.  
 
4.1.3 Growth factor (GF) receptor expression 
One simple way to determine lineage relationships between cells may relate to 
their growth factor receptor expression profile. The observation of the 
differential dependence of DC and monocytes on Flt3 and M-CSF signaling 
respectively, suggests that the expression of receptors for these cytokines may 
be helpful in determining relationships between DC and monocyte subsets in 
different tissues. Direct comparison of GF receptor expression on PB and skin 
APC has not been made. 
 
4.1.4 Local self-renewal of DC populations 
Another potential mechanism for the maintenance of tissue DC is the local 
proliferation of DC or their immediate precursors. This may either reduce the 
dependence on, or requirement for, blood-borne precursors for tissue DC 
homeostasis, or render the population independent of the bone marrow entirely, 
at least in the steady-state. Murine LC have been shown to be maintained in 
steady-state through self-renewal and independently of the BM. Evidence 
shows that a proportion of tissue DC populations are also in cell cycle (reviewed 
in (157)).  
  
Whether human tissue DC or potential pre-tissue DC are in cell cycle, or have 
the potential to enter cell cycle, has not been examined systematically in skin or 
PB.  
 
4.2 Materials and Methods for Chapter 4 
4.2.1 Antibodies use in the Flow cytometric analysis of CD34+ progenitors 
Table 4.1 shows the fluorochrome panel used for the flow cytometric analysis of 
CD34+ progenitors. It was necessary to have the flexibility to add a dead cell 
dye as previously frozen clinical samples were analyzed. Cells were stained at 
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a concentration of 1-2 x 106 cells in 50µl of flow buffer. Antibody volumes used 
in this staining volume were as follows: CD45RA, 1µl; CD34, HLA-DR, CD38, 




The major technical concern encountered was the difficulty of compensation 
between CD14 Q605 (488/610) and the PE channel (532/585), despite the use 
of the blue and green laser respectively, as the Qdot is excited by all lasers. 
This meant it was critical to include FMO isotype in the PE channel for any new 
PE-conjugated antigen to detect and confirm, in particular, small shifts in 
fluorescence intensity. 
 
4.2.2 Cell cycle analysis by Ki-67 and DNA content staining 
PBMC or skin cells from digested skin in a single cell suspension were surface 
stained as previously described. After staining, cells were washed in flow buffer, 
pelleted and mixed with 200µl of BD Cytofix/Cytoperm solution. This was left for 
20mins at RT in the dark before washing in diluted 10x BD permwash buffer, 
and resuspending the pellet in BD Cytoperm Plus buffer, 200µl, for 10mins on 
ice, washing in permwash, resuspending again in BD Cytofix/Cytoperm solution 
for 5mins at RT in the dark and a further permwash. Pelleted cells were 
resuspended in 50µl of permwash, blocked for 10mins with normal mouse 
serum, and stained with Ki-67 or isotype control at 40C in the dark. Cells were 
washed again in permwash and then resuspended in flow buffer containing 1:4 
DAPI (Partec), prior to analysis on flow cytometer. Other methods, such as 
ethanol fixation and Caltag reagents (www.caltagmedsystems.co.uk), were tried 
for intracellular staining, but the BD reagents were found to give the best 
preservation of surface staining and autofluorescence in macrophages. Figure 
4.1 shows a diagrammatic representation of the stages of the cell cycle (A) from 
Thermo Scientific; SJ Hong and how this relates to the phase of cell cycle as 
described by Ki-67 staining and DNA content analysis, Panel B.  





4.2.3 Ki-67 staining of epidermal sheets 
Fixed epidermal sheets were stained with anti-Ki-67 (rabbit monoclonal SP6; 
Vector Laboratories) at 1:200 in 100µl DPBS+0.1% Triton, overnight at 40C. 
This was then washed in DPBS+0.1% Triton in a 6 well plate for 40mins. Alexa 
fluor 555 conjugated goat-anti-rabbit IgG (H+L) (Invitrogen) was added at a 
concentration of 1:500 with anti-CD1a FITC (NA1/34; Dako) at 1:10 in 100µl of 
DPBS. A further 40min wash in DPBS was performed before mounting the 
sheet in a drop of VectaShield (Vector Laboratories) containing DAPI, with 
dermis side of the epidermis facing upwards and covering with a coverslip.  
 
4.2.4 Amine dead dye 
Where the V450 channel was used for antigen analysis, in place of DAPI, 
Invitrogen LIVE/DEAD® fixable dead cell stain was used (www.invitrogen.com), 
aqua yellow in the V525 channel. As this stains cellular amines, with greater 
uptake in dead cells where permeation of the compromised cell membrane 
allows intracellular staining, it cannot be used in the presence of any protein or 
antibodies. Cells therefore have to be stained with amine dye, in plain DPBS, 
prior to fluorescent antibody staining of surface (or intracellular) antigens. After 
cell isolation and washing, cells were resuspended at a concentration of 1x106 
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cells in 1ml DPBS and 1µl of amine dye added. This was incubated in the dark 
at 40C for 30mins before washing in DPBS. Cells were then resuspended in 
flow buffer (containing 2% FCS) and surface or intracellular staining performed 
as previously described. 
  
4.3 Results I: Stem Cell compartment/CD34+ Progenitors 
A basic understanding of the haematopoietic stem cell compartment is a critical 
step in tracing DC ontogeny. It was necessary to be able to identify cells within 
the CD34+ compartment thought to have DC potential as previously defined, 
and the method published by Doulatov et al., (89) was adopted for this purpose. 
This then allowed comparison of CD34+ subsets in BM and PB to identify the 
DC-potential contained in the circulating population, and later with populations 
in human disease. 
 
4.3.1 Identification of CD34+ progenitor subsets in Bone Marrow, resting 
Peripheral Blood and G-CSF mobilised peripheral blood. 
The first tissue analyzed was BM. The gating strategy for identification of CD34+ 
subsets is shown in Figure 4.2, BM. A CD45+ gate was used to exclude 
material such as debris, red cells and platelets. The CD34+ cells were then 
selected (Gate 1). Gate 2 defined CD38+ cells and was arbitrarily but 
consistently set to include 25% of CD34+ cells. This was found to include the 
majority of relevant cells and gave the most consistent results across normal 
controls (n=6). Gate 3 defined CD38- cells and again was arbitrarily but 
consistently set to include 17% of CD34+ cells. From the CD38+ cells B/NK 
progenitors were classified as CD10+. The CD10- cells (Gate 4) could be further 
subdivided into CD45RA-Flt3- Megakaryocyte erythroid progenitors (MEP), 
CD45RA-Flt3+ common myeloid progenitor (CMP) and CD45RA+Flt3+ 
granulocyte monocyte progenitor (GMP). From the more primitive CD38- cells, 
Haematopoietic stem cells (HSC) were gated as CD45RA-CD90(Thy-1)+, Multi-
potential progenitor (MPP) as CD45RA-CD90- and multi-lymphoid progenitor 
(MLP) as CD45RA+CD90-/low. All populations were HLA-DR+ (not shown) in 
keeping with the finding of CD34+ cells in the Lin-DR+ gate during DC analysis. 
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The second panel in Figure 4.2 shows the analysis of G-CSF mobilised PBSC 




4.3.2 The proportion of CD34 subsets in BM, PBMC and PBSC 
In order to determine whether there was any skew in the composition of CD34+ 
progenitors in G-CSF-mobilised PBSC (n=1) and resting PBMC (n=2) 
compared to BM (n=6), the proportion of cells in each tissue was analyzed.  
Specific to DC homeostasis was the question of whether circulating GMP or 
MLP could be found in resting PB.  
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The first clear difference was in the proportion of HSC, which represented 3.5-
4% of CD34+ cells in BM and PBSC, while virtually no HSC were found in 
resting PBMC from healthy volunteers (Figure 4.3). B/NK were found 
predominantly in BM (2.8%) compared to 0.06% in PBSC and 0.8% in PBMC. 
All other subsets were represented in all three conditions. Of note, MLP were 
relatively enriched in PBMC (8.7% versus 2.9% in BM and 0.7% in PBSC) while 
GMP constituted a relatively smaller population (1% in PBMC versus 7.9% in 





4.3.3 CD34+ progenitors are found in skin 
In light of the observation in mouse that haematopoietic progenitors are found in 
peripheral tissues, and the current finding that MLP and GMP, thought to house 
DC potential, were found circulating in resting human blood, human skin was 
examined for the presence of CD34+ cells. These were sought in the 
CD45+HLA-DR+ APC compartment of skin as CD34 is known to be abundant on 
skin CD45- cells, such as endothelial cells. These were found (compared to 
isotype control for anti-CD34 antibody) in digested dermis (n=4) and digested 
whole skin (n=1, not shown). Many of these CD34+ cells were found in the 
CD14-CD1a- DC gate, but CD34+ cells were also identified in all other DC gates 
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(Figure 4.4, A), including CD14+CD1a- (CD14+DC) and CD14-CD1a+ (DDC) (A, 
Gate 1). In addition, CD34+ cells were found in the AF+ gate (A, Gate 2) and 
expressed CD14 but not CD1a, similarly to macrophages. Like their CD34- 
counterparts, CD34+ cells in the AF- gate had lower SSC than those in AF+ 
gate. There was no CD34 expression in CD45+ HLA-DR+ cells migrated from 
skin (B, Gate 3). The findings in digested skin are comparable with PB where 
the majority of CD34+ cells are CD45+HLA-DR+ but negative for all lineage and 
DC markers. However, as seen in 3.3.1, some Lin+ CD34+ cells are always 
found. 
 
Unsurprisingly, CD34+ cells were abundant in the CD45- population of skin as 
this antigen is known to be present on endothelial cells, and cells around 
adnexal structures, such as hair follicles and sweat ducts. They showed low 
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4.4 Results II: DC Ontogeny and homeostasis in Health 
Attributes expected of pre-tissue DC were sought on potential DC precursors 
and tissue DC subsets. These included growth factor receptor expression 
profiles and analysis of DC populations in cell cycle.  
 
4.4.1 Growth factor receptor expression on CD34+ Progenitors 
The expression of CD135/Flt3, CD115/M-CSF-R and CD117/SCF-R was 
examined on the CD34+ compartment of BM and PBMC (Figure 4.5). All BM 
and PBMC CD34+ subsets expressed CD117 with the exception of B/NK. 
CD115 expression was negative on BM and PBMC CD34+. FLt3 was seen at a 




4.4.2 Growth Factor receptor expression on PB and skin DC 
The observation in mice that DC differentiation is dependent on Flt3L signaling, 
while signaling through the M-CSF-R drives differentiation towards a monocytic 
phenotype, suggests that the expression of these receptors may go some way 
to defining the lineage potential or lineage derivation of cells in DC ontogeny. 
The expression of Flt3 and M-CSFR was therefore examined on human PB 
monocytes and PB and skin DC (Figure 4.6). Flt3 expression was seen on both 
myeloid and plasmacytoid PB DC, and on dermal CD1a+DC, DN (CD1a-CD14-
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)DC and epidermal LC from digested and migrated whole skin, but was not 
seen on any CD14+ cells. In direct contrast, M-CSF-R was expressed on PB 
CD14+monocytes and dermal CD14+DC but none of the other DC populations. 
Dermal macrophages also expressed a low level of M-CSF-R compared to 
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4.4.3 Cell Cycle in PB 
To determine whether any populations of PB DC showed evidence of active cell 
cycling, a feature that might be expected in cells capable of supporting tissue 
DC populations, flow cytometric analysis of Ki-67 and DAPI staining in PB 
monocytes and DC subsets was undertaken (Figure 4.7). PBMC were sourced 
from whole-blood leukoreduction chambers, or ‘cones’. There was no Ki-67 
positivity in either monocyte subset. However, myeloid DC, CD34+ progenitors 
and pDC showed Ki-67 expression compared to isotype control; 21%, 30% and 
2.2% respectively, in keeping with their having proliferative potential. In all three 
populations, the Ki-67+ cells were diploid by DAPI staining, with no evidence of 
DNA replication at the time of analysis. By contrast, T cells from the same cone 
(gated on LinbrightDR- cells) showed 0.62% Ki-67+ but with 3.3% of these cells in 




4.4.4 Cell Cycle in Skin APC 
Similarly, skin DC and macrophage populations were examined for evidence of 
active cell cycling by flow cytometry, with Ki-67 and DAPI staining (Figure 4.8, 
A).  From the dermis there were virtually no Ki-67+ cells in the CD14+DC or 
macrophage populations (mean of n=7: 0.25% and 0.05% respectively) and 
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very few in the migrating LC population from the dermis (mean of n=5: 0.4%) 
(B). CD1a-CD14- (DN) DC showed up to 6% Ki-67+ (mean of n=5: 2.5%) and 
CD1a+ DDC had a mean Ki-67 positivity of 0.9% (n=7). LC from digested 
epidermis contained the highest proportion of Ki-67+ cells with a mean of 6.2% 
(n=6). Unlike PB, over half Ki-67+ cells in skin showed evidence of active DNA 
replication by DAPI staining, suggesting their position in S, G2 or M phases of 
the cell cycle. 
 
To verify the proportion of epidermal LC in cell cycle, nuclear Ki-67 expression 
was assessed by fluorescence microscopy of fixed epidermal sheets (C). A 
minimum of 100 nuclei from HLA-DR+ LC (green) were assessed for Ki-67 
positivity (Dual Red-Ki-67 and Blue-DAPI) in each sample. The mean 
percentage Ki-67+ LC from epidermal sheets was 5.5% (n=3: range 4-7%) (D). 
 
 




To further explore the pre-tissue DC potential of circulating CD34+ progenitors 
and PB DC, their growth factor receptor expression profile and proliferative 
capacity have been examined and compared to tissue DC. PB was also 
analyzed for the presence of circulating CD34+ cells which may carry DC 
potential, and the presence of CD34+ progenitors in skin was sought. 
 
4.5.1 CD34+ progenitors as immediate tissue DC precursors 
CD34+ progenitors from PB are known to differentiate to DC in vitro (158), in the 
presence of GM-CSF and TNF", over a time course of 12-14 days. However, 
whether tissue DC maintenance by circulating CD34+ cells occurs in vivo is 
unknown.  
 
With the techniques employed, it was possible to examine sufficient cells from 
clinical BM or PB samples to undertake CD34+ subset analysis. This allowed 
the phenotypic identification of the eight subsets described by Doulatov et al., 
(89). One of the two populations shown in vitro to have DC potential, the MLP, 
was found in relatively enriched proportions in PB. Although no functional 
studies have yet been performed on this PB CD34+ subset, it is tempting to 
speculate that the relative enrichment may have physiological relevance, 
particularly in relation to DC ontogeny and homeostasis. Doulatov 
demonstrated that MLP from BM and cord blood could readily form DC and 
monocytes/macrophages in culture and in an in vivo mouse model. It is 
therefore possible that PB cells identified by the same expression profile may 
behave similarly in vivo.  As CD45+HLA-DR+CD34+ cells (similar to the total 
CD45+HLA-DR+CD34+ population found in PB) have now been identified in skin, 
it is plausible that these cells may enter tissue directly. In addition, cytokines 
known to stimulate DC differentiation of CD34+ progenitors in vitro, including 
GM-CSF and TNF", are produced by cells in skin, such as keratinocytes (159) 
(160). Further work is required to ascertain whether the DC-antigen negative 
CD34+ cells in tissue can be assigned to any recognised CD34+ subset and 
whether these cells isolated from PB have DC potential.  
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Of additional interest, CD34+ cells were found in every dermal APC gate. This 
mirrors in vitro culture results where CD34+ cells differentiate to CD1a+ and/or 
CD14+ DC with GM-CSF and &'F"  (161), and to macrophages with M-CSF 
(162). It is also note worthy that CD34+ cells are not found in cells migrated 
from skin. This is possibly due to the transient expression of CD34 on these 
cells once DC-related antigens are expressed, with the 60hr migration providing 
sufficient time for down-regulation CD34.  Alternatively, CD34+ progenitors may 
be unable to migrate out of skin. However, the findings in mouse that 
haematopoietic progenitors can be found in lymphatics draining peripheral 
tissues suggests that these cells can maintain migratory capacity (108). 
 
The hypothesis that PB MLP may be able to support tissue DC maintenance 
would not negate the potential for GMP to play a role in DC homeostasis, as 
described by the model illustrating two routes to a DC/monocyte progenitor 
(MDP), via GMP or MLP (89). This could either occur again through the entry of 
GMP directly to tissue or, particularly given the reduced proportions of GMP 
found in normal PB, by differentiation to ‘pre-tissue DC’, hypothetically PB 
mDC, possibly in bone marrow, prior to entry into blood or tissues. Alternatively, 
one or other subset (GMP or MLP) may have a more prominent role in 
monocyte ontogeny in steady-state or inflammatory conditions.  
 
4.5.2 GF receptor expression highlights potential lineage relationships 
between PB and tissue APC. 
The bright expression of Flt3 by PB mDC and pDC is in keeping with their Flt3L 
dependence as described in mice and humans (163). This is in contrast to the 
relatively dim expression of this receptor on all CD34+ progenitor subsets, 
possibly revealing a quantitative or qualitative difference in signaling 
requirements for FL acting as a haematopoietic factor and as a ‘DC-poietin’. It is 
recognised that Flt3 expression is negatively regulated by Flt3L exposure, 
possibly through a mechanism involving receptor internalization or ligand 
blockade of antibody binding (164). However, this is unlikely to account for the 
different levels of Flt3 expression seen in PB CD34+ cells and DC as both 
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populations, at least in PB, are exposed to the same serum concentration of 
Flt3L. 
 
As Flt3 expression is thought to be essential for differentiation to DC (124), the 
expression of this receptor on PB DC, skin CD1a+DDC, CD11c+DN cells and 
epidermal LC suggests these populations are derived from a DC lineage. PB 
CD14+monocytes, dermal CD14+DC and macrophages do not express Flt3 but 
are positive for CD115/M-CSF-R, possibly indicating a shared origin or 
developmental pathway for these three populations. The expression of Flt3 on 
CD34+ progenitors may reflect their stem cell phenotype but may also indicate 
the potential for DC differentiation.  
 
The observation that GF receptor expression is maintained in migrated cells 
leads to the possibility that these receptors also play a role in cell maintenance 
or survival. It shows that expression of GF receptors is not a transient 
phenomenon suggesting their role may not be purely to direct differentiation 
pathways at a single point in the cell’s fate. 
 
 4.5.3 Cell cycle 
It has been shown in mice that LC maintain their numbers in steady-state 
through self-renewal. It is therefore possible that other DC populations may 
have similar capabilities. Although peripheral tissue DC are thought to be 
continuously recruited from blood borne precursors, it has been shown in mice 
that up to 20% of non-lymphoid (non-LC) tissue DC are dividing in the steady-
state (157). Analysis of cell cycle in human skin was therefore undertaken, and 
studies expanded to include PB DC.  
 
Before considering the physiological relevance of the results it is necessary to 
consider the potential pitfalls of Ki-67 analysis. Despite its now routine use in 
the assessment of the proliferative index of tumours, the exact physiological 
function of the Ki-67 protein remains unclear. One critical consideration when 
using Ki-67 to assess cellular participation in the cell cycle, is the kinetics of 
expression. Study of a normal human fetus cell line showed that Ki-67 is 
expressed in cells from G1, through S, G2 and M phases (165). After arrest of 
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cell cycle in G1, induced by serum deprivation, Ki-67 remained positive for 
approximately 24hrs. It has been reported to disappear approximately 1hr after 
mitosis in the promyelocytic leukaemic cell line studied (HL-60) (166). The exact 
kinetics of Ki-67 expression in normal adult tissue DC in vivo is not known, but 
when Ki-67 expression is accompanied by an increase in DNA content of cells 
by DAPI staining, it is highly suggestive of active cell cycling. Where DNA 
replication is not seen, Ki-67 positivity may indicate the potential for cell division 
and is likely to indicate cells in G1 phase of the cell cycle as only cells in G0 are 
Ki-67 negative (167). The relevance of this to DC analysis is discussed below. 
 
Perhaps unsurprisingly, given the findings in mice, the peripheral tissue DC 
population containing the highest proportion of Ki-67+ dividing cells was the LC. 
This was shown both by flow cytometric analysis and fluorescence microscopy. 
However, a proportion of DN DC (mean 2.5%) and a smaller proportion of 
CD1a+DC (mean 0.9%) were also in cell cycle. There was no Ki-67 positivity in 
CD14+DC or macrophages. In PB a large proportion of mDC (21%) and CD34+ 
progenitors (30%) were Ki-67+, together with a small proportion of pDC (2.2%). 
There was no evidence of cell cycling in monocytes.  
 
It is perhaps striking that the populations which show evidence of proliferative 
potential are those that are Flt3+, in contrast to the CD14+ APC which neither 
express Flt3 nor show signs of Ki-67 positivity. It has been shown in vitro that 
Flt3L induces CD34+ cell proliferation (168) and Flt3L administration in vivo 
results in expansion of Flt3+ progenitors as well as DC (119). Although the 
increase in DC numbers during Flt3L administration may be due in part to 
progenitor expansion and subsequent DC differentiation, lymphoid tissue DC 
expansion has been shown to occur through Flt3L induced cell cycling of DC 
themselves, (28). It is therefore possible that the expression of Flt3 on PB and 
skin DC may not only have directed their differentiation to DC but may also 
facilitate the entry of these cells into cell cycle, and contribute to their potential 
ability to self-renew. 
 
Another point of interest is that, aside from the LC, the skin DC population with 
the highest proportion of proliferating cells, up to 6%, was the CD1a-CD14- 
compartment. This, by phenotypic analysis, is where CD14- (non-monocyte) 
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tissue DC progenitors from PB may be found as there is no CD1a expression in 
PB. In keeping with this, it is where the majority of CD141high and CD1c+CD11c+ 
cells, with equivalent phenotypes to PB mDC, were found (chapter 3). The DN 
population also contains the CD34+ cells which do not express DC-related 
antigens. Further dissection of this compartment is required to identify exactly 
which populations house the ki-67 positivity and so the proliferation potential.  
 
One puzzle is why PB mDC and CD34+ cells, despite a significant proportion 
being positive for Ki-67, show no evidence of DNA replication ex vivo. There are 
several possible explanations. Firstly, they may be poised in G1, awaiting a 
signal to enter the DNA replication stages of cell cycle, on entry to tissues.  A 
less attractive alternative is that they have recently divided and temporarily 
remain Ki-67+. Finally, it is possible that the lack of DNA replication, and 
potential arrest in G1 phase, is an ex vivo artifact related to the processing of 
cells in leukoreduction chamber. Cells are stored in a massively concentrated 
suspension and may well result in conditions able to cause cell cycle arrest 
(165). It is less likely that Ki-67 expression is an ex vivo artifact as no 
conditions, apart from the entry of cells into cell cycle, are known to induce its 
expression. Analysis of freshly isolated PBMC is necessary to rule out ex vivo 
processing as a cause arrest of these cells in G1. 
 
4.5.4 Towards a unified hypothesis of DC homeostasis 
The reliance on either replenishment by blood borne precursors or local self-
renewal for tissue DC homeostasis may not be mutually exclusive, even in 
steady-state. It is conceivable that relative dependence on either mechanism 
could be specific to particular tissues or even particular DC populations. Along 
similar lines, it is conceivable that more than one blood-borne precursor 
population is involved in tissue DC homeostasis, either in a redundant or 
parallel fashion.  
 
The environmental circumstances may also influence the mechanism required 
for maintenance of DC numbers. For example, during inflammation the kinetics 
of DC activation and migration due to increased antigen exposure may 
necessitate a greater reliance on immediately available blood borne precursors, 
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possibly also drawing on ‘inflammation-specific’ populations, conceivably the 
monocyte. This has been shown in the case of LC which are able to self-renew 
in steady-state in mice, show increased proliferation in some inflammatory 
situations, such as atopic dermatitis in humans (169) but are replaced by 
monocytes in conditions severe enough to cause radical depletion of murine LC 
(110). Monocyte derived inflammatory tissue DC, or TipDC, are also recognised 
in mice (111) (113). 
 
4.5.5 Further work 
Further work will aim to clarify the tissue DC potential of PB cells in greater 
detail, including the CD141highDC and CD1c+DC and CD34+ progenitor subsets. 
More detailed Ki-67 and Growth factor expression analysis will be undertaken. 
Whether these cells are able to take on a tissue DC phenotype or enter cell 
cycle ex vivo will be examined in culture, using specific cytokines and skin 
conditioned medium. mRNA expression analysis in CD34+ and DC subsets 
from PB and skin may also suggest relationships between the cell populations.   
 
In vivo, circulating CD34+ and PB DC subsets will be monitored following 
allogeneic SCT, in parallel with DC phenotyping and CD34 expression analysis 
in patient skin. Determination of the kinetics of chimerism conversion in these 
populations, with specific focus on potential pre-DC compartments, may shed 
light on the repopulation of tissue DC compartments following HSCT. 
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Chapter 5. DC Monocyte and B/NK lymphoid deficiency 
5.1 Introduction  
Studies of kinetics of tissue DC repopulation following haematopoietic stem cell 
transplant (HSCT) have shown that human tissue DC are bone marrow derived 
(73) (109). However, it has not been possible to probe the distal relationships 
between monocytes and DC, or prove the independence of LC from BM, in 
human steady-state conditions. To recapitulate mouse models of DC or 
monocyte depletion, subjects with spontaneous and sustained monocytopenia 
or DC deficiency are required. 
 
5.1.1 The predicted effects of monocytopenia on DC homeostasis 
The identification of cases with isolated monocytopenia would allow the role of 
these cells in tissue DC homeostasis to be elucidated. Any populations able to 
maintain their numbers independently of monocytes, for example through self 
renewal, could be identified and the developmental relationship between 
monocytes and other potential pre-tissue DC, including PB mDC, could be 
interrogated. Whether clinical monocytopenia ever occurs independently of PB 
DC deficiency is entirely unknown as DC are not measured by routine 
automated blood counters. 
 
5.1.2 Immune regulation by DC 
The study of subjects with monocytopenia or DC deficiency would also allow 
the investigation of their role in immune regulation. The role of DC in controlling 
tolerance is receiving increasing attention. In particular, a direct homeostatic 
balance has been found between the frequency of murine DC and Treg. This is 
linked to changes in concentration of Flt3L (30). Depletion of Tregs increases 
DC proliferation in a Flt3L-dependent mechanism (27) (28), administration of 
exogenous FL induces Treg proliferation as a direct result of DC expansion  
and DC depletion in Flt3L KO mice leads to reduced numbers of Treg, with 
autoimmune sequelae (29). The proliferation of Treg in vivo is dependent on 
MHC Class II expression on DC (30). The homeostatic balance between DC, 
Treg and FL has not been tested in humans. 
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5.1.3 The identification of monocytopenic patients 
As PB DC are not measured in routine clinical practice, the most practical way 
to screen for potential APC deficiency was through the identification of 
monocytopenic patients. Clinical monocytopenia is found in a number of 
primary chronic haematological conditions, such as hairy cell leukaemia and 
aplastic anaemia. The initial thought was to investigate DC homeostasis in 
these diseases. However, a small group of 5 patients was identified, with a 
clinically-apparent, isolated monocytopenia. The main presenting features 
included mycobacterial infections, human papilloma virus (HPV) infection, 
pulmonary alveolar proteinosis and autoimmunity. Detailed analysis of PB, BM 
and tissue DC compartments was undertaken in all five subjects. During the 
course of the work the clinical details of a series of eighteen similar cases were 
published (170). 
 
The cases in this series were also identified through their susceptibility to non-
tuberculous mycobacterial, viral and fungal infections accompanied by profound 
monocytopenia and reduced B and NK cell numbers. In addition, ten patients 
developed malignancies, the majority of which were leukaemias, and five 
developed pulmonary alveolar proteinosis (PAP), a condition characterised by 
accumulation of proteinaceous material in alveolar spaces resulting in reduced 
gasseous exchange and respiratory failure. PAP is most commonly associated 
with reduced numbers or function of alveolar macrophages related to antibodies 
to or mutations in GM-CSF-R. Within these eighteen cases, five families were 
identified with 2 affected generations, and a pattern of inheritance in keeping 
with an autosomal dominant mode of transmission. 
 
5.2 Materials & Methods for Chapter 5 
5.2.1 Treg staining 
PBMC were alliquoted at 1x106 cells/tube and surface stained as previously 
described. Cells were then washed in flow buffer and fixed and permeabilised in 
ebioscience reagents (www.ebioscience.com), as per manufacturer’s 
instructions. Cells were then blocked with rat serum for 10mins prior to 
   
 100 
Intracellular FoxP3, or isotype, staining at 40C in the dark. Cells were washed 
with permeabilisation buffer (diluted 1:10) and resuspended in flow buffer prior 
to flow cytometric analysis. 
 
5.2.3 Bronchoalveolar Lavage (BAL) Fluid  
Cells from lung wash out were obtained from subject 4 during a routine clinical  
procedure. The fluid was centrifuged at 500g for 5 mins and the resulting pellet 
resuspended in DPBS prior to flow cytometric analysis or cytospin preparation. 
 
5.2.3 BM and Lung CD68 immunohistochemistry 
Formalin fixed, paraffin embedded tissue was sectioned and stained with anti-
CD68 K (clone KP1) in the NHS pathology laboratories, according to standard 
protocols. Images were attained using a Zeiss Axioplan 2 microscope EC Plan-




5.3 Results I: Clinical presentation 
There was a diverse range of presenting symptoms among the five subjects but 
all presented with clinical problems included in the case series (170). Human 
papilloma virus (HPV) infection was the most common symptom but not the 
primary presenting feature in any case. 
 
5.3.1 Clinical Symptoms 
Subject 1 presented at the age of 12 with disseminated BCG following routine 
vaccination. Subject 2 was diagnosed at the age of 27 with spontaneous 
Mycobacterium kansasii infection and HPV infection of hands and feet. Subject 
3 developed respiratory failure at age 21 due to PAP and had concurrent 
perineal HPV infection.  Subject 4 presented with recurrent erythema nodosum 
and HPV infection of hands at age 23.  Subject 5 presented at the age of 10 
weeks with disseminated BCG following routine vaccination, in addition to oral 
candidiasis and cachexia. Subjects 1, 2, 4 and 5 had no clinically affected 
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relatives, while subject 3 reported two generations of ancestors dying of early 
respiratory death or leukaemia, in keeping with an autosomal dominant pattern 




5.3.2 Clinical Investigations 
The subjects’ full blood counts (FBC) at the time of analysis are shown in Table 
5.2. Subjects 1, 2 and 4 had no significant anaemia, thrombocytopenia, 
leukopenia or myeloproliferation but showed a near absolute monocytopenia 
and variable reduction in lymphocytes. Subject 3 had values in keeping with an 
active systemic infection as counts were taken during an episode of pulmonary 
sepsis. Subject 5 initially presented with a marked anaemia (Hb 4.6) and mild 
thrombocytopenia (plt 66) in addition to myeloproliferation with WBCs 125. 
However, this was in the setting of severe illness requiring intensive care 
support. Blood count at the time of PB and tissue DC analysis still showed 
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evidence of anaemia, mild thrombocytopenia and myeloproliferation, but by this 




Bone marrow examination in subjects 1-4 was normal by standard clinical 
haematological methods including morphology, histology and cytogenetics, with 
the exception of subject 2 who’s first BM trephine showed ill formed 
granulomata positive for acid fast bacilli in keeping with mycobacterium kansasii 
infection. Subsequent marrow testing in this subject was normal. Subject 5, 
however, showed marked expansion of myelopoiesis with preservation of 
erythropoiesis and megakaryopoiesis (Figure 5.1). There were also 
granulomata seen in the first BM sample taken, which cleared after treatment 
for BCG infection.  
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Due to the myeloproliferative picture in subject 5, blood and BM were tested for 
Philadelphia chromosome, found in the myeloproliferative disorder ‘Chronic 
Myeloid Leukaemia’, but this was not detected. The subject also underwent 
biopsy of an enlarged axillary lymph node which revealed granulomata, in 
keeping with BCG infection, together with evidence of myeloid hyperplasia. 
 
5.4 Results II: Detailed Cellular Phenotype Analysis 
5.4.1 Flow cytometric evaluation of PB APC  
Detailed flow cytometric analysis of PBMC monocytes and DC from all five 
subjects showed a massive reduction of cells in the Lin-DR+ gate with very few 
CD14+ or CD16+ monocytes. In addition, all subjects showed a virtual absence 
of both pDC and mDC. The residual cells in the lin-DR+ gate were CD34+ 
progenitors (Figure 5.2, A). Flow cytometry of lymphocytes from PBMC 
revealed a more mixed picture with marked reduction, or near absence of 
CD19+CD3- B cells and CD56+CD3- and CD56brightCD3- NK cells in subjects 1-4 
but preservation of near normal B and NK cell proportions in subject 5 (B).  
 




5.4.2 PB of subjects compared to normal controls 
The proportions of monocytes, DC and lymphocytes in subjects were directly 
compared to normal controls. Monocyte subsets were severely depleted in all 
subjects. CD14+monocytes were between 0.1% and 5.5% of median normal 
values. CD16+monocytes were more variable ranging from 0.2% to 24.2% of 
normal median values. Of note, both monocyte subsets were virtually 
undetectable in subject 5. CD123+pDC and CD11c+mDC were virtually absent 
in all subjects. CD11c+ cells may normally be subdivided into CD141high and 
CD1c+ fractions but neither was detectable (not shown). The only remaining Lin-
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DR+ cells were CD34+ progenitor cells, which were relatively expanded (Figure 
5.3, A). 
 
Subjects 1-4 showed preservation of T cell frequencies but low or virtually 
absent NK and B cells with the exception of subject 4 who had B cells at the low 
end of the normal range. Subject 5, however, had preserved B and NK cells 




5.4.3 Functional consequences of cellular defect  
Data from Dr Rainer Doffinger, Principle Clinical Scientist, Department of 
Clinical Biochemistry and Immunology, Addenbrookes Hospital, Cambridge. 
 
Cytokines released into the supernatant were measured after whole blood was 
stimulated in vitro with LPS supplemented in turn with IL-12 or IFN!.  A paired 
‘travel control’ was run with each subject. Subjects 1-4 and their travel controls 
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were analyzed at least twice. Subject 5 and travel controls were analyzed 3 
times. Figure 5.4 shows results as mean+/-SD for all controls, subjects 1-4 and 
subject 5, each from one experiment.  
Subjects showed some reduction of IFN! production in response to LPS and IL-
12 compared to controls. However, there was a significant difference observed 
between all subjects compared to controls for IL-12 release after stimulation 
with LPS and IFN!. TNF" and IL-6 release after LPS stimulation were also 




5.4.4 Flow cytometric analysis of Dermis  
Having observed almost complete loss of DC and monocytes from the blood, 
macroscopically healthy skin was examined to determine if tissue DC were 
similarly affected. Flow cytometry of collagenase-digested dermis was 
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performed. The CD45+HLA-DR+AF- DC compartment was markedly depleted 
(Figure 5.5, A, Gate 1), and CD14+ and CD1a+ DC were virtually absent (B). 
There remained detectable CD1abrightLang+ cells, which represented migratory 
LC passing through the dermis. CD45+HLA-DR+AF+ dermal macrophages were 
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5.4.5 Whole mount fluorescence microscopy of Epidermis 
To see whether epidermal LC, the population showing the highest proliferative 
proportion in normal skin, were able to survive independently of other monocyte 
or DC subsets, examination of intact epidermal sheets by whole mount 
microscopy with anti-CD1a antibodies was performed. This confirmed the 
presence of an intact LC network in subjects 1, 3, 4 and 5 (figure 5.6, A). LC 
density was reduced in subjects 2 and 3 (C) and subject 2 showed patchy 
disruption of the network. Proliferating LC, as demonstrated by Ki-67 nuclear 
staining of HLA-DR+ cells in epidermal sheets, were found in all subjects (B) in 
similar or greater proportions than controls (D). 
 




5.4.6 Macrophages in BAL, BM and lung (and LN) 
The surprising observation of relative preservation of dermal macrophages, 
despite PB monocytopenia, and in contrast to dermal DC, prompted the search 
for macrophages in other tissues.  
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Flow cytometry of cells from broncheo-alveolar lavage (BAL) fluid (subject 3) 
revealed two populations of CD45+HLA-DR+AF+ macrophages; CD14+ and 
CD14-. Immunohistochemical staining for CD68+ macrophages in lung biopsy 
from the same patient confirmed essentially normal numbers of these cells in 
alveolae (Figure 5.7). Bone marrow macrophages were also detectable by 
immunohistochemistry in subject 3. CD68 staining in dermis confirmed the 
presence of macrophages in this tissue, in keeping with results from flow 




5.5 Results III: Role of DC in Immune Regulation 
The virtual absence of PB and tissue DC afforded an ideal opportunity to test 
the relationship between these cells, Tregs and Flt3L.  The mouse model 
predicts that loss of DC should result in reduced numbers of Tregs and high 
Flt3L concentrations (30). Serum Flt3L levels were measured and the numbers 
of Treg in PB was determined. As Flt3L is a stem cell factor as well as a DC-
poietin, the levels of stem cell factor were also measured. Due to the 
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accompanying monocytopenia, M-SCF concentrations were also tested as this 
cytokine has been shown to be necessary for monocyte development (122). 
The corresponding growth factor receptor expression was measured on CD34+ 
progenitors. 
 
5.5.1 Cytokine ELISAs and GF receptor expression on CD34s 
To assess the relationship between DC depletion and Flt3L, serum levels of this 
cytokine were measured by ELISA. Flt3L could be detected in normal serum but 
subjects 1-4 were found to have up to 100-fold elevation of Flt3L compared to 
controls. Subject 5 showed a 2 fold increase in Flt3L concentration. M-CSF 
levels were elevated in subjects 1-3 and at the upper limits of normal in subject 
4. SCF concentrations were entirely normal compared to controls (Figure 5.8, 
A). Neither M-CSF nor SCF was measured in subject 5 due to lack of available 
material. 
 
Expression of Flt3/CD135 was not detectable on BM CD34+ cells from subjects 
tested (1 and 3) or on PB CD34+ from subject 5 (B). CD117/c-kit expression 
was unaffected on BM CD34+ cells but, similarly to controls, CD115/M-CSFR 
was not detectable in the subject tested (subject 3). 
 




5.5.2 Relationship between DC and Treg and assessment of T cell 
phenotype  
DC depletion and massive elevation of Flt3L in subjects lead to the prediction 
that Treg numbers would be reduced.  
 
Figure 5.9, A shows the flow cytometric analysis of Tregs in a normal control. 
From PBMC a lymphocyte SSC v FSC gate was taken. CD3+CD4+ cells were 
gated and the number of these cells with dual expression of FoxP3 and bright 
CD25 was assessed. The figure shows the expression of these markers on 
CD4+ T cells from a control and subject 1. The absolute number of Tregs per ml 
of whole blood was calculated using the BD Trucount™ method as previously 
described. Where cells were analyzed after a freezing step, dead cells were 
excluded from the analysis with a dead cell dye. 
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Initially, twenty one healthy volunteers we were studied as the in vivo 
relationship of DC and Treg in healthy humans had not previously been 
examined. A positive correlation was found between the absolute frequency of 
Lin-HLA-DR+ cells (DC, monocytes and CD34+ cells) and CD4+CD25hiFoxP3+ 
Tregs in peripheral blood (p=0.0369). Analysis of Treg numbers in four subjects 
revealed that severe DC deficiency was associated with marked depletion of 
Tregs (B).  Plotting the four subjects together with normal blood profiles 
increased the significance of the relationship between DC and Tregs, without 
changing the slope of the regression (p<0.0001). The subjects had a 53-88% 
reduction in Treg count compared with the normal median value of 0.041 x 
106/ml. There was no statistically significant correlation between Treg numbers 
and specific DC subsets.  
 
An increase in the proportion of activated T cells has also been observed when 
mice are rendered Treg deficient, directly or via DC depletion (27, 30, 171, 
172). T cells from subjects were therefore examined for evidence of increased 
activation by their expression of CD56 and CD25. The ratio of CD4+ to CD8+ T 
cells was not significantly perturbed but there was an increase in the proportion 
of activated CD56+ CD3+ T cells and CD25+ CD3+ T cells in subjects 1-4, 
compared to normal controls (C). Subject 5 was not tested due to lack of 
material available. 
 




5.6 Results IV: Recovery post bone marrow transplant 
Subjects 1, 3 and 5 received definitive treatment with haematopoietic stem cell 
transplantation to treat potentially fatal complications of the condition. These 
were respectively: disseminated BCG infection, not curable with anti-microbial 
treatment; end stage respiratory failure due to PAP; progressive 
myeloproliferation with concerns about potential transformation to leukaemia. 
To examine whether DC were able to repopulate tissues following HSCT, PB 
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and skin were re-examined. Material was available post-transplant from 
subjects 1 and 3. 
5.6.1 PB 
Peripheral blood from subjects 1 and 3 was examined 130 and 40 days post 
transplant, respectively. Reconstitution of all PB monocyte and DC subsets was 
seen in both subjects  (Figure 5.10, A) with proportions similar to controls at 40 
days post transplant for other haematological conditions (B). By 130 days 
subject 1 had also recovered normal numbers of B, T and NK cells (C). Subject 
3 at day 40 had NK cells, a few T cells but no B cells, which is in keeping with 
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5.6.2 Skin 
Skin biopsy from subject 1 was also taken at Day 130 post transplant. The 
dermis was found to be repopulated with all DC subsets (Figure 5.11, A) and 
macrophages, to near normal proportions (B). The epidermis, as assessed by 
immunofluorescent microscopy of whole mount epidermis, remained well 
populated with LC (C). Chimerism assessment of skin APC populations by 
examination of X and Y chromosome distribution was not possible as both the 





The phenotypic study of subjects with the newly recognised syndrome of 
monocyte, DC and mixed lymphoid deficiency, now referred to as DCML 
deficiency, has revealed a number of novel insights to in vivo human DC 
homeostasis. Specifically, it has shown that tissue DC are reliant on blood-
borne precursors with the notable exception of LC which have now been shown  
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to maintain their numbers independently of the bone marrow in steady-state. 
Surprisingly, tissue macrophages were also still present. Finally, it has allowed 
the testing of a murine-derived model of DC and Treg homeostasis and shown 
that this model may hold true in vivo in humans. 
 
5.7.1 Discrepancies between subjects 1-4 and subject 5 
The clinical aspects of subjects 1-4 fit with those of the eighteen cases 
described in the recent publication (170) and, since the finding of DC deficiency 
in addition to monocyte and lymphocyte depletion, will be referred to as DCML 
deficiency.   
 
Subject 5, however, showed a striking dissimilarity with a presentation at 10 
weeks of age, as opposed to the mean age of presentation of DCML deficiency 
at 31yrs. The cellular phenotype was also different, although still encompassing 
severe monocyte and DC deficiency, B, T and NK cells were preserved and 
there was a marked accompanying myeloproliferation see in PB and BM. This 
suggests the possibility of a different pathophysiology underlying the clinical 
features in subject 5 and the early age of presentation raises suspicion of a 
congenital genetic mutation. This is discussed in more detail in Chapter 6.  
 
5.7.2 Functional consequences of the DCML phenotype 
The susceptibility to mycobacterial infections inevitably draws a comparison 
with a well recognised primary immune deficiency ‘mendelian susceptibility to 
mycobacterial disease’ (MSMD). In this condition, there is no gross cellular 
phenotype but there is disruption of the IFN!/IL-12 signaling pathway. Causative 
genetic mutations within this pathway have been described in at least 6 genes, 
and may have a recessive (autosomal or X-linked) or autosomal dominant 
pattern of inheritance (173). The susceptibility to mycobacterial infection is due 
to either impaired IL-12 dependent production of IFN! from T/NK cells or 
impaired monocytic cellular responses to IFN! (174). 
 
The severe reduction of IL-12 and reduction of IFN! production in whole blood 
with LPS challenge suggested a disruption in the IL-12/IFN! axis also in these 
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subjects. This correlates with their in vivo susceptibility to mycobacterial 
infection but is entirely explicable by the severe reduction of monocytes in PB. 
Some residual TNF" and IL-6 release is seen, which may be due to activation 
of neutrophils by LPS (175).  
 
5.7.3 Tissue DC homeostasis 
The most striking observation in terms of DC homeostasis was the presence of 
near-normal numbers (50-100%) of epidermal LC, despite the marked reduction 
of potential circulating precursors. In direct comparison, subjects 1, 3, 4 and 5 
had as few as 0.1% CD14+ and 0.2% CD16+ monocytes, and no dermal blood 
DC, but LC networks remained intact. The patchy distribution of LC in subject 2 
could potentially relate to previous skin inflammation. This suggests that human 
LC are able to maintain their numbers independently of bone marrow in steady-
state. This is most likely to be due to self-renewal as Ki-67+ LC were found in 
high normal or increased numbers in epidermal sheets from subjects.  
The absence of dermal DC, with the exception of migrating LC, suggests that 
tissue DC share a common origin with PB Lin-HLA-DR+ cells. As both 
monocytes and DC were depleted, it is not possible to determine which plays 
the prominent role in steady-state tissue DC homeostasis. Another cell that 
cannot be excluded as a potential DC precursor is the circulating CD34+ cell. 
The phenotype of near global absence of monocytes and DC suggests that 
haematopoietic progenitors are unable to differentiate along a monocyte/DC 
path. Therefore, even though CD34+ cells can be found in subjects’ PB, even in 




The presence of CD68+ macrophage populations in dermis, alveolar spaces 
and BM show that these cells can also persist independently of blood 
monocytes. However, at least in the case of alveolar macrophages, it is 
possible that these cells have impaired function as subject 3 developed severe 
PAP despite the histological and flow cytometric evidence of the presence of 
good numbers of alveolar macrophages.  
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There are several conceivable explanations for why macrophages persist 
despite the absence of monocytes. Firstly, uncertainty about the natural history 
of the syndrome, at least in subjects 1-4, adds complexity. It is possible that 
these subjects had circulating monocytes at some time and macrophages can 
be very long lived (176) (73). However, at presentation, subjects 1-4 had 
documented monocytopenia for at least 3 to 14yrs, and most likely longer as 
initial blood counts were taken incidentally. As subject 5 presented at only 10 
weeks of age, it is possible that circulating monocytes were never present, but 
tissue macrophages were still found.  
 
Secondly, at least a subset of adult tissue macrophages originate independently 
of BM. It has recently been shown that murine microglia arise from the 
embryonic yolksac (87) and yolksac phagocytes, prior to the development of 
liver haematopoiesis, are seen to populate other tissues within the embryo 
including lung and liver (177), reviewed in (178). To what extent these 
embryonic tissue phagocytes play a role in the adult is not clear. However, it is 
conceivable that tissue macrophages found in these subjects could be of 
embryological origin. 
 
A final route that cannot be excluded is the differentiation of macrophages 
directly from circulating CD34+ cells. It is known from in vitro culture that 
different cytokines, and therefore potentially different signaling pathways, are 
required to direct CD34+ progenitors to differentiate to macrophages rather than 
DC (162), however whether differentiation to macrophages has to be via a 
CD14+ monocytic cell is not clear. It is conceivable that conditions favouring the 
differentiation pathway from CD34+ cells to macrophages could exist in these 
subjects and that CD34+ progenitors retain their macrophage potential, despite 
their being no circulating monocytes. Further work is required to characterise 
the phenotype and function of macrophages present in DCML deficiency, 
compared to normal tissues.  
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5.7.5 Elevated Flt3L and M-CSF with normal SCF levels 
As with DC depleted mouse models, massive elevation of Ftl3L was found in 
DCML deficiency. Not only was there depletion of cells which would normally 
express Flt3 but Flt3 could not be detected on the surface of subjects’ CD34+ 
progenitor cells. An elevation of Flt3L has been seen in the treatment of mice 
with a small-molecule Flt3 inhibitor (164). This caused depletion of tissue DC, 
massive increase of serum Flt3L and undetectable surface Flt3 on lineage 
negative BM cells, suggesting a feedback regulatory loop between Flt3 
expression and Flt3L concentration. This may explain the absent Flt3 on CD34+ 
progenitors. This mechanism as the explanation for absent Flt3 on 
haematopoietic progenitors is supported by the fact that normal erythropoiesis, 
megakaryopoiesis and granulopoiesis was observed, suggesting that the lack of 
Flt3 on haematopoietic progenitors did not have a quantitative effect on the 
haematopoietic stem cell compartment. Similarly, SCF levels were normal, 
possibly reflecting a quantitatively normal stem cell population.  
 
In comparison, subject 5, despite only a modest 2 fold elevation of serum Flt3L 
demonstrated a marked myeloproliferation. In mice lacking CD11c+ DC, 
myeloproliferation is also found in association with elevated Flt3L (171). The 
lack of myeloproliferation in subjects 1-4, despite 10-100 fold increases in 
serum Flt3L suggests a differentiation block at an earlier stage of 
haematopoiesis than in subject 5. The modest elevation of Flt3L in subject 5, as 
opposed to the huge elevations seen in DCML deficiency, may be explained by 
the presence, due to myeloproliferation, of large numbers of cells expressing 
Flt3. 
 
Serum M-CSF was also raised in subjects 1-3 and high normal in subject 4. 
Subject 5 was not tested as material was not available. The corresponding 
receptor, M-CSF-R, was not present on CD34+ progenitors, nor on any other 
PB cell as the populations normally expressing this receptor, namely 
monocytes, were absent. Similarly to Flt3/Flt3L regulation, CSF-1 receptor (the 
murine homologue to M-CSF-R) knockout mice, have elevated serum CSF-1 
(M-CSF) levels (122) and CSF-1 receptor is down regulated by internalization 
on binding CSF-1 (179). However, in these cases, it is possible that the raised 
M-CSF serum levels are related to loss of receptor expression secondary to 
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lack of cells. It is therefore not clear whether the primary loss is of M-CSF-R 
expressing cells, or M-CSF-R itself. Whether the tissue macrophages found in 
these subjects express M-CSF-R has not yet been investigated.  
 
The implications of these observations on potential causative genetic defects 
will be discussed in chapter 6. 
 
5.7.6 DC in immune regulation 
The observation of spontaneous DC deficiency with elevated serum Flt3L 
presented a unique opportunity to examine human DC-Treg co-regulation in 
vivo. As predicted by the mouse models, Treg were found to be depleted. The 
model was also found to hold true in normal volunteers suggesting that inter-
individual variation in humans is sufficient to demonstrate this relationship. 
 
The fact that there was no significant relationship identified between individual 
DC subsets and Treg may be due to the small number of controls or to the 
possibility that Treg homeostasis occurs in an MHC class II dependent fashion, 
as predicted by the mouse model (30). 
  
Approximately one quarter of patients with DCML deficiency, including the 
fourth subject in this study, developed autoimmune syndromes (170). Treg 
depletion as a consequence of DC deficiency may contribute to this 
phenomenon.  
 
5.7.7 Post transplant 
In subjects 1 and 3 both PB and tissue DC subsets were restored following 
haematopoietic stem cell transplantation. Subject 5 also recovered PB counts 
as measured by routine clinical parameters. This suggests that, not only is the 
defect not of stromal origin, but that it is a primary bone marrow haematopoietic 
disorder. 
The genetic aetiology of DCML deficiency and the phenotype of subject 5 is 
considered in the next chapter. 
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Chapter 6. Genetic Regulation of DC and Monocyte 
Development 
6.1 Introduction 
Haematopoiesis is characterised by a progressive restriction of differentiation 
potential in progenitor populations. This process is orchestrated through 
transcription factor (TF) activity which, among other things, controls the 
expression of growth factor receptors and so the responsiveness of cells to 
growth factor (GF) signaling. Disordered haematopoiesis may therefore result 
from defects in TFs, GFs or GF-receptors. Following the identification of 
subjects with absent peripheral DC and monocytes, the opportunity was taken 
to establish whether any specific defects existed in the haematopoietic 
progenitor compartment and whether any causative genetic mutations could be 
identified.  
 
6.1.1 Stem cell compartment 
There is much current interest in tracing monocyte/macrophage and DC 
ontogeny back through the stem cell compartment in mouse with at least two 
specific subsets identified with DC potential.  Recent studies, using adoptive 
transfer models, have mapped the myeloid element of monocyte/DC 
differentiation. This pathway includes the GMP, which retains granulopoietic 
potential and gives rise to the MDP (monocyte dendritic cell progenitor). This 
cell has monocyte and DC potential. The CDP (common DC precursor), also 
from the GMP and possibly downstream of the MDP, gives rise to only pDC and 
mDC (101) (102) (180). Similarly, presumed lymphoid precursors (CLP) have 
been shown to be able to give rise to myeloid DC (96) (105).  
 
In DCML deficiency subjects, repopulation of missing cell compartments 
following HSCT would indicate that the defect causing the clinical phenotype 
lies in the haematopoietic stem cell compartment. To examine whether there 
were any identifiable defects in progenitor cell subsets, CD34+ cells from BM 
and PB were examined. Of particular interest, given the cellular phenotype of 
subjects 1-4, were previous reports of human CD34+ populations able to give 
rise to DC/monocyte, B and NK cells (106) (107). A cell with similar potential 
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was also recently identified in human cord blood and adult BM by Doulatov et 
al., (89). The flow cytometric protocol used in this study was adapted for 
progenitor cell analysis in DCML deficiency. 
 
6.1.2 Genetic work-up 
A number of TFs have been found to be essential for monocyte and/or DC 
development in mice (33). These include factors involved in the signal 
transduction of Flt3L and GM-CSF (181). Although M-CSF is known to play an 
important role in monocyte development, less is know about the TFs involved. 
Figure 1.8 (Chapter 1) summaries the current known genetic defects affecting 
DC ontogeny in mice (33) (125).  
 
The key signalling molecule directing DC differentiation in steady-state is Flt3L 
(182). This signals via STAT3 (183), whose downstream targets include PU.1, 
IRF8, M-CSF-R and Flt3 itself (126). GM-CSF signals through STAT5 which in 
turn activates STAT3 and IRF4 and may inhibit IRF8 (128) (127). Mutations in 
all these genes have been shown to cause monocyte/macrophage and/or DC 
deficiencies in mice. 
 
Many mutations lead to some selectivity in deficiency of DC subtypes, either 
reflecting the role of the gene in differentiation or the consequence of 
redundancy in unaffected populations. Whether monocytes are affected is not 
commonly documented and BM DC progenitors have been examined only in 
the case of Gfi-1 and IRF8 knockout models, revealing depletion and 
preservation of DC progenitors, respectively.  
 
Based on the comparison of subjects’ phenotypes and published mouse genetic 
models a number of candidate genes were sent for sequencing or sequenced 
locally.  
 
6.1.3 Family History 
Subject 5 presented in infancy suggesting an inherited or de novo constitutional 
genetic defect. In contrast, DCML deficiency subjects, including those in the 
case series from Vinh et al., (170), present mainly in adulthood with 
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heterogeneous phenotypes. Some are sporadic, with no family history while five 
pedigrees, with autosomal dominant pattern of inheritance, were identified in 
the case series.  
 
The identification of genetic mutations in sporadic genetic disorders through a 
candidate gene approach is frequently unrewarding. The availability of DNA 
from affected and unaffected members would allow much more powerful 
classical or post-genomic analysis. For this reason, and for the direct clinical 
benefit of potentially affected relatives, the kindred of subject 3 was explored to 
identify living undiagnosed individuals and to include unaffected family 
members. 
 
6.1.4 Inclusion of data from laboratory members and other collaborating 
laboratories   
Gene sequencing was carried out by a number of different laboratories, and 
some of the molecular genetic work by members of the Collin laboratory. The 
data are included here as results are central to the discussion and critically 
influence further work. Where this is the case, it is clearly indicated in the text 
and figure legends. 
 
6.2 Materials and Methods for Chapter 6 
6.2.1 Purification of CD34+ cells from PBMC 
Unmobilised circulating PB CD34+ cells were purified from PBMC by FACS. 
Control PBMC were isolated as previously described and stained with CD34 PE 
alone. Progenitor cells were identified by their CD34 expression and low SSC. 
Cells were sorted into 100µl RPMI in 1.5ml eppendorf at 40C and then kept on 
ice for transfer to the laboratory. They were pelleted and lysed in RNA lysis 
buffer, then stored at -800C until used to generate cDNA for QPCR analysis. 
 
6.2.2 PU.1 Gene sequencing 
PU.1 primers were designed from sequence data available at 
www.ncbi.nlm.nih.gov, tagged with M13 primers and synthesised by Sigma Life 
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Science Oligos (www.sigmaaldrich.com). The minimal tiling path contained 10 
probes and covered the five exons, the majority of the introns and the promoter 
region (Figure 6.1). Forward and reverse primer optimization was performed at 
1, 2 and 3mM MgCl2 concentrations and temperatures ranging from 60-70
0C on 
a PCR block, PTC-225 DNA Engine Tetrad Thermal Cycler (MJ Research/Bio-
Rad; www.bio-rad.com). Amplification and purity was checked by gel 
electrophoresis on a 2% agarose gel. DNA was isolated from both fibroblasts 
and neutrophils from control and subject 3, was amplified on a PTC-225 DNA 
Engine Tetrad Thermal Cycler (MJ Research/Bio-Rad; www.bio-rad.com) with a 
PCR program consisting of step 1, 940C for 4 mins; step 2, 940C for 30secs; 
step 3 Anneal 30secs; step 4, 720C 30secs; step 5, 720C 4 mins; with steps 2-4 
repeated for 34 cycles. Removal of excess primer and nucleotides was 
performed with ExoSAP-IT and incubated on PCR block at 370C for 15mins to 
degrade singlestranded DNA, then 800C for 15mins to inactivate ExoSAP-IT. 
Cleaned, amplified PCR product was then sent, with M13 tagged primers to 
DNA Sequencing and Services, College of Life Sciences, University of Dundee, 
Scotland DD1 5EH for sequencing on a 3730 Capillary DNA Analyzer 
(www.appliedbiosystems.com). Data was retrieved as .ab1 files and viewed 
with Chromas Lite Software. The sequence was then pasted into 
http://www.ncbi.nlm.nih.gov/ and run on the BLAST program.  Known Single 
Nucleotide Polymorphisms (SNPs) were identified and mapped using the 
ensembl genome browser at http://www.ensembl.org/index.html.  Information 
about the SNPs was gathered using links from ensembl to the ncbi SNP 
database at http://www.ncbi.nlm.nih.gov/SNP/.  Data were analyzed by 
laboratory member, Rachel Dickinson.  
 




6.3 Results I: Human IRF8 Deficiency 
Subject 5 showed a phenotype distinct from subjects 1-4 with preservation of 
lymphocytes and a myeloproliferation accompanying the monocyte and DC 
deficiency. In addition, the presentation as an infant highlighted the possibility of 
a congenital genetic mutation as a cause of the phenotype. 
 
6.3.1 Analysis of CD34+ progenitors in Subject 5 
In order to characterise the haematopoietic compartment more fully, and 
potentially identify where in DC and monocyte ontogeny a defect had occurred, 
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CD34+ progenitor subsets were analyzed as previously described. BM was not 
available from subject 5, but as CD34+ populations similar to BM are seen in 
normal PB, circulating CD34+ cells were analyzed in their place.  
 
An accumulation of both MLP (1.4 fold increase) and GMP (10 fold increase) 
was seen in PB (Figure 6.2). Some B/NK were detectable, but in relatively 
reduced proportions. Unlike PB from controls, circulating HSC were also 




6.3.2 IRF8 deficiency in subject 5 
The similarity between the combination of DC deficiency and myeloproliferation 
and mice with mutations in interferon regulatory factor 8 (IRF8; also known as 
ICSBP) was noted by Dr Sophie Hambleton. Genomic DNA from subject 5 was 
sent to Philippe Gros’ laboratory (Department of Biochemistry, McGill 
University, Montreal, Canada) and was sequenced by Sandra Salem. 
Sequencing revealed homozygosity for a point mutation in IRF8 leading to a 
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lysine to glutamic acid substitution at position 108 (K108E), within the DNA 
binding domain (DBD) (Figure 6.3, A).  
 
Molecular modeling by David Burk and Albert Berghuis (McGill University, 
Montreal, Canada), mapped K108 to a short beta strand running parallel to the 
major DNA-binding alpha helix (B by kind permission of Albert Berghuis). The 
mutation was shown to disrupt the hydrogen bonding, and thus binding, to DNA. 
This would have the effect of preventing the downstream transcriptional 
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6.3.3 Inheritance of K108E mutation 
In order to establish the inheritance pattern of the IRF8 K108E mutation, 
genomic DNA from both parents and the subject’s sibling (6yrs old at time of 
analysis) was also sequenced in Philippe Gros’ laboratory.  
 
Whilst DNA was being analyzed, PB phenotyping of subject 5’s parents and 
sibling was undertaken (Figure 6.4, A and B). At the time of testing, both 
sibling and mother were well. Father was being investigated for mild, 
asymptomatic lymphadenopathy, biopsy of which was shown to be negative for 
infection and malignancy, with no further investigation planned. There was no 
evidence of depletion of monocytes, DC or lymphocytes in parents or sibling.  
 
Heterozygosity for the K108E allele was confirmed in both parents (who were 
unrelated but originated from the same part of Ireland). The sibling was wild 
type. This confirms the classical recessive inheritance of the K108E mutation, 
demonstrating that heterozygosity for K108E mutation does not confer an 
abnormal phenotype (C). 
 




6.4 Results II: DCML Deficiency; genetic work up of subjects 1-4 
In contrast to IRF8 deficiency in which there is myeloproliferation, patients with 
DCML deficiency had normal BM cellularity (Figure 5.1).  To understand the 
genetic basis of DCML deficiency and the differences between this disorder and 
IRF8 deficiency, the CD34+ compartment from these subjects was analyzed as 
described, and steps were taken to identify any causative genetic mutations.  
 
6.4.1 CD34+ Compartment in DCML Deficiency 
Bone marrow was available for analysis from subjects 1, 3 and 4 (Figure 6.5, 
A). Total BM mononuclear cells analyzed are shown. The minimum number of 
CD34+ cells analyzed was 4500. Numbers in black type indicate % of CD34+ 
cells in each gate. All definitions are as described in Chapter 4. However, in this 
analysis it was not possible to separate Flt3+ CMP from Flt3- MEP as Flt3 was 
not expressed by CD34+ cells in the subjects 1-4, therefore CMP and MEP 
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were analyzed in a combined gate. Total CD34+ cells are depicted (‘Live 
CD34+’) in the central panel.  
In DCML deficiency, a complete absence of MLP from gate 2 was seen. In 
keeping with this, an immediate progeny of the MLP, the CD10+ B/NK 
precursor, was also absent. GMP were depleted by between 72% and 95%. 
 
To determine whether these deficiencies in BM were reflected in PB, circulating 
CD34+ cells from subject 3 were also analyzed (B). This was found to be the 
case as MLP and B/NK were virtually absent from PB and GMP were markedly 
reduced. All other populations were identifiable, including a small number of 
HSC, in contrast to normal PB (Figure 4.2). 
 




6.4.2 Familial case of DCML Deficiency: Subject 3  
Having identified the same distinct defect in haematopoiesis in all DCML 
subjects analyzed, despite their clinical heterogeneity, the possibility that this 
condition might be caused by a similar mutation in all subjects arose. Aside 
from individually sequencing candidate genes, the search for potential genetic 
cause of DCML deficiency would be significantly assisted by a complete 
pedigree of affected and unaffected relatives.  
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In the pedigree of subject 3, five individuals were identified as potentially 
affected according to their clinical history (Figure 6.6). All were deceased. The 
subject’s father was treated for arthritis and died approximately 40yrs old of 
‘lung problems’. The other affected relatives died of ‘leukaemia’ or ‘cancer’ 
around their 4th decade. As yet, there is no preserved genetic material available 




Subject 3’s mother, four second-cousins (A-D) and a cousin-once-removed (E) 
were available for phenotype analysis but had no symptoms relating to DCML 
deficiency at the time of analysis. E was 44yrs old with 2 healthy children (aged 
6 and 9yrs), born at term. 2nd cousins A-D were 25yrs, 23yrs, 22yrs and 18yrs 
old with no medical problems. A had 2 young, healthy children also born at 
term.  
The subject’s daughter was born prematurely at 28 weeks. This is a recognised 
complication of DCML deficiency as described by Vinh et al., 2010. At the age 
of 3yrs old there were still respiratory and nutritional problems relating to 
prematurity, but several full blood counts, taken during routine clinical care, 
showed no evidence of monocytopenia or lymphopenia. 
None of the other subjects had any relevant medical family history. 
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6.4.3 Phenotype of Subject 3’s relatives 
PB Monocyte, DC and lymphocyte subsets were analyzed for subject 3’s 
mother, four second-cousins and a cousin-once-removed (Figure 6.7, A and 
B). As the positive family history came from the paternal side, the mother was 
expected to be normal. Interestingly, she had a CD14+ monocyte count below 
the normal range but was clinically entirely asymptomatic from this. The 
remaining members of the family tested had results at the lower end of the 
normal range (dotted lines in Figure 6.7). All were well at the time of testing.  





6.4.4 Gene expression in CD34+ compartment 
Based on genes found to be important in murine DC development, the 
consequences of their disruption, and the observation of elevated serum Flt3L 
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and M-CSF levels in the subjects, PB CD34+ cells, from subjects 3 and 4, were 
analyzed for mRNA expression of a number of genes. CD34+ cells from PBMC 
were flow sorted by FACS from subjects 3 and 4, and 2 healthy controls. Figure 
6.8 shows the results of Q-PCR for STAT3, IRF8, Flt3, PU.1 and M-CSF-R. The 
results are expressed as mean of 2 subjects normalised against mean of 2 
controls, with each analysis performed twice. M-CSF-R mRNA, although 
detectable in controls, was undetectable in subjects (equivalent to <0.8% of 
controls). IRF8 expression was markedly reduced while Flt3 and PU.1 mRNA 
levels were approximately half that of controls. STAT3 was mildly reduced at 




6.4.5 Gene sequencing 
A number of candidate genes have been sequenced in the DCML subjects. 
Subject 1’s DNA was sent for IRF1 and IRF8 sequencing (Philippe Gros’ 
laboratory, Department of Biochemistry, McGill University, Montreal, Canada), 
and Flt3, Flt3L and Gfi-1 sequencing (Jacques van Dongen’s laboratory, 
Department of Immunology, Erasmus Medical Centre, Rotterdam, The 
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Netherlands). SPI1/PU.1 gene in subject 3’s granulocyte and fibroblast DNA 
was prepared in our laboratory (Sarah Pagan and Rachel Dickinson) and 
sequenced in Dundee (see Figure 6.1). No mutations have yet been identified. 
However, the upstream regulatory element (URE; proximal and distal units – 
PRU and DRU), located 17kb upstream of the transcription start site, has not 
yet been sequenced. 
 
6.5 Discussion 
The phenotyping of subject 5 lead directly to the diagnosis of autosomal 
recessive IRF8 deficiency, the first recognised genetic cause of DC deficiency 
in humans. Although very similar, the phenotype of DCML deficiency suggests 
an alternative defect which is yet to be identified. Meanwhile, analysis of the 
CD34+ compartment in these disorders has revealed not only further differences 
between the two conditions but also allows some inferences about DC and 
monocyte haematopoiesis to be drawn. 
 
6.5.1 IRF8 deficiency 
IRF8, a member of the Interferon Regulatory Factor family, is expressed at 
highest levels in DC (184) and plays a role both in DC differentiation (185) and 
the transcription response to interferons (186) and toll like receptor agonists 
(187). The IRF8 sequence is highly conserved across species and IRF8-/- mice 
have a very similar phenotype; they lack monocytes, pDC, and mDC and show 
marked myeloproliferation (85). 
 
As IRF8 is expressed almost exclusively in the haematopoietic system, it was 
likely that HSCT would be curative for IRF8 mutation, and no further 
consequences of germ line IRF8 mutation would be expected. Subject 5 
received a matched unrelated donor cord blood transplant at the age of 9 
months and is alive and well at 1yr post-transplant. There was no overt clinical 
or cellular phenotype associated with K108E heterozygosity, confirming the true 
recessive nature of this condition. 
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6.5.2 CD34+ progenitor compartment 
It has previously been demonstrated that DC potential resides in both myeloid 
and lymphoid compartments in humans (106) (188). Doulatov et al., have 
recently described the MLP, able to form DC, macrophages and lymphoid cells 
at a single cell level, but lacking erythroid, granulocyte or megakaryocyte 
potential. 
In keeping with the cellular phenotype of DCML deficiency, the MLP population 
in subjects 1-4 was absent. The GMP subset was also markedly reduced. 
Although clearly being able to support granulopoiesis, as the subjects had 
normal numbers of circulating neutrophils and eosinophils, they were unable to 
give rise to monocytes or DC. 
 
The phenotype in the CD34+ progenitor cell compartment proves that DCML 
deficiency arises as the result of a defect in bone marrow haematopoiesis. It 
also suggests that MLP at least contribute to the normal homeostasis of DC and 
monocytes and is consistent with models of haematopoiesis in which DC and 
monocytes may arise from both lymphoid (MLP) and myeloid (GM) origins 
(106), (188), (89). 
 
In comparison, IRF8 deficiency results in a defect later in DC ontogeny, as 
accumulation of MLP and GMP is seen. It is likely that myeloproliferation, driven 
by raised Flt3L, occurs as GMP are present in large numbers, are unable to 
differentiate down the DC/monocyte route but maintain their granulocyte 
differentiation potential. DCML deficiency subjects, despite massive elevation of 
Flt3L, are not myeloproliferative, again suggesting an earlier block in 
differentiation with either reduced responsiveness to Flt3L or insufficient 
numbers of GMP to allow myeloproliferation.  
 
6.5.3 Genetic work-up of DCML deficiency: Hereditability  
In order to observe the complete absence of a haematopoietic cell population 
due to a genetic lesion, the defect must be germ line or haematopoiesis must 
be clonal, having acquired a somatic mutation that confers a selective 
proliferative advantage.  It is also conceivable that a germ line mutation may 
predispose to the development of clonal haematopoiesis through a 
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predisposition to the acquisition of a further mutation(s), such as in the case of 
Fanconi’s anaemia. This is an autosomal or X-linked recessive disorder of DNA 
repair that leads bone marrow failure, and the development of haematological 
and/or solid tumours, probably due to the acquisition of further mutations.  
 
Another explanation is that the DCML mutation causes a stromal defect which 
renders the tissues unable to support DC. This was ruled out as both subjects 1 
and 3 showed complete repopulation of PB and tissue DC and monocyte 
subsets following haematopoietic stem cell transplantation. 
 
The family pedigree of subject 3 strongly suggests an autosomal dominant 
inheritance of a germ line mutation. The potential contradiction in this family 
tree is that none of the four second-cousins appear to be affected. In an 
autosomal dominantly inherited condition, the chance of four unaffected 
children being born to an affected parent is 6.25%. As the youngest is only 
18yrs and presentation of DCML deficiency can be as late as the 5th decade, it 
is possible that the phenotype is not yet apparent. However, subject 3 had a 
documented monocytopenia from the age of 10yrs and all affected relatives 
died in their 30s or early 40s with a prodromal illness of some years. 
 
The other three cases appear sporadic with no parental history of relevant 
illness. One pedigree shown in the case series by Vinh et al., (170) describes 
an affected individual who had clinically unaffected parents but produced a son 
who had severe HPV infection and died of leukaemia at the age of 17yrs, 
symptoms suggesting he also had DCML deficiency. This implies that the 
sporadic mutation in this case, originated at meiosis, giving rise to a germline 
mutation. The children of our subjects (subject 3, 1 child; subject 4, 2 children) 
have not been tested as all are under 10 years old and clinically well. 
 
It is hoped that comparison of DNA from fibroblasts and the haematopoietic 
system (available for subjects 3 and 4) may reveal whether any potential 
mutations were constitutional or acquired somatic mutations restricted to the 
haematopoietic compartment. Whether a molecular recessive mutation is 
sufficient to acquire the disorder, or whether a homozygous state is required is 
not clear at present. Inheritance that is consistent with an autosomal dominant 
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trait but recessive molecular pathology is shown by many cancer genes, for 
example retinoblastoma (189). 
 
There is some variation in the age of presentation, even within kindreds, and a 
significant variation in the type of symptoms experienced, despite a remarkably 
similar cellular phenotype. This phenomenon is also seen in paediatric immune 
deficiencies where mutations in one gene can be associated with a number of 
different phenotypes (190). However, the reverse is also true where several 
different genetic mutations can result in a similar phenotype. The phenotypic 
differences in DCML deficiency may therefore reflect the different environmental 
challenges encountered, the different consequences of mutations within one 
gene or suggest different genetic mutations which happen to result in a similar 
cellular phenotype.  
 
6.5.4 Genetic work-up of DCML deficiency: Candidate genes 
A number of candidate genes were sequenced in DCML deficiency subjects. 
The initial prime candidate was Flt3 as it has been shown to be essential for 
mouse DC development. Although high Flt3L levels can lead to down-regulation 
of Flt3 (164), a mutation of Flt3 could have been the primary defect. However, 
Flt3 mRNA was detectable in PB CD34+ progenitors by Q-PCR, at 40.1% of 
normal and no mutation was found on sequencing the gene.  
 
Figure 6.9 shows a diagramatic representation of the potential integration of 
signalling pathways for FLt3L, GM-CSF and M-CSF based in part on a figure 
from (191). Flt3 signalling is dependent on STAT3 (183) which in turn activates 
PU.1 and Flt3 itself. IRF8 and M-CSF-R are also downstream targets (126) 
(130). Stat3 and PU.1 mRNA were detectable in PB CD34+ cells at 76.5 and 
46.9% of normal, respectively, and no PU.1 mutation was detected on gene 
sequencing. IRF8 and M-CSF-R are also downstream targets of Stat3 
signalling. mRNA analysis, again from PB CD34 progenitors, showed a marked 
reduction in IRF8 mRNA (7.8% of control levels) and M-CSF-R was virtually 
undetectable (threshold 0.8%). However, IRF8 gene was sequenced in one 
DCML subject and found to be wild type. M-CSF-R mutation as a primary lesion 
is less likely as mice with CSF-1R deficiency show primarily macrophage 
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deficiencies, including osteopetrosis, and also lack LC. Interpretation of mRNA 
levels is slightly complicated by the absence of MLP and reduced numbers of 
GMP in DCML deficiency subjects compared to controls. It is therefore difficult 
to assess whether reduced levels of a particular mRNA are due to absence of a 




A number of other candidate genes have been sequenced in DCML deficiency, 
both in our subjects and those described by Vinh et al.. (170). In our subjects, 
the list of genes sequenced to date, with no mutations identified, includes PU.1, 
Flt3, Flt3L, Gfi-1, IRF1 and IRF8. Vinh et al., also sequenced the following 
genes: IL12Rb1, IFNGR1, IFNGR2, Stat1, Stat2, JAK2, GNB2L1, CSF2, 
CSF2RB, C/EBPA, C/EBPB, C/EBPD, C/EBPE, RUNX1, IRF4, ICSBP1, 
PDGFRB, RhoH, HSP90AB1, CXCL14, CCR5, CSCR4, CSCL12 (SDF-1) with 
no mutations found. A number of potential candidates have therefore not yet 
been sequenced, including stat3, stat5, IRF2 and Id2.  
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Another area of particular interest is the upstream regulatory element (URE) of 
PU.1. Targeted disruption of this URE has been shown to reduce PU.1 
expression by 80% (134). Sequencing of this region is in progress. 
 
Work on the genetic basis of DCML deficiency is therefore ongoing. 
 
6.5.5 Further biological implications 
The absence of DC, B- and NK-cells in DCML deficiency, together with the 
absence of the MLP, suggests that at least some of these cells share a 
common origin from HSC up to, and including, the MLP. These observations 
are in keeping with the hypothesis that a divide into myeloid and lymphoid 
lineages is not the first step in haematopoiesis and that myeloid and lymphoid 
progenitors may loose erythrocyte and megakaryocyte potential prior to the 
myeloid/lymphoid division.  
 
This may have implications for the pathophysiology of a number of 
haematological malignancies. These include biphenotypic leukaemia, 
characterised by leukaemic blasts expressing both myeloid and lymphoid 
antigens. Hairy Cell Leukaemia (HCL) presents typically with an absolute 
monocytopenia by standard blood counting methods, and the presence in PB 
and BM of leukaemic cells with DC-like cytoplasmic villi, expressing both DC 
and B cell antigens. Finally, the pathological cells of Hodgkin’s Disease also 
express DC and B cell markers. Defining whether these diseases developed as 
disorders of stem cell differentiation, or due to the clonal expansion of more 
mature cells, may lead to identification of signaling pathways and potentially 
genes involved and would help define more specific treatment strategies.  
 
6.6 Further work 
Further work will aim to discover the genetic basis for DCML deficiency. 
 
The following strategies are being taken: 
1. Collaboration with John Dick’s group (Division of Cell and Molecular Biology, 
University Health Network and Department of Molecular Genetics, University of 
Toronto, Toronto, Ontario M5G 1L7, Canada). Expression array data from 
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CD34+ progenitor subsets has been collected and a list compiled of genes 
expressed preferentially in MLP and GMP, and a list of those in HSC, MLP and 
GMP.  
 
2. ‘Exomics’ analysis of PB granulocytes and skin fibroblasts from subjects 3 
and 4. The exomic sections of DNA from these samples will be sequenced and 
screened for mutations in candidate genes identified from the literature and the 
lists from John Dick’s laboratory. 
 
3. More detailed history of subject 3’s family will be undertaken and any 
material suitable for genetic analysis from apparently affected relatives will be 
sought. 
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Chapter 7. Langerin Positive Dendritic Cells 
7.1 Introduction 
Langerin was so named after its discovery on Langerhans cells. It was believed 
to be specific to LC until the recent description of Lang+DC subsets, 
independent of LC, in mouse spleen and peripheral tissues. Whether Lang+ DC 
can be found in humans has not been examined.  
7.1.1 Langerin History 
Langerin has been presumed to be specific to LC as it was first identified on 
these cells, and so named, in 1999 by Valladeau et al. (192). It was shown to 
be C-type lectin, recognizing glycosylated moieties on pathogens. It is an 
endocytic receptor which, when internalised, associates with Birbeck Granules 
(71). Langerin is expressed on the cell surface, intracellularly in the endosomal 
recycling compartment and together with CD1a in Birbeck granules; tennis 
racket-shaped, cytoplasmic organelles (193). 
 
7.1.2 Langerin expression in the mouse 
As discussed in Chapter 1, langerin expression in mice is not specific to 
epithelial LC. It is also found on CD8+ LN resident DC and on a proportion of 
interstitial skin, lung, liver and kidney CD8-CD103+ migratory DC (35). These 
Lang+DC subsets have been shown in mice to be independent of LC by their 
GF requirement and different repopulation kinetics following bone marrow 
transplant (34). Work with KO mice has demonstrated the dependence of 
epidermal LC on M-CSF-R (110) and TGF# (194), where Lang+ dermal DC are 
dependent on Flt3 signaling (33) (195). Lang+ DC were also distinguishable by 
their lack of expression of other LC markers, such as EpCam and E-Cadherin, 
both cell adhesion molecules, thought to be LC-specific (196) (197). 
 
7.1.3 In vitro induction of human langerin expression 
A number of in vitro systems have been shown to induce langerin expression 
on human cells. A proportion of CD34+ cells, cultured with either GM-CSF and 
TNF", or under the influence of TGF#, show langerin expression. However, the 
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phenotype of langerin expressing cells, cultured with TNF", more closely 
resembles that of a DC due to their expression of CD1c and CD11c and virtual 
lack of E-Cadherin (75).  
 
Similarly, monocytes cultured with GM-CSF, IL-4 and TGF#, but not those 
without TGF#, express E-cadherin (83). However, Lang+ cells differentiated 
from monocytes in vitro, unlike freshly isolated LC, were able to produce IL-12 
in response to LPS stimulation (198), a function typical of DC (199). Whether 
these Lang+ cells derived in vitro are LC, LC-like, or whether they are Langerin 
expressing DC is not clear. 
 
7.1.4 Langerhans Cell Histiocytosis 
Whether langerin is specific to LC has direct relevance to the pathophysiology 
of Langerhans cells histiocytosis (LCH). This rare, but potentially fatal condition 
is characterised by the accumulation of Lang+CD1a+ cells (LCH cells), admixed 
with lymphocytes, eosinophils, neutrophils and macrophages, in tissues 
including bone, bone marrow, skin, pituitary and central nervous system, liver, 
lung and gastrointestinal tract. Due to their langerin expression, LCH cells have 
been presumed to arise from LC. However, if langerin expression is not 
confined to epidermal LC, the cellular origin of the LCH cell may be questioned. 
Determining the origin of LCH cells is a critical step in the understanding of LCH 
pathogenesis and may potentially guide treatment strategies. 
 
7.2 Materials and Methods for Chapter 7 
7.2.1 FACS sorting of Langerin+ skin cells from control skin 
Whole skin, cut with a size 8 dermatome knife, was collagenase digested as 
previously described. Cells were filtered through a 100micron mesh and stained 
for flow cytometry with the equivalent of 1-2x106 cells in 50µl of flow buffer with 
5µl of each antibody. After washing and resuspending the cells, DNAse I 
(Roche, www.roche.com) was added at 0.1mg/ml, to prevent cell clumping due 
to DNA release from dying cells during the 2-3hr sorting process. Cells were 
collected into RPMI and immediately pelleted and lysed in RNA lysis buffer prior 
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to dispatch on ice to Texas (Carl Allen, Texas Children’s Cancer Center, Baylor 
College of Medicine, Houston, TX 77030) for QPCR analysis. 
7.2.2 FACS sorting of Langerin+ skin cells from clinical samples 
Typically, a maximum of 100,000 cells would be available from a digested 
clinical skin biopsy, of which approximately 60% would be CD45+, half of these 
HLA-DR+ and 2/3 of these DC. Due to their rarity, cells were sorted directly onto 
glass slides, into a drop of buffer.  Slides were allowed to air dry prior to fixing 
with cold methanol. This was achieved by pipetting 100µl drop of methanol onto 
the slide and allowing it to air-dry prior to 2mins in methanol in a coplin jar. The 
number of cells varied with the size of the biopsy and efficiency of the digestion.  
 
7.2.3 LCH sample preparation 
LCH lesions were processed to a single cells suspension for flow cytometric 
analysis. Lesion 1, vitreous fluid, was dissociated with a 20G needle and 
syringe and stained directly. Lesions 2, 3 and 5, biopsy of a neck mass, mouth 
lesion and sphenoid were dissected into pieces approximately 2mm diameter 
and digested in RF10 with 0.8mg/ml collagenase at 370C for 4hrs. These were 
then filtered through a 100micron filter and stained for flow cytometry. Lesion 4 
was processed identically to all other skin samples as previously described.  
 
7.3 Results I: Langerin positive Dermal DC 
Langerin expression in humans has only been described on epidermal LC. 
Following the description of Lang+DC in mouse dermis, the distribution of 
langerin expression in human skin was re-examined. 
 
7.3.1 Flow cytometric analysis of langerin expression in skin 
To determine whether human peripheral tissue DC populations, other than LC, 
expressed langerin in healthy tissue, whole skin was collagenase-digested and 
stained for flow cytometry with fluorescent antibodies against CD45, HLA-DR, 
CD14, CD1a and langerin, with a channel free for autofluorescence. The 
CD45+HLA-DR+AF- DC compartment of digested whole skin contained a 
population of CD1abright Lang+ cells, consistent with the phenotype of LC (Figure 
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7.1, red gate). There was also a proportion of CD1a+ cells seen to express 
langerin (blue gate) above background levels as defined by isotype control. 
This Lang+DC population (LDC) represented 1.47-7.53% (mean 3.67%, n=15) 
of CD14- cells in whole skin. There was no langerin expression seen in the 




7.3.2 Langerin+ DC distribution in healthy skin 
Having identified two possibly independent Lang+ populations in whole skin, the 
compartmental distribution of these cells was examined. Dermis and epidermis 
were digested and analyzed separately. In addition to cells obtained through 
digestion, migrated cells were studied to assess the stability of the phenotype 
and the migratory ability of LDC. As both LDC and LC expressed CD1a, albeit 
at different intensities, Epithelial Cell Adhesion Molecule (EpCam), shown in 
mice to be specific to LC, was investigated as an antigen to distinguish between 
the two Lang+ cells types. 
 
CD1a+Lang+ LDC could be identified in digested dermis, but not in epidermis 
(Figure 7.2, A). In contrast to LC, and as predicted by mouse, LDC did not 
express EpCam. Identification of LDC by EpCam and Langerin expression 
demonstrated similar numbers of cells as by CD1a and Langerin expression, 
suggesting the same population was being described. When migrated cells 
were examined, similar proportions of LDC were found as to when the same 
skin preparation was digested (n=5). Migratory CD1a+Lang+EpCam- LDC could 
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be identified from dermis and whole skin, but not epidermis. CD1a and langerin 
expression were found to be slightly less intense on all migrated cells (A). LDC 
and LC were still distinguishable by their differing levels of CD1a and 
contrasting EpCam expression. The stability of the LDC phenotype during 
migration suggests that this population may constitute a DC subset independent 
of LC.  
 
The ratio of number of LDC:LC in digested skin compartments, identified by 
CD1a and EpCam expression, suggested a compartmental independence of 
the two cell subsets (B). The highest ratio was found in digested dermis, where 
most LC had been removed when the epidermis was removed; the only 
remaining LC being those migrating via dermal lymphatics to skin-draining LNs. 
The lowest ratio was in epidermis, where only LC were found. Whole digested 
skin contained both subsets. 
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7.3.3 Intracellular Langerin 
As well as being expressed on the cell surface, langerin is known to exist 
intracellularly in endosomes and BGs in LC. Analysis of intracellular langerin in 
LDC was undertaken. Intracellular langerin staining identified similar proportions 
of LC and LDC as extracellular langerin staining in digested whole skin with 
CD1a or EpCam included (Figure 7.3).  
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7.3.4 Distinct antigen expression profile of LDC compared to LC 
In order to identify any antigens, besides EpCam, expressed discrepantly by 
LDC and LC, cells were examined for surface protein and cytoplasmic mRNA 
expression of a panel of DC- and myeloid-related antigens. 
  
As part of an ongoing collaboration, LDC, LC and CD1a+DDC populations were 
sorted locally by FACS and sent as RNA lysate to Carl Allen, Texas Children’s 
Cancer Center and Hematology Service, Baylor College of Medicine, Houston, 
TX 77030, where they were interrogated with QPCR techniques to reveal 
mRNA expression differences (Figure 7.4, B).  
 
While LDC showed surface expression of CD13, CD31, CD11c and CD11b, LC 
were negative for these antigens (Figure 7.4, A). When plotted against 
langerin, similar proportions of LDC were identified with these antigens as with 
CD1a or EpCam. mRNA expression results were concordant for these antigens, 
as well as CD207/langerin and EpCam. Although it was not possible to confirm 
the expression of E-Cadherin by flow cytometry, mRNA analysis showed 
greater expression in LC.  





7.3.5 Microscopy of LDC and LC 
To examine the cellular distribution of langerin in LDC and LC, these 
populations, together with CD1a+DDC, underwent FACS cell sorting, according 
to the gating strategy in figure 7.1, using a panel of antibodies including 
mouse-clonal-anti-langerin antibody. The sorted cells were cytospun onto slides 
and then stained for cytology with giemsa staining, or immunofluorescence 
microscopy with goat-polyclonal-anti-langerin and rabbit-anti-goat-secondary, 
anti-HLA-DR and DAPI and imaged with Zeiss axioplan 2 microscope.  
 
This revealed differences between LDC and LC in both the cellular morphology 
and the cellular distribution of langerin. Morphological differences were seen 
with giemsa staining (Figure 7.5). CD1a+DDC and LDC had similar 
appearances with more compact chromatin within the nucleus and a higher 
nuclear:cytoplasmic ratio than LC. LC were more likely to have preserved 
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dendrites. By fluorescence microscopy, examination of langerin expression 
revealed that LC had a distinct perinuclear distribution of langerin, particularly 
concentrated in the golgi zone, while LDC had a more diffuse cytoplasmic 




7.3.6 Kinetics of LDC and LC chimerism following haematopoietic stem 
cell transplantation 
Differing kinetics of APC donor chimerism have been seen at D40 following 
human HSCT when DDC are mainly donor in origin while LC remain 
predominantly recipient (73). In order to determine whether the homeostasis of 
LDC following HSCT was more similar to DDC or LC, the chimerism of skin LC 
(n=4), LDC (n=4) and CD1a+DDC (n=2) was examined at Day 40 (D40) 
following sex-mismatched, reduced intensity conditioned, human HSCT. 
Patients had no prior or concurrent graft versus host disease (GvHD). This was 
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compared to the chimerism of peripheral blood monocyte and DC in paired 
samples. Peripheral blood CD14+ and CD16+ monocytes, mDC and pDC were 
sorted according to the gating strategy in figure 7.6, A. Whole skin shave 
biopsies from HSCT subjects were collagenase digested overnight and then cell 
populations sorted directly onto glass slides. From CD45+HLA-DR+AF- cells LC, 
LDC and CD1a+DDC were identified as depicted in Figure 7.6, B (red, blue and 
green gates respectively). The number of cells sorted and fixed onto slides was 
variable. LC ranged from 4-349 cells/slide, LDC from 84-229 and DDC from 




These were examined by Fluorescence in situ hybridization (FISH) for X and Y-
chromosomes. A minimum of 100 cells was counted, where possible, otherwise 
all cells present on the slide were assessed.  
 
PB monocytes and DC were 100% donor at D40 in all patients studied. In skin, 
LDC and CD1a+DDC had a mean % donor chimerism of 92.6% and 95.0% 
respectively, while LC showed a mean of 12.9% donor chimerism, significantly 
lower than LDC (p=0.004; paired t-test). The homeostasis of LDC following 
HSCT therefore more closely resembles that of DDC than LC, suggesting that 
these cells have a physiological behavior more in keeping with DDC. 
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7.3.7 Langerin expression in dermis of DCML deficiency patients 
As discussed in Chapter 5, DCML deficiency subjects maintain their LC 
population in the absence of other PB or dermal DC populations. Again to 
examine whether LDC and LC were homeostatically independent, the skin of 
DCML subjects was examined for the presence LDC.  
 
Figure 7.7 shows CD45+HLA-DR+AF-CD14- DC from digested dermis of 
subjects 1 and 4 compared to control (the same control as in Figure 7.2) with 
CD1a plotted against Langerin. As previously, CD1abrightLang+ LC are gated in 
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red and CD1a+Lang+ LDC in blue. Plots are normalised to display the same 
number of cells in the LC gate (30 cells). Subjects 1 and 4, despite the finding 
of migrating LC in the dermis, had no LDC. This is in marked contrast to 




7.3.8 Lung tissue 
To examine the biological independence of LDC from LC, tissue with no 
resident LC population was examined. Macroscopically normal lung 
parenchyma from tumour resection specimens was examined. This was 
collagenase digested and analyzed with the same fluorochrome panel and 
gating strategy as for skin DC (Figure 7.8, A). As expected, no CD1abrightLang+ 
LC were present (red gate) but CD1a+Lang+ LDC were found, representing 
10.4% (mean of n=3, range 7.9-13.5%) of CD45+HLA-DR+AF-CD14- lung DC. 
Similarly to LDC in skin, these cells were negative for EpCam expression (B). 
 




7.3.9 Langerin expression in PB 
No langerin expression was seen on PB monocytes or DC in freshly isolated, 
ficoll-prepared PBMC. However, when cells from a leukoreduction chamber, or 
‘cone’ were examined, 1.2% of CD11c+mDC showed langerin expression (n=2) 
(Figure 7.9). No langerin was seen on monocytes or pDC, compared to isotype 
control. The Lang+ mDC were negative for CD1a expression. 
 




7.4 Results II: Analysis of LCH lesions 
In order to explore whether LCH cells may more closely resemble LDC than LC, 
flow cytometry was used to further phenotype LCH cells and to compare them 
with the two Lang+ cells subsets found in healthy skin: LDC and LC. In addition, 
the immunohistological diagnosis of LCH in routine clinical practice takes 
approximately 4-5 days. With the methodology available to extract single cells 
from tissues and analyse langerin-expressing cells by flow cytometry, the 
possibility of obtaining a diagnosis in a few hours became apparent.  
 
7.4.1 Flow cytometric analysis of LCH lesions 
Five lesions from four patients, suspected on clinical grounds to have LCH, 
were examined for the presence of CD45+HLA-DR+CD1a+Lang+ LCH cells by 
flow cytometry. Where sufficient material permitted, analysis for surface 
expression of DC-associated markers was undertaken. Clinical details of 
patients and anatomical locations of lesions are given in table 7.2. All material 
was from diagnostic biopsies of suspected LCH cases, with no prior treatment. 
Where solid material was received (lesions 2-5), this was collagenase digested 
for 4-12hrs prior to analysis. Where material was viscous (lesion 1) this was 
dissociated mechanically with needle and syringe prior to analysis. 
 





Figure 7.10 shows flow cytometric analysis of five lesions, revealing in all 
samples CD45+DR+AF-CD1a+Lang+ cells with a phenotype in keeping with LCH 
cells. Gated in this way CD1a+Lang+ LCH cells constituted 46-82% of lesional 
DC cells.  
 




7.4.2 Antigen expression profile of LCH cells compared to LC and LDC 
To determine whether LCH cells shared any phenotypic characteristics, other 
than langerin expression, with LC or LDC, the cell surface expression and 
mRNA levels of antigens found to be discrepant between LDC and LC were 
analyzed. 
 
Phenotypic similarities of LCH cells to LDC by flow cytometry included the level 
of CD1a and CD11c expression and negativity for EpCam. Similarities with LC 
included lower expression of CD11b and CD13 (Figure 7.11, A).  The intensity 
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of langerin expression on LCH cells fell between that of LC and LDC while 
expression of CD14 varied between lesions.  
 
When interrogated by QPCR, results were concordant with surface expression 
of Langerin, EpCam and CD13. In addition QPCR for E-Cadherin and CD31 
showed mRNA levels in LCH cells similar to LDC and CD1a+DDC. No Langerin 
or EpCam mRNA was detected in the DDC pool (Figure 7.11, B). There was 
discrepancy between surface expression and QPCR results for CD11c. By flow 
cytometry, LC were clearly negative while LDC and LCH cells (and CD1a+DDC, 
shown previously, figure 3.10) were positive. QPCR showed a greater similarity 
in CD11c mRNA although LCH cells were closest to CD1a+DDC.  
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7.4.3 Cell cycle in LCH cells 
Sufficient cells were available from lesion 2 (neck mass) for cell cycle 
assessment by Ki-67 and DAPI staining (Figure 7.12). Once again LCH cells 
were identified as CD45+HLA-DR+CD1a+Langerin+ and then singlets excluded 
by gating DAPI-area versus DAPI-width. 9.5% of LCH cells were found to be Ki-
67+ corresponding with cells in G1, S, G2 or M phase. However, there was 
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some background staining with isotype control so subtracting this gave a figure 





Langerin expression has been found on a subset of human dermal DC which 
have phenotypic distinctions from LC and appear to show different homeostatic 
mechanisms in disease. Furthermore, analysis of the Lang+ LCH cell has 
shown it to be at least as closely related to this newly described LDC as to LC.  
 
7.5.1 LDC represent a subset of DC distinct from LC 
LDC appear phenotypically and homeostatically distinct from LC and may be 
more closely related to CD1a+ dermal DC. Langerin expression in LDC is found 
to be genuine as it was seen by flow cytometry above background, compared to 
isotype controls, was found intracellularly, detected by microscopy and mRNA 
expression confirmed by QPCR. The distinction of LDC from LC is seen on a 
number of levels. LDC and LC show phenotypic differences in antigen 
expression, are found in distinct anatomical compartments, are able to exist and 
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maintain their numbers independently in different tissues and show distinct 
kinetics following HSCT.  In contrast, LDC have phenotypic and homeostatic 
similarities with CD1a+DDC as they express CD11c+, CD13+, CD31+, CD11b+, 
have similar morphological features and are replaced by donor cells at a similar 
rate following HSCT.  
 
The identification of Lang+EpCam-CD1a+DC in digested whole skin and dermis, 
and their absence from epidermis, suggests that these cells are anatomically 
distinct from EpCam+CD1abright LC of the epidermis.  This is corroborated by the 
presence of LDC in lung parenchyma where LC are not found. The reverse is 
seen in the skin of DCML deficiency subjects who are able to maintain LC 
numbers despite the absence of DDC, including LDC. 
 
Although the concept of LDC as LC precursors cannot be disproved, their 
presence in tissue devoid of LC, and their absence in DCML deficiency argues 
against this, at least as their inevitable fate. It is possible that the small numbers 
of cells available in DCML deficiency patient biopsies were below the level of 
detection, but were they necessary to maintain LC numbers they might be 
expected to be present in relatively increased proportions due to the absence of 
all other DDC subsets, whereas the reverse is seen. 
 
In addition, LDC could be found in similar sized shave biopsies from patients 
who had undergone HSCT. Although this experiment was technically 
challenging, sufficient LDC could be sorted for successful analysis by FISH. 
The % donor chimerism found in LC and DDC is in keeping with a previous 
published study of the turnover of dermal DC following reduced intensity 
haematopoietic stem cell transplantation in the absence of GvHD, where the 
mean donor chimerism of CD14-DDC at Day 40 was 91.0% and of LC was 
43.1% (73). LDC in the four patients analyzed therefore compare more closely 
to DDC with a mean percent donor chimerism of 92.6% and 95.0%, 
respectively. In contrast, in the same experiment, LC were only 12.9% donor. 
 
If DDC are reliant on blood borne precursors for maintenance of their numbers, 
as suggested by DCML deficiency and HSCT experiments, and as there is no 
langerin expression in fresh PB, it is likely that LDC up-regulate langerin in the 
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tissues. It will be critical to identify any factors that drive or trigger langerin 
expression, and whether this langerin-expressing potential is pre-programmed 
and inherent to a particular cell type, or dependent entirely on the 
microenvironment. Of interest is the observation of langerin expression on >1% 
of mDC isolated from cones. These cells have a very different ex vivo history 
from freshly isolated PBMC. Leukocytes are filtered into the cone during the 2-
3hr platelet apheresis procedure, for which time cells in the cone will be at or 
near 370C. Following isolation of the cone from the apheresis circuit, it is stored 
at room temperature over night. Up to 2 x109 total cells and 1.5 x 109 PMBC 
can be isolated from a cone, from a volume of approximately 5-10ml (143). 
Cells are therefore massively concentrated both during their 2-3hrs at 370C and 
during storage overnight at room temperature. This inflammatory cellular 
suspension might be expected to have phenotypic differences to freshly 
isolated PBMC. Literature published on the viability and activity of cells has 
shown good results but in general cells have been analyzed 3hrs after the 
apheresis procedure, in contrast to the cones available for general use (200). 
 
The ability to express langerin in vitro is seen in CD14+ monocytes and CD34+ 
progenitors in culture with inflammatory cytokines including GM-CSF and TNF". 
As discussed previously, these culture conditions lead to the differentiation of 
cells to a phenotype more similar to LDC than LC; CD11c+CD1c+CD1a+ and E-
Cadherin negative/low (75). It may be that the addition of TGF# is necessary for 
induction of more LC-like cells in terms of CD1a, Langerin and E-Cadherin 
expression (83) (201). Regardless of the semantics, the ability of non-LC cells 
to up-regulated langerin in culture or ex vivo, and independently of other 
antigens specific to LC, suggests that its expression is not sufficient to confer 
an LC phenotype. 
 
7.5.2 Comparison with Murine Lang+DC 
Although Lang+DC are found in mouse dermis, the expression of langerin on 
human LDC is not be sufficient to assign these cells the status of murine dermal 
Lang+DC counterparts. In contrast to LC, both mouse and human dermal 
Lang+DC express CD11c (77) but human LDC constitute a smaller population 
of dermal DC than in mouse. Murine Lang+CD8- dermal DC represent 10% total 
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dermal DC and 2% of total dermal leukocytes (34). In contrast, LDC represent 
only 3.7% of CD14-DC (3% of all DDC) and approximately 1% of total dermal 
leukocytes.  
 
It has been shown that murine dermal Lang+CD8- DC are related to Lang+CD8+ 
LN resident DC, by their dependence on Flt3 and IRF8 and their ability to cross-
present antigen (35). More recently, this LN resident DC has been found to be 
similar to the human CD141high PB mDC in humans as both cell types express 
CLEC9A and XCR1 and can cross-present antigen (67). However, LDC do not 
fall in the human dermal CD141high cell populations identified in Chapter 3, as 
CD141high cells are all langerin negative (Figure 3.10). To determine whether 
there is functional homology between the langerin expressing DC subsets in 
mouse and human, further functional and phenotypic analysis of human LDC is 
required to determine whether these cells express CLEC9A and XCR1 and 
whether they are able to cross-present antigen. 
 
7.5.3 LCH 
The presence in LCH cells of langerin and CD1a on the surface, and Birbeck 
Granules intra-cellularly, has lead to the precept that these cells must originate 
from LC. Several key points raise the possibility that an alternative route to the 
LCH cell may be possible. For example, LCH cells may be inflammatory DC 
which have up-regulated Langerin, suggested by the following points: the 
demonstration of langerin on dermal DC independently of LC; the concept that 
langerin expression may be inducible; the known inflammatory nature of the 
LCH lesion and the tissue distribution of LCH lesions which it is not limited to 
tissues with resident LC populations. 
 
Limited phenotypic and mRNA expression analysis of LDC, LC and LCH cells 
have shown that LCH cells are at least as similar to LDC, or even DDC, as they 
are to LC by the intensity of their expression of CD1a, CD11c, CD13 and lack of 
EpCam and E-Cadherin. 
 
A critical step to taking this argument further will be to identify which cellular or 
soluble factors can induce expression of langerin in situations such as the cone 
   
 165 
(and the LCH lesion). The study of PB monocytes and DC in patients with LCH, 
both their phenotype ex vivo and their culture responses in vitro may also shed 
light on potential circulating LCH cell precursors. 
 
During the course of these studies, a flow cytometry technique has been 
developed for the diagnosis of LCH. This technique is fast, 4-12hrs from biopsy 
to result, as opposed to 4-5 days for immunohistochemistry, can be applied to 
any tissue biopsy, allows simultaneous analysis of large numbers of all lesional 
cell types and has the flexibility to add further diagnostic markers as LCH 
becomes better understood. However, it does not give the additional anatomical 
information afforded by histology. Further work is required to validate the results 
against standard histological findings and to test the negative predictive value of 
the test. 
 
7.6 Further work 
Further work will aim to: 
 
i) Identify cellular or soluble factors involved in langerin expression and test 
their ability to induce langerin expression on potential DC precursors in vitro.  
 
ii) Examine other normal tissues, including liver, gut and lymphoid tissue, to 
develop a map of langerin expression in humans. 
 
iii) Examine human LDC for their expression of CLEC9A and XCR1 and ability 
to cross present antigen. 
 
iii) Examine non-LCH inflammatory lesions to determine whether langerin up-
regulation may be specific to LCH or seen also in other inflammatory conditions. 
For example, lesions of lichen planus have been shown to contain increased 
numbers of Lang+ cells (202).  
 
iv) LCH work will include analysis of PB for potential LCH cell precursors, 
analysis of lesions for soluble factors/cytokines and in vitro culture of potential 
precursors. The flow-cytometric diagnostic analysis will also be validated. 
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Chapter 8. Summaries, Conclusions and Further Work 
8.1 Summary of novel findings 
This work explores the homeostasis of DC and LC in health and disease.  In the 
course of these studies methods to examine human peripheral blood, skin and 
progenitor cell compartments were developed to study the distribution of DC 
and their potential precursors.  Whilst the identity of human DC-restricted BM 
progenitors and blood borne tissue-DC precursors remain unproven, a number 
of novel observations concerning DC homeostasis were made: 
 
i) Cells phenotypically analogous to PB mDC and CD34+ progenitors are 
found in the DC compartment of skin. These cells show characteristics which 
might be expected in ‘pre-tissue DC’ including expression of Flt3 and the 
potential to enter into cell cycle as demonstrated by Ki-67 expression. 
 
ii) Autosomal recessive IRF8 deficiency presents in infancy and results in 
a near absence of monocytes and tissue DC. This demonstrates the in vivo 
reliance of DC and monocyte ontogeny on IRF8 signaling. The haematopoietic 
defect can be traced back to the progenitor cell compartment where 
accumulation of two CD34+ populations, MLP and GMP, is seen, suggesting 
these cells may normally play a role in DC/monocyte ontogeny. 
Myeloproliferation is seen in association with raised Flt3L and expanded GMP 
compartment. 
 
iii) The novel syndrome DCML deficiency presents in early adulthood with a 
propensity to mycobacterial and viral infections, is characterised by near 
absolute DC and monocyte deficiency in PB, with marked reduction in B and 
NK cells, and DC deficiency in tissues. Specific defects in bone marrow 
haematopoietic stem cell compartments are seen with absence of MLP and 
marked reduction in GMP, advancing the idea of a potential dual myeloid and 
lymphoid origin of DC. Despite massive elevation of serum Fl3L, there is no 
accompanying myeloproliferation suggesting a block in haematopoiesis earlier 
than seen in IRF8 deficiency. 
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iv) Human LC homeostasis is independent of PB precursors in the steady-
state. IRF8 and DCML deficiency reveal that LC are able to self-maintain in the 
absence of potential blood-borne precursors. Demonstration of Ki-67+ LC 
suggests the mechanism of LC homeostasis involves self-renewal. 
 
v) The model illustrating interdependence of Treg and DC homeostasis 
and Flt3L in mouse holds true in humans. In both IRF8 and DCML 
deficiency, depletion of DC is associated with reduction in Treg numbers and 
elevation of Flt3L, in keeping with the model proposed in mice. 
  
vi) A population of Lang+DC, independent of LC, is found in human 
peripheral tissues. A subset of DC in dermis and lung express langerin. They 
are shown to be most closely related to mDC through phenotypic analysis, and 
to be independent of LC by their differing homeostatic mechanisms in DCML 
deficiency and following HSCT. 
 
vii) The pathognomonic Langerhans cell histiocytosis cell is at least as 
closely related to a dermal DC as to an LC. LCH cells share phenotypic 
characteristics with LDC and LC. This crucially influences the understanding of 
the origin of LCH cells and changes the emphasis of LCH research.  
  
8.2 PB mDC as pre-tissue DC 
The exact physiological function of PB mDC remains to be determined. They 
are unlikely to be able to interact directly with T cells in blood, requiring cell-cell 
contact. Therefore, in order to function as DC, they must be able to enter either 
peripheral or lymphoid tissue where they can encounter antigen and/or T cells. 
This has been shown for pDC which are found in lymphoid tissue but rarely in 
peripheral tissues, suggesting they transit directly from PB to lymphoid tissue. 
 
A number of observations from this work have strengthened this argument: i) a 
significant proportion of PB mDC are Ki-67+ suggesting they have the potential 
to enter cell cycle. ii) Cells analogous to CD11c+CD141high and CD11c+CD1c+ 
mDC are found in the CD1a-CD14- DC compartment of skin; iv) this skin 
compartment is where the highest proportion of cells in cell cycle is found, 
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excluding epidermal LC; v) When analyzing the CD141high cells in skin, there is 
a spectrum of CD1c and CD1a expression, tempting speculation that these 
cells are able to acquire these markers, perhaps during maturation in tissues. 
 
It is therefore conceivable that mDC act as pre-tissue DC in the steady state 
and are able to divide on receiving further signaling, potentially from tissues. 
Once in tissues, they are able to up-regulate ‘traditional skin DC markers’ 
including CD1a and CD1c.  
 
Further work will aim to build evidence to support or refute this hypothesis 
through in vitro culture work, further analysis of the precise nature of cells in 
cell-cycle in the skin, detailed analysis of repopulation of dermal compartments 
following HSCT and comparative gene expression array analysis of PB and skin 
counterparts. 
 
8.3 Circulating CD34+ progenitors as immediate tissue DC precursors 
It has been shown in mice that circulating progenitors can be found in 
peripheral tissues where they are able to divide and differentiate into myeloid 
cells, or even re-enter the circulation via the lymphatics (108). Work in this 
thesis has shown that CD34+ progenitors are found in human skin where they 
are apparently able to express DC-related antigens, possibly before down-
regulating CD34, as suggested by the absence of CD34 expression in migrating 
cell populations.  
 
The circulating CD34+ progenitors are enriched relative to BM for a subset 
hypothesised as a DC progenitor population, the MLP. Whether this subset is 
preferentially able to enter tissue will be the subject of further research. 
 
Future studies will explore whether these circulating CD34+ progenitors are able 
to contribute to the blood-derived support of tissue DC in the steady-state, 
possibly in a redundant or complementary system with PB mDC, and aim to 
clarify which specific CD34+ subsets are able to perform this role in vivo.  The 
contribution of monocytes to this steady-state process also requires 
investigation.  
   
 169 
 
8.4 Autosomal recessive IRF8 deficiency 
Through the DC profiling work, characterization of the first genetically identified 
defect associated with human DC deficiency has been made. Flow cytometric 
confirmation of the absence of monocytes and DC, in association with a 
myeloproliferation, led to the comparison of the phenotype with that seen in the 
murine model, and so to the diagnosis of IRF8 deficiency. In addition, the 
techniques were able to demonstrate that the heterozygous form of this IRF8 
mutation is not associated with a cellular phenotype.  
 
The cellular phenotype of IRF8 deficiency revealed the dependence of tissue 
DC but independence of LC and tissue macrophages on IRF8 signaling for their 
differentiation or survival. It also highlights the ability of LC to self-renew in 
steady-state and shows that this is not an IRF8 dependent phenomenon.  
 
The accumulation of MLP and GMP suggests that IRF8 signaling is necessary 
beyond this stage of differentiation. However, the myeloproliferation shows that 
granulopoiesis is not dependent on IRF8 signaling and is likely to be driven by 
Flt3L signaling in the expanded GMP population. 
 
Further work will examine the in vitro potential of IRF8 deficient CD34+ 
progenitors to differentiate along DC and monocyte/macrophage pathways that 
may be relevant in steady-state or inflammation and examine responses to 
cytokines and growth factors in an attempt to further understand the IRF8 
signaling pathways. In particular, the preservation of tissue macrophages in the 
absence of monocytes begs the question as to whether CD34+ progenitors can 
differentiate to macrophages without monocyte intermediates, even in IRF8 
deficiency. 
  
8.5 DCML Deficiency 
In contrast to IRF8 deficiency, DCML deficiency was associated with an 
absence of MLP and marked reduction in GMP, suggesting a distinct but as yet 
unidentified genetic abnormality, likely earlier in the differentiation pathway. This 
haematopoietic phenotype was reflected in the circulating CD34+ populations 
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which, despite a relative increase in numbers, was also depleted of MLP and 
GMP. The deficiency of MLP was, not unexpectedly, associated with reduced 
numbers of B and NK cells. Although granulopoiesis was maintained, there was 
no evidence of myeloproliferation, despite massive elevation of serum Flt3L 
concentrations, suggesting some reduction in granulopoietic potential, at least 
in response to Flt3L. 
 
The preservation of LC despite the lack of circulating progenitors once again 
demonstrates the self-renewing capacity of LC. Again, some tissue 
macrophages could be identified, seemingly in reasonable numbers. However, 
the development of PAP, generally associated with poor alveolar macrophage 
function, suggests that these cells may have impaired function in DCML 
deficiency, at least in lung. 
 
One very tangible consequence of the description of DCML deficiency and its 
identification as a bone marrow defect is the justification of therapeutic HSCT 
for patients with serious complications of the disease. This is proven by two of 
the four cases experiencing resolution of symptoms following HSCT. In 
contrast, one subject who was treated conservatively succumbed suddenly and 
unexpectedly to H1N1 influenza. In conversation with colleagues two similar 
cases came to light, although not proven to be DCML deficiency, they 
presented with PAP in association with clinical monocytopenia and died from 
their pulmonary failure due to progressive and untreatable alveolar proteinosis. 
Likewise, the early death of relatives of subject 3, if shown to be due to the 
same disorder, illustrates the fatal nature of this condition if left untreated. It is 
hoped that increased awareness of the disorder will allow other patients the 
opportunity for this curative treatment. 
 
Further work will aim to: 
i) Identify the genetic defect in DCML deficiency through ‘Exomics’ 
analysis, family DNA comparisons and, if necessary, other 
approaches such as microRNA analysis.  
ii) Examine the in vitro potential of DCML deficiency CD34+ progenitor 
subsets to differentiate to monocytes/DC under a variety of cytokine 
conditions, compared to IRF8 deficiency and normal controls. 
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iii) Analyse in more detail the tissue macrophage subsets present and 
assess their function. 
iv) Follow cases of DCML deficiency longitudinally, through the early 
identification of any affected family members. Were the underlying 
genetic abnormality(ies) to be identified, this may allow diagnosis 
prior to the development of symptoms, or even potentially prior to the 
detection of a cellular phenotype, depending on the early natural 
history of the disorder and the compartmental localization of the 
genetic abnormality (germ line or somatic). 
v) Disseminate knowledge of the disease for earlier identification and 
treatment of patients. 
 
8.6 Flt3L concentration, Treg and DC homeostasis are interdependently 
regulated.  
Analysis of Treg numbers and FLt3L concentrations in DC deficiency 
syndromes in humans has revealed the likely interdependence of these 
elements, as predicted by mouse models. In humans with varied genetic 
backgrounds and environmental influences, this relationship holds true in 
normal volunteers without the extremes of DC depletion or exogenous Flt3L 
administration. Further work will examine the influence of individual DC subsets 
to this relationship through the inclusion of larger numbers of controls and 
analysis of greater numbers of cells/control. In addition, Treg and Flt3L 
concentrations in conditions conferring loss of specific subsets of monocytes or 
DC (for example, hairy cell leukaemia – discussed later) will be examined. 
  
8.7 Langerin expression is not specific to LC in humans 
Langerin expression has not previously been knowingly described on any 
human non-LC cell. Work in the thesis has led to the suggestion that the 
langerin expressing DC in dermis is unrelated to the LC and more likely to 
represent a proportion of dermal CD1a+ DC. This has been shown through both 
phenotypic analysis and observation of the different homeostatic behaviours in 
DCML deficiency and following HSCT. The presence of LDC in tissues lacking 
LC populations, and their presence in cell populations migrated from skin, 
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suggests that this is a relatively stable phenotype and not an immediate or 
inevitable precursor of LC. 
 
Whether the human LDC bares any phylogenetic relationship to the murine 
CD103+Lang+ dermal DC remains to be studied. The murine CD103+DC is 
know to cross-present antigen, express CLEC9A and XCR1, similarly to the 
human PB CD141high mDC. The expression of these antigens will be tested in 
human LDC and CD141high skin DC by mRNA expression analysis to determine 
if either or both subsets show any functional similarities with the murine 
CD103+Lang+DC.  
 
Although langerin has been presumed to be a ‘lineage marker’ of LC, its 
expression on a subset of DC suggests this is not the case. In addition, langerin 
expression can be induced in vitro on monocytes or CD34+ progenitors as they 
differentiate in response to inflammatory cytokines (including TNF"), or in 
response to TGF#. Finally, the observation of langerin expression on CD11c+ 
DC extracted from ‘cones’, and the unpublished observation of others, that 
langerin can be induced on PB mDC on overnight culture in the absence of any 
cytokines (38), suggests that induction of langerin expression is not necessarily 
specific to a single DC subset.  
 
Further work will investigate factors triggering langerin expression, and the cell 
subsets in which this can occur, in vitro, particularly without the necessity for 
further cellular differentiation.  Increased langerin expression is reported in 
some inflammatory conditions, such as in the lung of patients with smoking 
related ‘Chronic Obstructive Pulmonary Disease’ (203), and in some 
inflammatory skin diseases such as lichen planus (204). Further 
characterization of Lang+ cells in these and related conditions may reveal them 
to be LDC, rather than LC, perhaps enabling comparisons to be drawn with 
LCH lesions and subsequently leading to insights into the regulations of 
langerin expression in tissues. 
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8.8 Langerhans Cell Histiocytosis 
The origin of the LCH cells is of key interest when attempting to elucidate the 
pathophysiology of the LCH lesion. The possibility that the LCH cell is not a 
direct derivative of the LC highlights the relevance of studying other monocyte 
and DC compartments in the disease. We now have techniques to thoroughly 
and quantitatively interrogate all tissue DC compartments in patients with LCH 
and potentially identify any subtle changes in proportions or phenotype that may 
indicate aberrant homeostasis in ‘DC-poiesis’.  
 
Why some LCH cases present with a single lesion and some with multifocal or 
multisystem disease is entirely unknown. Mechanisms may include i) the 
dissemination of disease from an original focus, in a similar manner to 
metastatic cancer; ii) may reflect the normal tissue tropism of the LCH cell 
‘precursor’; iii) may be related to tissue factors which cause recruitment of LCH 
and other inflammatory cells at a local level. In any of these cases, a careful 
examination of PB populations, and their behaviour in inflammatory conditions, 
may shed light on circulating cells able to cause or respond to these conditions.  
 
Whether LCH contains a malignant component, and if so, whether this is the 
driving force of the disease, is still debated. It is conceivable that a lesion, which 
may start as an inflammatory focus causing upregulation of langerin on a local 
or recruited monocyte/DC population, leads to the proliferation of these cells 
which have inherent ability to enter into cell cycle in tissues. This continuous 
polyclonal proliferation, under the constant stimulus of inflammatory cytokines, 
may result in the development of a malignant clone. If this were the case, it 
might be expected that individual lesions within one case of multisystem 
disease would have the potential to generate different malignant clones. 
However, this is not something that has been examined in vivo as, traditionally, 
only one affected site would be biopsied to make a diagnosis.  
 
The recent identification of recurrent BRAF mutations in 57% of LCH lesions 
(205) lends weight to the argument that a malignant component can exist in 
LCH. Identifying whether the same mutation was present in all LCH lesions 
from one case would greatly enhance our understanding of the role of clonality 
and malignancy in LCH pathogenesis. 
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Further work will concentrate on: 
i) Validating flow cytometric analysis as a rapid diagnostic test for LCH 
by comparison with traditional histopathological methods  
ii) Defining and characterizing the cells in LCH lesions 
iii) Further detailed comparison of LCH cell with ex vivo skin, PB 
DC/monocytes and cells differentiated under inflammatory conditions 
in vitro. 
iv) Analysis of soluble mediators in serum and in vitro conditioned 
medium of LCH lesions to better understand the pathophysiology of 
LCH and identify potential disease markers or prognostic factors of 
use in the clinical setting. 
v) Assessment of clonality and search for BRAF mutations, ideally in 
lesions from >1 site in individual cases. Additionally, the malignant 
potential of LCH cells or monocyte/DC from LCH patients (and normal 
controls) after long-term in vitro culture will be assessed. 
 
8.9 Human lymphoid tissue 
The clear next step in classifying human DC populations is to examine LN and 
splenic tissue. While normal human LN is rarely available, normal spleen is 
more commonly accessible as splenectomy may be performed due to trauma or 
therapeutically for disorders such as structural red cell abnormalities or immune 
related cytopenias. This would allow a far greater understanding of the 
dynamics of human DC populations and allow direct comparisons between the 
PB, peripheral tissue and lymphoid tissue populations. 
 
8.10 Further avenues 
Some of the concepts developed in this thesis have a broad application to both 
basic science and clinical medicine. In particular, the analysis of the bone 
marrow stem cell compartment, identification of specific defects leading to 
clearly defined cellular phenotypes and the concept of a myeloid/lymphoid split 
later in ontogeny than previously thought have implications in the pathology of 
haematological diseases and malignancies. 
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In particular, hairy cell leukaemia (HCL) is characterised by malignant cells 
expressing both B cell and DC markers. This raises the possibility that it could 
be related to an MLP defect, particularly as it is typically accompanied by an 
absolute monocytopenia as defined by automated blood counters. Investigation 
of the presence or absence of monocyte and DC subsets in this condition, 
further phenotyping of HCL cells and detailed analysis of the BM compartment 
may lead to insights into the pathophysiology of this disease and the genetic 
pathways of DC/monocyte ontogeny. 
 
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder defined by 
the presence of the t(9;22) translocation, or ‘Philadelphia chromosome’ (Ph) in 
malignant cells. As cells from the malignant myeloid clone are able to 
differentiate to apparently normal end-stage cells, it might be predicted that 
tissue DC, replenished by myeloid precursors, would also become Ph+. Many 
groups have shown the ability of Ph+ monocytes to differentiate to moDC in vitro 
but whether DC are involved in the malignant clone in vivo has not been 
studied. Using the Ph chromosome as a ‘lineage marker’ may provide insights 
into the lineage derivation of these cells, particularly with regard to the myeloid 
versus lymphoid haematopoietic divide. 
 
8.11 Conclusion 
Future work will aim to test the hypothesis that: 
Human peripheral tissue DC are maintained in the steady state through 
replenishment by PB mDC and circulating CD34+ progenitors in a redundant or 
complementary fashion. This process is amplified by the ability of precursors to 
proliferate within tissues. In perturbed situations, such as inflammation, where 
these mechanisms may be insufficient to support increased DC migration, or 
DC possessing specific functions are required, alternative precursors, such as 
the PB monocyte, may be recruited. The exception is the LC which has now 
been shown to be independent of blood-borne precursors in the steady-state 
with maintenance of numbers through self-renewal.  













Advance, and never halt, for advancing is perfection. 
Advance and do not fear the thorns in the path, for they 
draw only corrupt blood.  
Khalil Gibran (1883-1931) 
 
 
Somewhere, something incredible is waiting to be known.   
Carl Sagan (1934 - 1996) 
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